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Consumers have begun to take a more proactive approach to their healthcare by accessing 
pharmaceutical companies Websites to obtain health and drug information, support 
groups, rebates, coupons, as well as free drug trials.  In exchange for these benefits, 
companies require consumers to voluntarily disclose information.  However, research has 
shown that consumers continue to be concerned about how their information is managed, 
used, and distributed by companies, especially if accessed via the Web.  To date, there 
has been limited empirical research to examine the actual online practices of companies 
when it comes to privacy, especially those of pharmaceutical companies.  Using Delphi 
expert panel process, the components of a benchmarking index were identified to 
examine the documented and actual online practices of 100 Website registrations with 
pharmaceutical companies.  The evolution for the development of an index to measure 
the personal information privacy violations of pharmaceutical companies is presented. 
Second, empirical evidence is provided regarding the magnitude of voluntary adherence 
to the Fair Information Practices (FIPs) by pharmaceutical companies based upon the 
personal information privacy violations.  The results revealed that companies with 
headquarters in Europe had fewer personal information privacy violations than those in 
Asia, UK, and the US.  Moreover, the results indicate that fewer personal information 
privacy violations occur for chronic conditions than for non-chronic conditions, as well 
as fewer violations occur with Website registrations for updates than for discounts.  
Finally, both Europe and UK demonstrated more overall adherence to FIPs than the US 
and Asia.  This suggests that self-regulation may not be sufficient, while more 
enforcement may be necessary to decrease personal information privacy violations.  
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Chapter 1 
Introduction 
 
Background 
The technological advancement of the Internet has revolutionized the way 
companies interact with consumers by enabling the ability to collect, store, transfer, sell, 
and analyze consumer information (Jaisingh, Barron, Mehta, & Chaturvedi, 2008; Kim & 
Byramjee, 2014; Lanier & Saini, 2008; Rapp, Hill, Gaines, & Wilson, 2009; Xu, 2009).  
Companies are able to leverage the Internet to establish relationships with consumers 
through the selling of products and services or to be a source for information.  However, 
in order to establish this relationship and engage in target marketing, companies must 
collect information either by voluntary or involuntary methods (Christiansen, 2011).  “A 
user’s voluntary sharing of such information” (Christiansen, 2011, p. 509) is considered 
voluntary disclosure and one of the methods of collecting information.  Another method 
of voluntary disclosure is by providing information on blogs or social networking sites 
(Christiansen, 2011).  Christiansen (2011) also noted that involuntary methods are 
malicious and “involve the use of technology to collect data and track movements by 
Internet users without their knowledge and/or permission” (p. 511).  Examples of 
involuntary methods include cookies, deep packet inspection, and scraping. Cookies are 
used to track consumer activities such as Internet viewing history (Christiansen, 2011). 
Contrary to one’s belief, according to Vega (2010), cookies can re-establish themselves 
even if the file has been deleted.  Deep packet inspection is used to monitor all consumer 
  
 
2 
online activity by reading and analyzing packets of information across the Internet 
(Stecklow & Sonne, 2010).  Christiansen (2011) noted that: 
Scraping, a particularly worrisome method of data collection, involves gathering 
personal details shared on forum discussions and social media sites in order to 
expand and flesh-out personal profiles of specific people, even when sites are for 
members only or are intended to be confidential (p. 511).   
The company manages the storage, access, and distribution after the information 
is collected (Milne, Rohm, & Bahl, 2004).  As a result, the information becomes at risk 
for secondary use, unauthorized access, and sharing with third parties (Milne et al., 
2004).  Hoffman, Novak, and Peralta (1999) defined secondary use as “the use of 
personal information for other purposes, subsequent to the transaction where the 
information was originally collected” (p. 131).  In the same context, Hoffman et al. 
(1999) noted that online practice of information sharing (OPIS) is “manifested by 
consumers’ concern that Web providers are selling their personal information to third 
parties without their knowledge or permission” (p. 131).  Because of these risks, 
consumers are exposed to threats, such as identity theft and unsolicited marketing, which 
contribute to an elevation of consumer personal information privacy concerns (Federal 
Trade Commission [FTC], 2000; Zorotheos & Kafeza, 2009).  As a result, consumers are 
hesitant to provide personal information on the Internet (Nam, Song, Lee, & Park, 2006). 
Likewise, Lanier and Saini (2008) noted that, while consumers appreciate the 
convenience and benefits of various technological advancements, they are concerned 
about how the voluntary and involuntary information collection practices impact their 
privacy.  Therefore, consumers take prudent actions, such as decreasing Internet use, 
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fabricating or falsifying their information, and refusing to disclose information about 
themselves (Cromer, 2010; Poddar, Mosteller, & Ellen, 2009; Yang & Wang, 2009).  In 
this respect, Meinert, Peterson, Criswell, and Crossland (2006) noted that e-commerce 
suffered an approximate $15 billion in unrealized revenue due to lack of consumer trust 
regarding companies’ ability to protect or use their personal information in an ethical 
manner.  In an effort to alleviate consumer concerns, companies post privacy seals and 
privacy policies on their Website to provide awareness of their information handling 
practices (Pollach, 2007).  Jafarr and Abdullat (2009) defined the documented practices 
of the privacy policy (DPPP) as a “written, published statement that articulates the policy 
position of an organization on how it handles the personally identifiable information that 
it gathers and uses in the normal course of business” (p. 126).  Regardless of privacy 
seals and DPPP, consumers expect companies to have an ethical responsibility to engage 
in practices that maintain information integrity and protect consumer information from 
unauthorized disclosure, access, use, or loss (Kelly & Rowland, 2000; Peltier, Milne, & 
Phelps, 2009).  Geva (2008) noted that society expectations of companies regarding 
corporate social responsibility (CSR) are four fold: “economic (‘make profit’), legal 
(‘obey the law’), ethical (‘be ethical’), and philanthropic (‘be a good corporate citizen’)” 
(p. 7).  Mohr, Webb, and Harris (2001) defined CSR as “a company’s commitment to 
minimizing or eliminating any harmful effects and maximizing its long run beneficial 
impact on society” (p. 47).  Moreover, customers’ expectations are heightened for 
financial, medical, and health information (Gupta, Iyer, & Weisskirch, 2010; Yang & 
Wang 2009).  Therefore, given the significant rise in the use of healthcare Websites 
(Davis, 2012; Kim & King, 2009) and the sensitivity of consumers’ information privacy, 
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pharmaceutical companies’ Websites are the focus of this research study.  The purpose of 
this research study was to investigate the documented practices of the privacy policy and 
the actual online practices of information sharing and consumer control that are 
contributing to the proliferation of personal information privacy violations (PIPV).  
This research study developed a benchmarking instrument that assessed and 
compared the documented and actual online practices implemented by pharmaceutical 
Websites.  Using multiple hierarchical measures, a single composite index was derived 
that represents an assessment of PIPV.  The Personal Information Privacy Violations 
Index (PIPVI) benchmarking instrument was used to compare the practices implemented 
from 100 Website registrations of pharmaceutical companies that market chronic and 
non-chronic prescription medications directly to consumers.  These two sub-categories of 
the pharmaceutical markets were selected, as both appear to have a significant market 
share and appear to collect personal information.  A breach of such personal information 
can cause substantial embarrassment or even harm to consumers.  For example, revealing 
the names of elected officials who are taking medications for a mental or other disorder 
can certainly be harmful to their reputation, possibly threatening their ability to stay in 
office.  The remainder of this paper is organized to describe the problem statement, 
dissertation goals, and research questions any hypotheses that this research study 
addressed.  Next, a literature review of the independent and dependent variables, along 
with the methodology are presented, followed by the barriers and issues, as well as the 
approach for this research study.  Afterwards, the results, conclusions, study limitations, 
and recommendations for future research are presented.  Finally, the appendix includes 
the PIPVI benchmark instrument that was used to record the data for each pharmaceutical 
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Website and the PIPVI expert panel instrument that was used to elicit responses from the 
expert panel.   
 
Problem Statement 
The research problem that this research study addressed is the proliferation of 
online privacy violations by companies (Anton, Earp, & Young, 2010; 2013; Kim & 
Byramjee, 2014; Li, Sarathy, & Xu, 2011; Nam et al., 2006; Nhan, Kinkade, & Burns, 
2009; Peltier et al., 2009).  Westin (1976) noted that information privacy is defined as, 
“the right of individuals, groups, or institutions, to determine for themselves when, how, 
and to what extent information about them is communicated to others” (p. 7).  Jafar and 
Abdullat (2009) noted that “the personal information privacy of an individual is violated 
when electronic personal information that was entrusted to third parties is electronically 
shared or crossed referenced with other parties without the consent of the individual” (p. 
126).  Specifically, consumers continue to be concerned with unsolicited email, identity 
theft, and negligent information loss through the selling and unauthorized use of their 
information when using the Internet (Anton et al., 2010; Lanier & Saini, 2008; Pollach, 
2007).  Therefore, prior to disclosing information, consumers engage in a risk-benefit 
analysis to evaluate if the benefit of the transaction surpasses the risk of information 
disclosure (Xie, Teo, & Wan, 2006; Xu, 2009; Yang & Wang, 2009).  For example, when 
conducting online banking transactions, consumers will voluntarily disclose information, 
but information sharing by the bank to third parties is unacceptable.  This behavior is 
consistent with the value and stimulus propositions of the Social Exchange Theory 
(SET).  The value proposition noted that “the more valuable to a person is the result of 
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his action, the more likely he is to perform the action” (Emerson, 1976, p. 340).  The 
stimulus proposition noted that: 
If in the past the occurrence of a particular stimulus, or set of stimuli, has been the 
occasion on which a person's action has been rewarded, then the more similar the 
present stimuli are to the past ones, the more likely the person is to perform the 
action, or some similar action now. (Emerson, 1976, p. 339)  
In other words, Emerson (1967) noted that if the consumers perceived that the expected 
benefit would prevail over the risk of information disclosure, they would voluntarily 
disclose information.  Likewise, if consumers have previously disclosed information and 
received the reward without perceptions of PIPV, they will be more willing to disclose 
information in similar conditions (Emerson, 1976).  However, Nam et al. (2006) noted 
that “media scrutiny of Internet fraud, hacking, and identity theft has heightened people’s 
awareness of the risks of conducting transactions on the Internet” (p. 212). 
Identity theft and other personal information privacy violations in the United 
States (US) have continued to rise and receive media attention.  As a result of a breach in 
2010, the federal regulators issued its largest HIPPA penalty that totaled $4.8 million due 
to an incident involving unsecured patient data for 6,800 patients (McGhee, 2014).  FTC 
(2013) reported that in 2012, identity theft was the top consumer complaint, with 369,212 
incidents.  Likewise, the Privacy Rights Clearinghouse (2013) reported that since 2005, 
932,729,111 records have been breached containing personal information from 4,478 
reported incidents.  Meanwhile, the Internet Crime Complaint Center (IC3) (2014) noted 
that over three million incidents have been reported since 2000.  It is important to note 
that the IC3 reported that the first million complaints occurred over seven years, with the 
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next million occurring in 3.5 years, indicating a significant escalation in cyber crimes 
each year.  The IC3 (2010) indicated that a substantial number of complaints are due to 
loss of personally identifiable information (PII).  Culnan and Armstrong (1999) defined 
PII as “information identifiable to an individual” (p. 105).  PII is represented by 
information such as name, postal address, email address, phone or fax number, Social 
Security Number (SSN), or credit card number (FTC, 2000).  Similarly, non-PII is 
defined as “information that, taken alone, cannot be used to identify or locate an 
individual” (FTC, 2000, p. 170).  Age, gender, income, and education level are examples 
of non-PII.  The aforementioned incidents are significant indicators of the growth and 
occurrence of personal information privacy violations occurring through the use of the 
Internet and are key contributors to the escalation of consumer concerns (Lanier & Saini, 
2008; Zorotheos & Kafeza, 2009).    
The online practices of consumer control (OPCC) are also important to consumers 
(Liu, Marchewka, Lu, & Yu, 2005).  In this context, Hoffman et al. (1999) defined 
consumer control as “the consumer’s ability to control the dissemination of information 
related to or provided during such transactions or behaviors to those who were not 
present” (p. 131).  Liu et al. (2005) noted that consumers expect to maintain some level 
of control over how their information is used and distributed.  However, the above 
incidents give rise to consumer concern regarding the inability to control their 
information.  Consumers’ concerns regarding the loss of control are substantiated by 
Clarke, Flaherty, and Zugelder (2005), who noted that 16% of major email marketers’ 
OPCC did not comply with the opt-out requirements established by the FTC.  By not 
honoring consumers’ requests to opt-out of further communications, consumers will 
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continue to receive unsolicited emails, also known as spam, and perceive that their 
personal information privacy has been violated.  Ahmed and Oppenheim (2006) noted 
that the Mail Abuse Prevention System defined spam as:  
An email is “spam” IF: (1) the recipient’s personal identity and context are 
irrelevant because the message is equally applicable to many other potential 
recipients; AND (2) the recipient has not verifiably granted deliberate, explicit, 
and still-revocable permission for it to be sent; AND (3) the transmission and 
reception of the message appears to the recipient to give a disproportionate benefit 
to the sender. (p. 157) 
In fact, Bhuleskar, Sherlekar, and Pandit (2009) reported that 45% of emails represent 
spam and approximately 14.5 billion spam emails are distributed on a daily basis with 
consumers receiving an estimated annual spam of 2,500 emails.  
Given the consistent rise in personal information privacy violations over the 
years, the FTC has made consumer protection a critical aspect of its mission (FTC, n.d). 
The FTC has the statutory authority and responsibility for prohibiting unfair and 
deceptive practices by holding companies accountable for privacy practices regarding 
information collection, use, and security (Earp & Baumer, 2003).  Mohr, Webb, and 
Harris (2001) noted that companies continue to be confronted with pressure to maintain 
profitability and govern themselves in a socially responsible manner.  Geva (2006) stated 
that “the greatest problem of ethical conduct in business, lies in compliance” (p. 7).  Geva 
(2008) further noted that “it is the financial interest of businesses to comply with the law, 
to engage in ethical behavior, and to exercise philanthropy” (p. 14).  In response to the 
reoccurrence of information breaches in the US, the FTC established and adopted laws 
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and regulations to protect consumers online.  First, the Fair Information Practices (FIPs) 
are “global principles that fairly balance the need for business to collect and use personal 
information with the legitimate privacy interests of consumers to be able to exercise 
control over the disclosure and subsequent uses of their personal information” (Milne, & 
Culnan, 2002, p. 345).  FIPs are generally contained in a Website’s DPPP.  Next, the 
Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 (CAN-
SPAM Act) is “a law that sets rules for commercial email, establishes requirements for 
commercial messages, gives recipients the right to have you stop emailing them, and 
spells out tough penalties for violations” (FTC, 2009, para. 1).  As a result, some 
companies enable consumers to opt-in or opt-out of email communications.  However, 
enforcement of FIPS and CAN-SPAM Act occur through self-regulation (FTC, 2000; 
Lanier & Saini, 2008; Nemati & Dyke, 2009; Xu, 2009).  According to Xu (2009), “self-
regulation involves the setting of standards by an industry group or certifying agency and 
the voluntary adherence to the set of standards by members or associates” (p. 24).  In 
other words, companies are responsible for voluntarily compliance with these laws and 
regulations (Nemati & Dyke, 2009; Storey, Kane, & Schwaig, 2009).  Geva (2006) noted 
that “a compliance problem is primarily one of ability and willingness (p. 137).  Despite 
the existence of a Website’s DPPP and other US laws and regulations, the FTC (2013) 
noted that it continues to address cases of personal information privacy violations in the 
US with multi-million dollar settlements.  
Although consumers’ concerns are increasingly rising, Internet use is also on the 
rise, which implies that consumers are being more meticulous about interaction with 
particular Websites (Cromer, 2010).  For instance, Nam et al. (2006) noted that the use of 
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the Internet as an informational source has surpassed the purchasing of products.  In this 
respect, as consumers begin to take a more proactive approach to their healthcare, the use 
of the Internet to obtain medical drug information is also on the rise (Davis, 2012).  Davis 
(2012) indicated that the Internet is the second most used source for prescription drug 
information after healthcare physicians.  However, Davis (2012) further noted that 
consumers prefer pharmaceutical companies’ Websites as a primary source of 
information.  Kim and King (2009) noted that consumers’ access of pharmaceutical 
companies’ Websites tripled from 2000 to 2003. Joseph, Spake, and Finney (2008) 
supported this proliferation and also noted that less than 10% of consumers indicated 
physicians should be the primary source for pharmaceutical information.  This is evident 
by consumer use of pharmaceutical companies’ Websites to access health and drug 
information, support groups, free drug samples, and rebates (Sheehan, 2005).  It is 
important to note that to acquire those benefits, consumers are required to disclose 
personal information.  Equally important, consumers are more cautious about disclosing 
personal information with health Websites due to the sensitivity of information that may 
be required and the risk of companies developing inferences using information collected. 
For example, Bansal, Zahedi, and Gefen (2010) noted that employers or insurance 
agencies could use personal health information to discriminate against consumers. 
Therefore, it is important for consumers to understand the documented and online 
practices of the company (Milne, Rohm, & Bahl, 2004; Van Dyke, 2007).  Thus, 
additional research of the online information practices of Websites was warranted to 
understand the practices that are contributing to the proliferation of personal information 
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privacy violations (Kim & Byramjee, 2014; Lanier & Saini, 2008; Schwaig, Kane, & 
Storey, 2005).   
 
Dissertation Goals 
The main goal of this research study was to develop the Personal Information 
Privacy Violation Index (PIPVI) benchmarking instrument that can be used to assess the 
DPPP, OPIS, OPCC, and compute the PIPVI while using it to compare 100 Website 
registrations of pharmaceutical companies that market chronic and non-chronic 
prescription medications.  For example, Palmer (2012) noted that contraceptives are an 
$8 billion annual drug market.  In addition, Chordas (2011) stated that “in 2009, more 
than 90 million prescriptions for contraceptives were dispensed” (p. 64).  Likewise, a 
report by Global Industry Analysts, Inc. (GIA) (2010) noted that consumers experiencing 
allergies are constantly rising, and by 2015, this market is expected to surpass $14.7 
billion.  Hoy and Park (2014) and Davis (2012) noted that consumers use the Internet as a 
source for medical information in addition to their physician.  Kim and King (2009) also 
asserted that, “internet sources are more important for prescription drugs than for non-
prescription drugs” (p. 5).  Likewise, consumers use of the Internet as a source for 
prescription drugs increased from 45.7 million in 2004 to 116 million in 2012 (Hoy & 
Park, 2014).  Moreover, Hoy and Park (2014) noted that pharmaceutical companies are 
predicted to spend $1.86 billion by 2015 on online advertising.  Based upon the growth 
projections for prescription medications and the projected expenditure in online 
advertising, it is expected that consumer use of pharmaceutical Websites will continue to 
rise.  Therefore, it is important to understand the documented and actual online 
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information practices of pharmaceutical companies to gain insight into how information 
is used that is collected through their Websites.  With the use of actual counting of 
violations, as opposed to perception-based survey, the expectation was that this research 
study would provide insight into the practices that are contributing to PIPV.  Given the 
heightened concerns of consumers regarding personal information privacy, the results of 
this research study provided consumers with empirical evidence of how information is 
managed and used by pharmaceutical companies.  In addition, consumers will be able to 
assess the magnitude of information sharing and ability (or lack thereof) to control their 
information. A high magnitude of personal information privacy violations could 
negatively impact consumers’ trust, concerns, and interactions with the Websites, which 
could continue to constrain the growth of e-commerce.  Because enforcement of the FIPs 
occurs through self-regulation, the results of this research study provided evidence 
regarding the magnitude of voluntary adherence to the FIPs by pharmaceutical 
companies.  This evidence can assist advocacy groups and regulators with understanding 
the effectiveness of self-regulation. Furthermore, it can aid in determining if more 
stringent laws and regulations or enforcement are necessary.  In addition, companies can 
use the PIPVI benchmarking instrument to perform a self-assessment of their Website 
documented and online practices, while seeing how these differ or change over time.  
The need for this research was demonstrated by the work of Schwaig et al. (2005), 
who examined the DPPP for Fortune 500 companies and their adherence to the FIPs. 
Their results indicated that only 3% of the DPPP included all notices of the FIPs, while 
31% contained at least one item for each notice.  In comparison to the FTC (2000), which 
noted that 32% of the sites examined partially implemented four of the FIPs, there has 
  
 
13 
been minimal improvement over the years.  Schwaig et al. (2005) contended that 
companies considered the existence of the DPPP more important than the content or 
enforcement.  They argued that some companies use the DPPP as disguises for their 
limited practices, and further research is warranted to determine the gap between the 
DPPP and the actual online information practices. O’Connor (2007) examined the DPPP, 
OPIS, and OPCC of hotel Websites. O’Connor (2007) further indicated that none of the 
hotel Websites fully complied with the FIPS. Even though O’Connor (2007) also 
assessed OPIS and OPCC, only overall percentages of the online practices were provided. 
Therefore, this research study will extend O’Connor’s (2007) study with a different 
population and provide an extended focus on the volume of third-party emails received. 
This dissertation builds on the previous research by Schwaig et al. (2005), 
Sheehan (2005), and White (2010).  Sheehan (2005) examined the Websites of 94 
branded-drug companies’ types of information collected, planned use, and 
communication of the DPPP.  First, Sheehan’s (2005) results indicated that 94% of the 
Websites displayed privacy notices.  Second, even though approximately 80% to 90% of 
the Websites complied with the FIPs for notice, less than 30% complied with access, 
choice, and security.  Third, the types of information consumers were expected to 
disclose represented over 50% demographic, 40% medical, and 33% other information. 
Finally, Sheehan (2005) contended that the evaluation of the DPPP represented claims 
and does not constitute the actual practices implemented.  Sheehan (2005) was limited to 
the DPPP and did not assess the online practices.  Similar to Sheehan (2005), this 
research study assessed the documented practices of the privacy policy against the FIPs 
and the PII collected by the Websites.  However, this research study overcame Sheehan’s 
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(2005) limitation by assessing the DPPP, OPIS, and the OPCC to provide a holistic view 
of how pharmaceutical companies are using the information collected through their 
Websites.  
The first specific goal of this research study was to develop and assess the 
experts’ approved components and weights for the DPPP implemented by pharmaceutical 
companies using the Delphi expert methodology.  The second specific goal of this 
research study was to develop and assess the experts’ approved components and weights 
for the OPIS implemented by pharmaceutical companies using the Delphi expert 
methodology. The third specific goal of this research study was to develop and assess the 
experts’ approved components and weights for the OPCC implemented by 
pharmaceutical companies using the Delphi expert methodology.  The fourth specific 
goal of this research study was to develop the components of the single, integrated 
measure of PIPVI and assess the DPPP, OPIS, and the OPCC implemented by 
pharmaceutical companies using the Delphi expert methodology.  The fifth specific goal 
was to assess and compare the DPPPM of pharmaceutical companies whose headquarters 
are based in the United States versus Europe, Asia, or United Kingdom.  The sixth 
specific goal was to assess and compare the OPISM, OPCCM, and PIPVI for 100 
Website registrations of pharmaceutical companies that a) market chronic versus non-
chronic prescription medications, b) market registrations for prescription medication 
discounts versus updates, c) their headquarters are based in United States versus Europe, 
Asia, or United Kingdom.  The seventh specific goal was to assess and compare the 
differences for 100 Website registrations between the documented and actual online 
practices of consumer control for choice and access of pharmaceutical companies that a) 
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market chronic versus non-chronic prescription medications, b) market registrations for 
prescription medication discounts versus updates, c) their headquarters are based in 
United States, versus Europe, Asia, or United Kingdom. The eighth specific goal of this 
research study is to assess and compare the OPISM, OPCCM, and PIPVI between 
pharmaceutical companies that collect a limited amount of PII and those that collect a 
high amount of PII.  The last and ninth goal is to measure if there are any significant 
differences in the pharmaceutical companies’ DPPPM, OPISM, OPCCM, and PIPVI 
based on their size, reported annual revenues, and years in existence.  Figure 1 represents 
the conceptual model for the PIPVI.  
 
            
Figure 1: Conceptual Model for the Personal Information Privacy Violations 
Index (PIPVI) 
 
Research Questions and Hypotheses 
 The main research question (RQ) that this research study addressed was: are there 
any significant differences in the PIPVI, DPPPM, OPISM, and the OPCCM between 
pharmaceutical companies that market chronic and non-chronic prescription medications 
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directly to consumers?  This entailed using the PIPVI benchmarking instrument to assess 
the DPPPM, OPISM, OPCCM, and PIPVI scores for pharmaceutical companies’ 
Websites that market prescription medications directly to consumers.  Afterwards, the 
DPPPM, OPISM, and OPCCM scores were used to derive the PIPVI for each sample and 
then used to compare the groups of pharmaceutical companies’ Websites.  
The first seven research questions are focused on the examination of the 
documented and the actual online information practices of pharmaceutical companies as 
well as their adherence to U.S. laws and regulations.  To date, there have been several 
studies that examined how well a company’s documented DPPP adhered to the FIPs 
(FTC, 1998, 2000; Milne, & Culnan, 2002; Pollach, 2007; Schwaig et al., 2005; Storey et 
al., 2009).  Schwaig et al. (2005) and Sheehan (2005) noted that the DPPP do not 
guarantee the actual practices.  Therefore, this research study addressed the gap in the 
literature by assessing the DPPP, OPIS, and OPCC over a five-month period with a focus 
on pharmaceutical companies’ Websites that market chronic and non-chronic prescription 
medications directly to consumers.  
RQ1a: What are the experts’ approved components of the DPPP implemented by 
pharmaceutical companies using a Delphi expert methodology?   
RQ1b: What are the experts’ approved weights of the DPPP’s components 
implemented by pharmaceutical companies using a Delphi expert 
methodology?   
RQ2a: What are the experts’ approved components of the OPIS implemented by 
pharmaceutical companies using a Delphi expert methodology?   
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RQ2b: What are the experts’ approved weights of the OPIS’s components 
implemented by pharmaceutical companies using a Delphi expert 
methodology? 
RQ3a: What are the experts’ approved components of the OPCC implemented by 
pharmaceutical companies using a Delphi expert methodology?   
RQ3b: What are the experts’ approved weights of the OPCC’s components 
implemented by pharmaceutical companies using a Delphi expert 
methodology? 
RQ4: What are the experts’ approved weights of the single, integrated hierarchical 
measure of PIPVI’s components of DPPP, OPIS, and the OPCC 
implemented by pharmaceutical companies using a Delphi expert 
methodology? 
RQ5: Are there any statistical significance mean differences for DPPM between 
pharmaceutical companies that headquarters are based in United States 
versus Europe, Asia, or United Kingdom? 
RQ6: Are there any statistical significance mean differences for OPISM, OPCCM, 
and PIPVI between pharmaceutical companies that a) market chronic versus 
non-chronic prescription medications, b) market registrations for 
prescription medication discounts versus updates, c) their headquarters are 
based in United States, versus Europe, Asia, or United Kingdom?  
RQ7: Are there any significant differences between the documented and the 
actual online practices for choice, and access of pharmaceutical companies 
that a) market chronic versus non-chronic prescription medications, b) 
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market registrations for prescription medication discounts versus updates, c) 
their headquarters are based in United States, versus Europe, Asia, or United 
Kingdom? 
 The next research question addressed the quantity of PII collected by 
pharmaceutical companies.  Sheehan (2005) noted that pharmaceutical companies’ 
Websites collect PII or anonymous information through mechanisms such as site 
registrations and questionnaires in exchange for information, rebates, and free trials.  The 
type of information collected influences the consumer’s level of privacy concern and 
interaction with the Website (Li et al., 2011; Sheehan, 2005; Xu, 2009; Yang & Wang, 
2009).  In this respect, Sheehan (2005) argued that consumers are most concerned about 
disclosing financial and health information.  According to Zimmer et al. (2010), 
“consumers have become increasingly protective of the information they disclose” (p. 
395) because they continue to be concerned about information management by 
companies.  Therefore, this research study examined the PII collected by pharmaceutical 
companies’ Websites to gain insight into what PII consumers are expected to disclose. 
RQ8: Are there any statistical significance mean differences for OPISM, OPCCM 
and PIPVI between pharmaceutical companies that collect a limited amount 
of PII and those that collect a high amount of PII? 
 Last, the three null hypotheses used the demographic information collected for 
each pharmaceutical company to assess if there are significant differences in the 
pharmaceutical company's DPPPM, OPISM, OPCCM, and PIPVI based on its size, 
annual revenues, and years in existence. 
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H1: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will 
not be significantly different when controlling for company size.  
H2: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will 
not be significantly different when controlling for annual revenue. 
H3: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will 
not be significantly different when controlling for years in existence. 
 
Relevance and Significance of the Study 
Relevance 
  Due to the occurrence of online privacy violations, research in this area continues 
to be relevant (Belanger & Crossler, 2011; Peltier et al., 2009).  The proliferation of 
online privacy violations continues to be a problem for consumers (K. Kim & Kim, 2011; 
Koorzaan & Boswell, 2008; Li et al., 2011).  Lee, Ahn, and Bang (2011) noted that even 
though companies have implemented FIPs, personal information privacy violations 
continue to rise.  In addition, online identity theft has rapidly emerged as the top identity 
crime, and the number of threats to consumers continues to rise year after year (Racolta-
Paina & Luca, 2010).  As previously noted, the FTC (2010) continues to address cases of 
personal information privacy violations in the US with multi-million dollar settlements. 
Because adherence to the FIPs is self-regulated, it is challenging to regulate and enforce. 
Pratt and Conger (2009) noted that technological advancements have contributed to the 
erosion of personal information privacy over the last 30 years.  Technology maturity has 
significantly decreased the challenges for companies to collect, integrate, and aggregate 
consumer information (Nemati & Dyke, 2009; Pratt & Conger, 2009; Taylor, Davis, & 
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Jillapalli, 2009).  It is important to note that prior to the Internet, this capability was 
practically impossible (Pratt & Conger, 2009), except through a manual effort.  For 
example, prior to the Internet, consumers may have completed a post card in a 
physician’s office, clinic, or hospital, which became at risk for unauthorized use or 
information sharing by the staff or mail handlers if reply was sent by mail. 
A poll by CBS News and The New York Times reported that 83% of 1,167 
Americans interviewed expressed negative views of companies’ information collection 
practices (Roberts, 2009).  Once consumers disclose information, they have relinquished 
control and are unaware of how their information will be managed and used (Li et al., 
2011; Rapp et al., 2009; Reay, Dick, & Miller, 2009).  Therefore, consumers will 
continue to be at risk for personal information privacy violations if their information is 
exposed to threats such as unauthorized access, secondary use, or sold to third parties.  
Secondary use is defined as “use of information for other purposes, subsequent to the 
transaction where the information was originally collected” (Hoffman et al., 1999, p. 
131).  Because of the consistent occurrence of personal information violations, the 
growth of e-commerce is at risk (Kim & Byramjee, 2014; K. Kim & Kim, 2011; Li et al., 
2011).  However, Lee et al. (2011) noted that implementation of the FIPs could mitigate 
consumer concerns and increase their willingness to disclose personal information.  As 
Internet use of pharmaceutical companies’ Websites continues to rise, it is important to 
understand the extent their privacy policy complies with the FIPs, information sharing, 
and consumer control to assess their contribution to personal information privacy 
violations (Sheehan, 2005).  This will assist consumers with determining if 
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pharmaceutical companies can be trusted with their information, given the sensitivity of 
health information.   
Although there are several research studies (Earp & Baumer, 2003; Gupta et al, 
2010; Joinson, Reips, Buchanan, & Schofield, 2010; K. Kim & Kim, 2011; Li et al, 2011; 
Phelps, Norwak, & Ferrell, 2000; Vlasic, 2006) evaluating different aspects of consumer 
information privacy concerns, research that examines the actual online practices of 
companies is limited.  Various studies have examined specific aspects of online practices, 
such as assessment of privacy policies against the FIPs, consumer control, and secondary 
use (FTC, 1998, 2000; Lai & Hui, 2006; Milne & Culnan, 2002; O’Connor, 2007; 
Pollach, 2007; Schwaig et al., 2005; Storey et al., 2009; White, 2010).  However, there is 
a gap in the literature of comprehensive empirical research examining information 
privacy with an assessment of privacy policies against the FIPs, information sharing, and 
consumer control in one study for a particular population.  This research study addressed 
that gap by conducting an assessment of these constructs for pharmaceutical companies’ 
Websites that provide information about prescription drugs.  Websites that sell 
prescription drugs were excluded from this research study. 
W. J. Kim and King (2009) noted that “the pharmaceutical market is one of the 
world’s leading industrial sectors with worldwide sales volume estimated as $534.8 
billion in 2005” (p. 5).  The pharmaceutical industry is under the regulation of the Federal 
and Drug Administration (FDA) under the authority of the Federal Food, Drug and 
Cosmetic Act and, therefore, must comply with more stringent guidelines than other 
industries.  The pharmaceutical market is comprised of both prescription and non-
prescription drugs.  W. J. Kim and King (2009) defined prescription drugs as drugs that 
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cannot be dispensed without a prescription, while a prescription is not required for non-
prescription drugs.  They also noted that prescription drugs represent significant revenue 
for this industry.  Prior to 1997, pharmaceutical marketing was primarily directed toward 
physicians.  Because of the relaxation of direct-to-consumer (DTC) advertising 
regulations in 1997, pharmaceutical companies expanded advertising to include DTC. 
Because considerable profits have been realized from advertising, the pharmaceutical 
industry has radically increased their direct-to-consumer (DTC) advertising (Joseph et al., 
2008; W. J. Kim & King, 2009).  For example, pharmaceutical companies in the US have 
increased DTC advertising spending for prescription drugs from $242 million in 1994 to 
an estimated $4.2 billion in 2005 (W. J. Kim & King, 2009).  Advertising of prescription 
drugs is not limited to such media as television and radio, but also includes the Internet. 
W. J. Kim and King (2009) noted that the Internet has increasingly become a popular 
medium for consumers to obtain information regarding prescription drugs.  The 
aforementioned factors provide impetus for pharmaceutical companies’ Website being 
selected as the unit of analysis. 
Significance 
The significance of this research study is its results provided an understanding of 
the magnitude of personal information privacy violations by pharmaceutical companies.  
Since the FIPs are governed by self-regulation (FTC, 2000; Lanier & Saini, 2008; Nemati 
& Dyke, 2009; Xu, 2009), this research study provided evidence regarding the extent of 
voluntary adherence by pharmaceutical companies. Next, this research study also 
provided insight into the secondary use and third party sharing of consumer information.  
Because consumers are highly concerned about information management and use, the 
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results of this research study provided insight into how well pharmaceutical companies 
are addressing consumer concerns. 
Furthermore, other researchers can use the PIPVI benchmarking instrument to 
assess Websites for new populations.  This research study sought to provide a mechanism 
to assess the document and actual online practices of a Website to gain a better 
understanding of the practices contributing to PIPV.  Those responsible for the design 
and development of companies’ Websites can use this tool to conduct a self-assessment 
of the Website’s documented and online practices.  The use of the PIPVI can also provide 
an increased awareness of the practices that are important to regulators and consumers to 
assist with improving the Website’s practices.  Furthermore, this evidence will assist 
advocacy groups and regulators with understanding the effectiveness of self-regulation to 
aide in determining if more stringent laws and regulations or enforcement are necessary. 
 
Barriers and Issues 
This research study had several potential issues with conducting this experiment. 
First, an issue of concern was that the responses of the experts solicited for participation 
in the expert review panel might not be constructive.  Therefore, to address this concern, 
the expert panel survey consisted of questions that elicited both binary and open-ended 
responses.  Because this research study developed the PIPVI benchmarking tool, the 
reliability of this instrument was also a concern.  To address this concern, a methodical 
analysis of literature and evaluation by the expert panel was conducted to ensure the 
intention of the instrument.  
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In addition, the data collection for this research study was an issue due to 
potential revisions to the Websites or practices during the length of the study because the 
data collection from the Websites occurred over a five-month period.  For instance, the 
privacy policy or online practice could have been revised during the five months that may 
alter the results.  O’Connor (2007) noted that it is common practice for companies to 
provide notification of privacy policy updates.  To address this issue, a copy of the 
privacy policy was downloaded and assessed at the beginning and the end of the research 
study.  If notifications were received during data collection or analysis, the privacy policy 
would have been reviewed for modifications that would significantly alter the results and 
determine if the Website results should be excluded from the study or updated.  However, 
no notifications were received, nor changes to the privacy policy occurred. In addition, 
the results represented data for a specific date range.  Data received after the specified 
date was excluded. 
Another issue that required consideration was that because information was 
collected from online transactions, aggregation of information by the Websites of 
pharmaceutical companies could be an issue.  To mitigate this issue, a unique email and 
name was identified for each Website registration initiated on the pharmaceutical 
company Website to ensure results were maintained separately.  A new domain name was 
purchased to set up an email account for each registration for the pharmaceutical 
companies’ Websites.  For example, a Website may allow separate registrations for a 
newsletter and discounts.  Therefore, registration for the newsletter had a different name 
and email address than the registration for the discount for the same pharmaceutical 
company Website.  
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Because secondary use by the pharmaceutical companies was measured by 
emails, the use of personal information may be understated because postal mail received 
cannot be measured by pharmaceutical company, since all Website registrations used the 
same postal address.  Therefore, to address this concern, a unique name was used for all 
Website registrations to ensure postal mail received could be aggregated appropriately. 
One more issue that required consideration is that because some Website 
registrations required an address, the same P.O. Box was used for all registrations. 
Therefore, it may have been difficult to determine which pharmaceutical company 
Website the mail originated from.  To address this issue, as mentioned above, a unique 
name was used for each pharmaceutical company Website registration to assist with 
determining the origin of the mail.  
Furthermore, the sample represents a random selection of pharmaceutical 
companies’ Websites and results may not be representative of the industry as whole.  
This research study was conducted using pharmaceutical companies’ Websites that 
provide information about chronic and non-chronic prescription drugs in the US.  The 
companies may be headquartered in and outside of the US, such as in France, Germany, 
Japan, Switzerland, or the UK.  In an effort to get a valid cross section of pharmaceutical 
companies’ Websites, the sample included 100 registrations initiated through 53 
Websites across 25 pharmaceutical companies with a proportionate distribution between 
US and non-US headquarters.  The sample excluded pharmaceutical companies’ 
Websites that sell prescription drugs. 
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Limitations and Delimitations 
Limitations 
Because this research study developed a new benchmarking instrument, one 
limitation was the set of measures that was combined to form the PIPVI.  Another 
limitation was that the reliability and validation of the instrument relied on an expert 
panel.  The expert panel assigned the relative weights for the document and online 
practices measures.  As a result, generalization of the results from this research study was 
cautioned.  Further studies will be required with other populations to increase 
generalizability of the results. 
An additional limitation of this research study was the inability to assess the 
actual security practice.  The inability to observe the companies’ actual information 
protection methods for transmittal and storage prohibits observation and information 
collection for examination.  Next, it is important to note that while the focus of this 
research study is online practices, it is believed that information is being shared through 
other sources, such as physician offices and pharmacies.  The actual practices for OPIS 
for several of the Websites could not be adequately assessed because no emails were 
received during the research study.  Moreover, the actual practices of OPCC regarding 
the deletion of personal information could not be assessed.  Most of the pharmaceutical 
companies required a request for deletion to be submitted by email, phone, or mail, which 
was beyond the scope of this research study.  The last limitation is that the information 
represented a point in time due to unpredictable modifications of privacy policies or 
practices that could occur after data collection.  
 
  
 
27 
Delimitations 
First, a delimitation of this research study was that the experts recruited for the 
panel were based upon a convenience sampling.  Sekaran (2003) defined convenience 
sampling as “the collection of information from members of the population who are 
conveniently available to provide it” (p. 276).  Experts, including professional contacts 
with those associated with this project, and members in professional societies and social 
media networking sites, were solicited to participate. Because of this convenience 
sampling, other qualified experts may not have been contacted and therefore not included 
in the expert panel.  
Second, another delimitation of this research study was that the pharmaceutical 
companies’ Websites included in the examination were limited to prescription drugs and 
not over-the-counter drugs.  A third delimitation was that the pharmaceutical companies’ 
Websites were limited to manufacturers that advertise pharmaceutical drugs in the US 
even though their headquarters may be located in and outside the US, such as in France, 
Germany, Japan, Switzerland, or the UK.  A fourth delimitation was that if a postal 
address is required, a P. O. Box was used instead of a street address.  The P. O. Box is 
preferred to mitigate receipt of a high volume of mail at the personal home address.  
After completion of this research study, the P. O. Box was terminated with no forwarding 
address.  A fifth delimitation was that the Website registration was limited to newsletters, 
updates, discounts or support programs.  Last, a delimitation regarding confinement of 
the Website registrations was that secondary use and email metrics may be understated 
because specific triggers may not have been invoked for other transactions not included 
in this research study.  For example, the experiment included Website registrations for 
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newsletters, discounts, or support programs, which may not trigger the same processes as 
completion of a survey or quiz.  
 
Definition of Terms 
 The following represent terms and definitions.  
Analysis of Variance (ANOVA) - “to determine group differences when two or more 
factors create these groups” (Mertler & Vannatta, 2010, p. 90) 
Analysis of Covariance (ANCOVA) - “adjusts the effects of variables that are related to 
the dependent variables” (Mertler & Vannatta, 2010, p. 93) 
Cronbach Alpha - “a reliability coefficient that indicates how well the items in a set are 
positively correlated to one another” (Sekaran, 2003, p. 307) 
Construct Validity - “a determination of the significance, meaning, purpose, and use of 
scores from an instrument” (Creswell, 2002, p. 184) 
Consumer Control (OPCC) – “individuals could exercise control over the accuracy, 
completeness, timeliness, use, distribution, and disposition of their personal information” 
(Zuo et al., 2007, p. 452) 
Content Validity - “the extent to which the questions on the instrument and the scores 
from the questions are representative of all the possible questions that could be asked 
about the content or skills” (Creswell, 2002, p. 18) 
Controlling the Assault of Non-Solicited Pornography and Marketing Act (CAN-
SPAM Act) - “a law that sets rules for commercial email, establishes requirements for 
commercial messages, gives recipients the right to have you stop emailing them, and 
spells out tough penalties for violations” (FTC, 2009, para. 1). 
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Convenience Sampling – “the collection of information from members of the population 
who are conveniently available to provide it” (Sekaran, 2003, p. 276) 
Corporate Social Responsibility (CSR) - “a company’s commitment to minimizing or 
eliminating any harmful effects and maximizing its long run beneficial impact on 
society” (Mohr, Webb, & Harris, 2001, p. 47) 
Delphi Expert Methodology – “devised in order to obtain the most reliable opinion 
consensus of a group of experts by subjecting them to a series of questionnaires in depth 
interspersed with controlled opinion feedback” (Dalkey & Helmer, 1963, p. 458) 
Fair Information Practices (FIPs) - “global principles that fairly balance the need for 
business to collect and use personal information with the legitimate privacy interests of 
consumers to be able to exercise control over the disclosure and subsequent uses of their 
personal information” (Milne, & Culnan, 2002, p. 345). 
Federal Trade Commission (FTC) - A U.S. government organization whose mission is 
“to prevent business practices that are anticompetitive or deceptive or unfair to 
consumers; to enhance informed consumer choice and public understanding of the 
competitive process; and to accomplish this without unduly burdening legitimate business 
activity” (FTC, n.d., para. 1). 
Homogeneity of Variance - “the degree of variance within each of the samples should 
be about the same” (Terrell, 2012, p. 245) 
Inter-rater Reliability - “two or more individuals observe an individual’s behavior and 
record scores, and then the scores of the observers are compared to determine whether 
they are similar” (Creswell, 2002, p. 182) 
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Involuntary Disclosure - “this malicious method involves the use of technology to 
collect data and track movements by Internet users without their knowledge and/or 
permission” (Christiansen, 2011, p. 511)  
Non-Personally Identifiable Information (Non-PII) - “information that, taken alone, 
cannot be used to identify or locate an individual” (FTC, 2000, p. 169).  
Online Practices of Information Sharing (OPIS) - “manifested by consumers’ concern 
that Web providers are selling their personal information to third parties without their 
knowledge or permission” (Hoffman et al., 1999, p. 131) 
Opt-in – “consumers must give permission before marketer can use their personal 
information” (Milne & Rohm, 2000, p. 238) 
Opt-out - “consumers can remove their names from a list by checking a box on a form 
provided by the marketer or by calling or writing the marketer” (Milne & Rohm, 2000, p. 
238) 
Outlier - “cases with unusual or extreme values at one or both ends of a sample 
distribution” (Mertler & Vannatta, 2010, p. 27) 
Personal Information Privacy Violation - “the personal information privacy of an 
individual is violated when electronic personal information that was entrusted to third 
parties is electronically shared or crossed referenced with other parties without the 
consent of the individual” (Jafar & Abdullat, 2009, p. 126). 
Personally Identifiable Information (PII) - “information that can be used to locate or 
identify an individual” (FTC, 2000, p. 169). 
Pre-Analysis Data Screening - “pre-analysis data preparation deals with the process of 
detecting irregularities or problems with the collected data” (Levy, 2006, p. 150). 
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Privacy - “the right of individuals, groups, or institutions, to determine for themselves 
when, how, and to what extent information about them is communicated to others” 
(Peltier et al., 2009, p. 192). 
Privacy Policy (DPPP) - “a written, published statement that articulates the policy 
position of an organization on how it handles the personally identifiable information that 
it gathers and uses in the normal course of business” (Jafarr & Abdullat, 2009, p. 126). 
Ratio Scale – “a scale that has an absolute zero origin, and hence indicates not only the 
magnitude, but also the proportion of the differences” (Sekaran, 2003, p. 422) 
Reliability - “individual scores from an instrument should be nearly the same or stable on 
repeated administrations of the instrument, they should be free from sources of 
measurement error, and they should be consistent” (Creswell, 2002, p. 180) 
Response Set - “cases where respondents submitted the same score for all items” (Levy, 
2006, p. 151) 
Secondary Use - “use of information for other purposes, subsequent to the transaction 
where the information was originally collected” (Hoffman et al., 1999, p. 131).  
Self-regulation - “the setting of standards by an industry group or certifying agency and 
the voluntary adherence to the set of standards by members or associates” (Xu, 2009, p. 
24) 
Spam - “an email is ‘spam’ IF: (1) the recipient’s personal identity and context are 
irrelevant because the message is equally applicable to many other potential recipients. 
AND (2) the recipient has not verifiably granted deliberate, explicit, and still-revocable 
permission for it to be sent; AND (3) the transmission and reception of the message 
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appears to the recipient to give a disproportionate benefit to the sender” (Ahmed & 
Oppenheim, 2006, p. 157). 
Validity - “draw meaningful and justifiable inferences from scores about a sample or 
population” (Cresswell, 2002, p. 185) 
Voluntary Disclosure - “a user’s voluntary sharing of such information” (Christiansen, 
2011, p. 1). 
 
Summary 
 The purpose of chapter one was to first introduce the research study. 
Identification of the research problem, barriers and issues, along with the limitations to 
conducting this research study, were discussed.  Next, a theoretical justification for the 
research study was provided.  The research problem that this study addressed was that 
although there are laws and regulations for consumer protection when interacting online, 
there continues to be a proliferation of online privacy violations by companies.  Valid 
literature supporting the research problem and the need for this study was presented. 
 Furthermore, chapter one presented the main goal, specific goals, research 
questions, and hypotheses for this research study.  The main goal of this research study 
was to develop the Personal PIPVI benchmarking instrument that can be used to assess 
the DPPP, OPIS, OPCC, and compute PIPVI while using it to compare 100 registrations 
initiated through 53 Websites of 25 pharmaceutical companies that market chronic and 
non-chronic prescription medications.  Prior literature that supports the main goal was 
presented (Belanger & Crossler, 2011; Lee, Ahn & Bang, 2011; Li et al., 2011; K. Kim & 
Kim, 2011; Peltier et al., 2009; Koorzaan & Boswell, 2008).  The nine specific goals, 
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along with the relevance and significance for this research study, were also discussed.  
According to literature, the number of threats to consumers, such as online identity theft, 
continues to rise year after year (Racolta-Paina & Luca, 2010).  Because of the consistent 
rise in online privacy violations such as online identity theft, research in this area 
continues to be relevant (Belanger & Crossler, 2011; Peltier et al., 2009).  This research 
study added to the body of knowledge by providing insight into the documented and 
actual online practices of pharmaceutical companies that contribute to personal 
information privacy violations. In addition, this research study provided empirical 
evidence on how information is managed and used by pharmaceutical companies’ 
Websites. 
 Furthermore, chapter one continued by identifying the barriers, issues, and 
mitigations for this research study pertaining to the expert panel participation, data 
collection, aggregation of the information, and Website registrations.  The limitations and 
delimitation of the research study were discussed.  The chapter concluded with a 
definition of terms used during the research study along with relevant acronyms.  
  
 
34 
Chapter 2 
Literature Review 
 
Introduction 
In this chapter, a literature review was presented to provide a synopsis of the 
relevant literature pertaining to Website practices and to lay the theoretical foundation for 
this research study.  Hart (1998) noted that the literature review provided the foundation 
for the research and stressed the importance of adequate knowledge of the history and 
current research to identify areas of concerns, interest, and neglect.  To acquire the 
knowledge and understanding, a comprehensive literature search for quality peer 
reviewed and secondary literature was conducted that was also used to lay the foundation 
for this research study.  This is a critical process and, as noted by Levy and Ellis (2006), 
“in any systematic approach, if the system input is either incorrect, of low quality, or 
irrelevant, the resulted output is going to be ineffective regardless of the quality of the 
processing stage or, colloquially, garbage-in/garbage-out” (p. 185).  This examination is 
interdisciplinary in nature and, therefore, an extensive search of the Information Systems 
(IS) literature domain was conducted using several databases from multiple fields 
including the following: IS, business, and marketing.  From this literature review process, 
three important constructs were identified in the literature domain relating to personal 
information violations: privacy policy, information sharing, and consumer control.  A 
comprehensive examination of these areas was conducted to ascertain what is already 
known, research questions, approach, and theoretical foundation for this research. 
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Moreover, information regarding composite indices and the Delphi expert methodology 
was presented. 
 
Personal Information Privacy Violations 
 Personal information privacy violations using the Internet continue to receive 
media attention and continue to be a growing concern for consumers (K. Kim & Kim, 
2011; Koorzaan & Boswell, 2008; Li et al., 2011).  While the advancement of technology 
has provided significant benefits to companies and consumers, it has also had an adverse 
effect.  Research has shown that information privacy remains a top concern for 
consumers (Smith, Dinev, & Xu, 2011).  
Personal information privacy violations can occur in multiple ways through the 
information collection and management practices by companies.  Companies collect 
information through voluntary and involuntary methods (Christiansen, 2011).  Even 
though consumers are voluntarily providing information, companies are able to collect 
additional information without consumer consent, using methods such as cookies and 
Web bugs (Smith et al., 2011).  Cookies and Web bugs are designed to capture 
information about consumers, including their Web browsing activities.  The information 
collected from those activities can be aggregated and used to create a consumer profile. 
Therefore, whether information has been collected through voluntary or involuntary 
methods, the information becomes at risk for unauthorized use, management, and 
distribution (Milne et al., 2004).  The persistent growth of identity theft and spam are also 
key indicators that companies are mismanaging consumer information.  Gomez, Pinnick, 
and Soltani (2009) indicated that companies such as Google®, Yahoo®, Microsoft®, and 
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Facebook® share consumer information with a significant quantity of affiliates.  Because 
of the persistent personal information privacy violations and the heightened concerns of 
consumers, Van Dyke (2007) noted the importance of understanding the online practices 
of Websites.  Furthermore, Smith et al. (2011) stated that there are very limited empirical 
descriptive studies that address the organizational unit of analysis. 
 
Table 1 
 
Summary of Personal Information Privacy Violations Literature 
 
Study Methodology Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Christiansen, 
2011 
Standard  Personal privacy 
and Internet 
marketing 
Provides an overview 
of technology and 
personal privacy in 
marketing along with 
recommendations for 
the marketing and 
government industries. 
 
Gomez et al., 
2009 
Literature 
review and 
experiment 
50 
Websites 
Data handling 
practices, consumer 
concerns 
 
Consumers are 
concerned about 
privacy and do not 
support information 
collection and 
disclosure by Websites 
without their 
permission. 
 
K. Kim & J. 
Kim, 2011 
Empirical 
study via 
experiment 
223 
Under-
graduate 
students 
Trusting intentions, 
trusting beliefs,  
perceived privacy 
empowerment, 
purchase decision 
involvement, 
disposition to trust, 
privacy-protection 
self-efficacy 
The presence of a 
well-known third party 
seal on an unfamiliar 
retailer website 
increased trust in the 
website and the seal 
presence was mediated 
by perceived privacy 
empowerment. 
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Table 1 
 
Summary of Personal Information Privacy Violations Literature (continued) 
 
Study Methodology Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Koorzaan & 
Boswell, 2008 
Empirical 
study via 
survey 
230 under-
graduate 
students 
 
International 
personality item 
pool 
Personality traits 
impacts concern for 
information privacy. 
Li et al., 2011 Empirical 
study via 
experiment 
220 
students 
Emotions, 
fairness levers, 
general privacy 
concern, situation 
specific privacy 
calculus, sensitivity 
of information 
Emotions influence 
information disclosure. 
 
During e-commerce 
transactions with an 
unfamiliar vendor, 
information disclosure 
is based upon 
competing influences 
of exchange benefits 
along with privacy 
protection belief and 
privacy risk belief. 
 
Milne et al., 
2004 
Empirical 
study via 
survey 
2468 
adults, 
300 
students, 
40 non-
students 
Online protection 
behavior, attitudinal 
behaviors, 
demographic 
antecedent 
Consumers are not 
taking adequate 
precautions to protect 
themselves against 
identity theft.  
     
Smith et al., 
2011 
Literature 
review and 
analysis 
320 
privacy 
articles, 
128 books 
and book 
sections 
 
APCO macro 
model  
Provides an 
interdisciplinary 
review of privacy-
related research and 
recommendations for 
future research. 
 
Van Dyke, 
2007 
Empirical 
study via 
experiment 
124 
employees, 
under-
graduate 
and 
Privacy concern, 
website 
personalization 
preference 
Increased awareness of 
data collection 
techniques elevated 
consumer privacy 
concerns and reduced 
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graduate 
students 
preference for Web 
site personalization. 
 
 
Privacy Policy and the Fair Information Practices  
Websites’ compliance with the FIPs has been a topic of discussion for personal 
information privacy when using the Internet.  The FTC has been examining online 
privacy violations since 1995.  In 1998, the FTC issued its first FIPs report to Congress 
with a recommendation for Websites to implement the FIPs (FTC, 1998).  These 
principles were established prior to the Web and have been recognized by government 
agencies in the US, Canada, and Europe since 1973 (FTC, 2000).  Park (2011) noted that 
“the FIPs are global principles that balance business needs for data collection with 
consumer protection” (p. 651).  However, enforcement of the FIPs is through self-
regulation and companies are responsible for voluntary compliance and monitoring.  The 
four widely accepted FIP principles are notice, choice, access, and security (FTC, 2000). 
The FTC (2000, p. iii) defined these principles as:  
§ Notice – Websites would be required to provide consumers clear and 
conspicuous notice of their information practices, including what information 
they collect, how they collect it (e.g., directly or through non-obvious means 
such as cookies), how they use it, how they provide choice, access, and 
security to consumers, whether they disclose the information collected to 
other entities, and whether other entities are collecting information through 
the site. 
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§ Choice – Websites would be required to offer consumers choices as to how 
their personal identifying information is used beyond the use for which the 
information was provided (e.g., to consummate a transaction).  Such choice 
would encompass both internal secondary uses (such as marketing back to 
consumers) and external secondary uses (such as disclosing data to other 
entities).  
§ Access – Websites would be required to offer consumers reasonable access to 
the information a Website has collected about them, including a reasonable 
opportunity to review information and to correct inaccuracies or delete 
information. 
§ Security – Websites would be required to take reasonable steps to protect the 
security of the information they collect from consumers. 
In 1998, the FTC examined the online practices of 1402 US commercial 
Websites.  While 85% of the Websites collected large amounts of information, only 14% 
of the random sample disclosed some type of information regarding the Website’s 
information practices and only approximately 2% provided notice in a comprehensive 
privacy policy (FTC, 1998).  Two years later, the FTC (2000) examined 426 US 
commercial Websites and over 90% of those Websites collected PII.  While there was an 
increase in posting at least one privacy disclosure for these Websites, there continued to 
be very limited compliance of at least one element for each principle of the FIPs.  The 
FTC (1998, 2000) also indicated that a significant number of companies failed to provide 
the basic principle of notice and overall had not implemented the FIPs.  It is important to 
note that, because privacy policies are not required, some companies cannot be held 
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accountable for their privacy practices until they are stated (Storey et al., 2009).  For 
example, it may be difficult to file a claim against a company without posted privacy 
policies because they have not made any declarations regarding information collection 
nor usage practices.  The FTC (1998) report to Congress noted that there is a need for 
companies to implement the basic principles of the FIPs, but no legislation was 
recommended at that time.  In addition, the FTC (1998) noted that if consumer concerns 
are not addressed, “electronic commerce will not reach its full potential” (FTC, 1998, p. 
43).  Two years later, based upon minimal improvement in adherence to the FIPs, the 
FTC’s report to Congress recommended that Websites that collect PII comply with the 
following FIPs: notice, choice, access, and security (FTC, 2000).  
In response to the FTC (1998), Culnan (2000) examined 361 of the most visited 
US commercial Websites using the FTC (1998) as the foundation to provide support for 
self-regulation and to discourage legislation.  Culnan (2000) argued that the FTC sample 
was not representative of Websites consumers frequently visited.  The results suggested 
that 65% posted some type of privacy notice, which was higher than the FTC (1998).  
The Direct Marketing Association (DMA) argued that Culnan (2000) provided evidence 
that companies were voluntarily adhering to the FIPs and self-regulation was an effective 
approach (Culnan, 2000).  To the contrary, Consumer Federation of America supported 
the FTC (1998) and noted that “meaningful and effective privacy protections for 
consumers are largely missing” (Culnan, 2000, p. 24).  Likewise, the Center for 
Democracy and Technology (CDT) (1999) also disagreed with the DMA and stated that 
“privacy policies are the exception and not the rule” (p. 10).  The CDT (1999) also noted 
that there is very limited adherence to the complete set of FIPs.  While Culnan (2000) 
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noted that the DMA reported positive results regarding posting of privacy policies, the 
CDT (1999) argued that the information presented in the privacy policies were not 
reflective of consumer concerns.  The CDT (1999) acknowledged that while some 
progress is apparent, more is required to establish information privacy as the rule rather 
than the exception.  Years later, O’Connor’s (2007) examination of hotel Websites 
continued to reveal evidence of non-adherence to the complete set of FIPs and privacy 
policies continued to ignore the concerns of consumers.  The FTC (1998, 2000) and 
Culnan (2000) focused on a broad population of commercial Websites across multiple 
industries. In contrast, this research study will focus on a specific industry.  Belanger and 
Crossler (2011) noted that the type of industry impacts a company’s privacy concerns and 
practices because some industries may be required to adhere to certain regulations.  In 
addition, well-known brand names may take additional precautions regarding privacy in 
an endeavor to maintain brand reputation (Belanger & Crossler, 2011). 
Likewise, Storey et al. (2009) examined the privacy policies of U.S. Fortune 500 
companies against the FIPs.  Storey et al. (2009) believed these companies were expected 
to be leaders in personal information privacy issues and were scrutinized more closely by 
privacy advocates and the government.  Their results indicated that a company’s 
dependency on consumer information influenced the quality of the privacy policy.  For 
example, business to consumer, electronic commerce, informational, heavy traffic, and 
large company Websites that are dependent upon consumer information are more likely 
to adhere to the FIPs than those of companies that are not dependent upon consumer 
information.  Storey et al. (2009) stated that the results contradict consumers’ perceptions 
that information dependent companies are more likely to violate consumers’ information 
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privacy.  However, Storey et al. ’s (2009) findings were concluded based upon the stated 
practices opposed to actual practices.  Pratt and Conger (2009) argued that, while the 
FIPs are commendable, they could give consumers a false illusion of privacy protection.  
While the privacy policy quality may be high, the statements do not guarantee actual 
practices (Schwaig et al., 2005; Sheehan, 2005), as is evident by the continued growth in 
personal information privacy violations (Lee et al., 2011).  Lee et al. (2011) noted that, 
even though companies have implemented the FIPs, personal information privacy 
violations continued to rise.  But there is a belief that implementation of the FIPs could 
reduce consumer concerns (Beldad, Jong, & Steehouder, 2009; Culnan &Armstrong, 
1999; Lee et al., 2011).  Furthermore, the CDT (2011) stated that “Fair Information 
Practices (FIPPS) must be the foundation of any comprehensive privacy framework” (p. 
7).  
 
Table 2  
 
Summary of Privacy Policy and the Fair Information Practices Literature 
 
Study Methodology Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Belanger & 
Crossler, 
2011 
Literature 
review and 
analysis 
142 journal 
articles,  
102 
conference 
proceedings 
 
Information 
privacy 
There is more to be 
explored or explained 
about Information 
Privacy research. 
 
Beldad et al., 
2009 
Empirical 
study via 
experiment 
77 Dutch 
municipal 
Websites  
Fair Information 
Practices 
While 50% complied 
with notice, they fell 
short in access, 
choice, and security. 
 
 
  
 
43 
Table 2 
Summary of Privacy Policy and the Fair Information Practices Literature (continued) 
 
Study Methodology Sample Instrument or 
Construct 
Main Finding or 
Contribution 
CDT, 1999 Literature 
review and 
analysis 
Industry 
reports 
Fair information 
practices, privacy 
Companies are not 
fully adhering to the 
Fair Information 
Practices.  
 
CDT, 2011 Literature 
review and 
proposal 
 Data breach Summarized the 
framework of federal 
and state data breach 
and security laws, as 
well as recommended 
legislative proposals. 
 
Culnan & 
Armstrong, 
1999 
Empirical 
study via 
secondary 
data analysis  
1000 US 
adults 18 
years or 
older 
Information 
privacy concerns, 
procedural 
fairness, 
impersonal trust  
Companies can 
increase customer 
retention by 
recognizing 
procedural fairness. 
 
FTC, 1998 Empirical 
study via 
experiment 
1400 
Websites 
Fair information 
practices 
Companies are not 
adhering to 
guidelines regarding 
online collection and 
use of consumer 
information. 
 
FTC, 2000 Empirical 
study via 
experiment 
521 
Websites 
Fair Information 
Practices 
Industries have made 
limited progress in 
protecting consumer 
privacy online. 
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Table 2 
 
Summary of Privacy Policy and the Fair Information Practices Literature (continued) 
 
Study Methodology Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Lee et al., 
2011 
Literature 
review and 
analysis 
 Privacy 
protection 
 
 
Enforcement of the 
Fair Information 
Practices can be 
beneficial from the 
social welfare 
perspective by 
limiting the 
competition-
mitigation firm 
incentives.  
 
O’Connor, 
2007 
Empirical 
study via 
experiment 
97 hotel 
Websites 
Fair Information 
Practices 
No website fully 
complies with the 
Fair Information 
Practices. 
 
Park, 2011 Empirical 
study via 
experiment 
398 
Websites 
Notice,  
Choice 
The minimal levels of 
privacy provision 
suggested the 
deficiency of 
marketplace benefits. 
 
Pratt & 
Conger, 2009 
Literature 
review and 
analysis 
 Personal 
information 
privacy 
Privacy violations are 
still occurring despite 
legal and self-
protection policies. 
 
Schwaig et 
al., 2005 
Empirical 
study via 
experiment 
Fortune 
500 
companies’ 
websites 
Fair Information 
Practices 
Companies are not in 
full compliance with 
the Fair Information 
Practices. Companies 
are more concerned 
about the existence 
rather than the 
content. 
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Table 2 
 
Summary of Privacy Policy and the Fair Information Practices Literature (continued) 
 
Study Methodology Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Sheehan, 
2005 
Empirical 
study via 
experiment 
94 DTC 
branded-
drug 
Websites 
Fair Information 
Practices 
Websites have more 
adherences to notice 
and choice than 
access and security of 
the Fair Information 
Practices.  In 
addition, readability 
of privacy policies is 
difficult to 
understand 
     
Storey et al., 
2009 
Empirical 
study via 
experiment 
Fortune 
500 
companies’ 
Websites 
Fair Information 
Practices 
A company’s 
dependence upon 
consumer 
information may 
influence the strength 
of their privacy 
policy. 
 
 
Information Sharing 
One of the top concerns of consumers is information disclosure to third parties 
without consent (Anton et al., 2010; Lanier & Saini, 2008; Pollach, 2007).  Jaisingh et al. 
(2008) noted that this type of information sharing represented a “collection and release of 
consumer information” (p. 858) that would be considered a PIPV.  As a result of 
unauthorized information sharing, research has shown that consumers continue to be 
concerned about information management (Pratt & Conger, 2009; Roberts, 2009; Zimmer 
et al., 2010).  This concern is supported by constant evidence of companies sharing 
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information without consumer knowledge, which contributes to PIPV.  Pratt and Conger 
(2009) contended that once companies integrate and aggregate information, it would be 
shared or sold.  
Wu, Lau, Atkin, and Lin (2011) argued that, while companies benefit from the 
sale of personal information, it could be more detrimental to consumers than illegal 
information collection.  For example, Wu et al. (2011) noted a 1999 incident of a 
murdered female resulting from the purchase of her Social Security Number (SSN) from 
the Internet for only $45. While this is an extreme case, it clearly demonstrated that 
secondary use can be life-threatening and that consumers have reason for heightened 
concerns.  Pratt and Conger (2009) noted that once information disclosure occurs, 
consumers should expect their information will be sold or shared and their privacy cannot 
be restored.  With technology, the ability for companies to easily integrate information 
has had both a positive and negative impact on consumers’ personal information privacy.  
While consumers also benefit from information disclosure, the negative impact on their 
personal information privacy could outweigh the benefits (Pratt & Conger, 2009).  For 
example, consumers may receive information, free drug samples, or coupons in exchange 
for spam from other companies with whom they did not engage, which leads to increased 
risks such as identity theft, secondary use, and an increase in spam because their 
information was shared or sold.  Therefore, the perception of personal information 
privacy violations may not be worth the exchange for information, free drug sample, or 
coupon. Furthermore, Pratt and Conger (2009) noted that it is important to understand the 
information sharing practices of companies.  
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Identity theft continued to be the primary concern for 11 consecutive years (Lane 
& Sui, 2010; Racolta-Paina & Luca, 2010; Wu et al., 2011).  In 2009, there were 11.1 
million cases of reported identify theft (Moore, 2010).  Consumers will attempt to 
mitigate this threat by falsifying information to avoid providing legitimate personal 
information (O’Connor, 2007).  In addition, consumers also provide a secondary email 
address to mitigate receipt of spam to their primary email address.  Consumers receive 
2,500 spam emails annually (Bhuleskar, Sherlekar, & Pandit, 2009).  Given the continued 
growth of information sharing by companies, there seems to be no relief in sight.  While 
consumers benefit from falsifying information, there is a negative impact on the accuracy 
of company information, which also has financial impacts (O’Connor, 2007; Poddar et 
al., 2009).  Data inaccuracy is a $600 billion annual cost due to unnecessary postage, 
printing, and staff overhead (Poddar et al., 2009).  Therefore, companies must find a 
balance between information disclosure benefits and personal information privacy 
(Christiansen, 2011). 
Table 3  
Summary of Information Sharing Literature 
Study Methodology Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Anton et al., 
2010 
Empirical 
study via 
survey 
2094 
Internet 
users in 
and 
outside of 
the US 
Privacy concerns of 
personalization, 
notice/awareness, 
information transfer, 
information 
collection, 
information storage, 
and 
access/participation 
The top concern for 
both U.S. and non-U.S. 
respondents was 
information transfer. 
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Table 3  
Summary of Information Sharing Literature (continued) 
Study Methodology Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Bhuleskar et 
al., 2009 
Literature 
review and 
proposal 
 Spam filtering 
techniques 
Summarized spam 
filtering techniques 
and proposed a hybrid 
filtering technique. 
 
Christiansen, 
2011 
Standard  Personal privacy 
and Internet 
marketing 
Provides an overview 
of technology and 
personal privacy in 
marketing along with 
recommendations for 
the marketing and 
government industries. 
 
Lanier & 
Saini, 2008 
Literature 
review and 
analysis 
Consumer 
privacy 
articles 
published 
from 1989 
to 2007 in 
academic 
journals 
Conceptualization of 
consumer privacy, 
consumer related 
privacy issues, firm 
related privacy 
issues 
There is an opportunity 
for more theoretically 
driven research to 
develop a model that 
identifies the domain 
of consumer privacy 
including the 
relationships, 
antecedents and 
consequences. 
 
Lane & Sui, 
2010 
Literature 
review and 
synthesis 
 Identify theft 
patterns 
Identify theft crimes 
are higher in the 
southwestern states 
and lower in the New 
England and northern 
plain states.  
 
Jaisingh et al., 
(2008) 
Literature 
review and 
synthesis 
 Privacy When the benefits of 
personalized products 
or services are less 
than the privacy loss, 
companies should 
consider not collecting 
consumer information. 
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Table 3 
Summary of Information Sharing Literature (continued) 
 
Study Methodology Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Moore, 2010 Standard  Cybercrime  Summarizes 
cybercrime issues and 
risks to organizations 
and the use of the 
COSO framework to 
identify risks. 
 
O’Connor, 
2007 
Empirical 
study via 
experiment 
97 hotel 
Websites 
Fair Information 
Practices 
No website fully 
complies with the Fair 
Information Practices. 
 
Poddar et al., 
2009 
Empirical 
study via 
interviews 
21 
Internet 
users 
Information 
exchange 
Consumers are 
challenged with 
maintaining control of 
their online identities 
and lacked trust of 
how their information 
is being managed 
online. 
  
Pollach, 2007 Empirical 
study via 
experiment 
50 
commer-
cial 
Websites  
Privacy concerns, 
data collection, data 
storage, data 
sharing, unsolicited, 
marketing 
communications 
 
The privacy policy 
content is more 
focused on mitigating 
lawsuits rather than 
addressing consumer’s 
privacy concerns. 
Pratt & 
Conger, 2009 
Literature 
review and 
synthesis 
 Personal 
information privacy 
Privacy violations are 
still occurring despite 
legal and self-
protection policies. 
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Table 3  
Summary of Information Sharing Literature (continued) 
 
Study Methodology Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Racolta-Paina 
& Luca, 2010 
Literature 
review and 
synthesis 
 Online consumer 
characteristics and 
behaviors 
Describes the 
importance of the 
online consumer in the 
21st century along with 
their characteristics 
and behaviors. 
 
Roberts, 2009 Empirical 
study via 
telephone 
survey 
1167 
adults 
nation-
wide 
Privacy concerns: 
right to privacy, 
data collection, 
threat to privacy, 
federal government 
regulation 
Consumers are 
concerned about data 
collection practices, 
identify theft and feel 
that more regulation is 
necessary from the 
federal government. 
 
Wu, Lau et 
al., 2011 
Literature 
review and 
analysis 
Legal 
documents 
along with 
blogs and 
black 
board 
systems 
 
Government, 
institution, citizens 
China consumers are 
less aware than U.S. 
consumers that 
technology can be 
used to protect against 
online privacy 
violations. 
 
Zimmer et al., 
2010 
Empirical 
study via 
experiment  
264 
business 
manage-
ment 
students 
Intent to disclose, 
dyadic relationship 
There is a relationship 
between intent to 
disclose and disclosure 
behavior. 
 
 
Consumer Control 
  Another top concern of consumers is loss of control (Cromer, 2010; Hough, 2009; 
Poddar et al., 2009).  Zuo and O’Keefe (2007) contended that “to honor individuals’ 
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rights over their personal information, privacy protection should ensure that individuals 
could exercise control over the accuracy, completeness, timeliness, use, distribution, and 
disposition of their personal information” (p. 452).  Culnan and Armstrong (1999) noted 
that consumers perceived they had lost the ability to control the use and distribution of 
their personal information.  Once consumers disclose their information, they have ceded 
their rights to the company (Zuo & O’Keefe, 2007).  However, consumers still expect to 
maintain control of how their information will be used and distributed with the intention 
of mitigating threats such as secondary use, identity theft, and spam.  Belanger and 
Crossler (2011, p. 1017) indicated that 85% of those surveyed expressed the need to 
control information access.  Culnan and Armstrong (1999) noted that consumers are less 
likely to perceive their personal information privacy has been violated if they are able to 
control the use of their information.  Companies address this concern by providing the 
ability to opt-in or opt-out of originating or third party communications.  Consumer 
choice is also one of the principles of the FIPs that stated that consumers should be given 
the opportunity to control their information.  To opt-out of communications or 
information distribution “consumers can remove their names from a list by checking a 
box on a form provided by the marketer or by calling or writing the marketer” (Milne & 
Rohm, 2000, p. 238).  The DMA prefers the opt-out approach because the consumer 
consent is implicit until a request for removal is received (Clarke et al., 2005).  To the 
contrary, opt-in is the recommended approach by the European Union Data Directive 
(Lai & Hui, 2006).  This approach requires that “consumers must give permission before 
marketer can use their personal information” (Milne & Rohm, 2000, p. 238).  With this 
approach, information cannot be sent or disclosed unless the consumer provides consent. 
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This approach would be detrimental to companies who specialize in selling consumer 
information because they would be relying on voluntary consent (Hough, 2009).  Even 
though some companies provide the ability to opt-out or opt-in, Milne and Rohm (2000) 
noted that these options are often intentionally invisible on Websites.  O’Connor’s (2007) 
examination of hotel Websites indicated hotels lacked principles of choice, access, and 
the security of information transferred to third parties.  In addition, 38% of the Websites 
did not provide consumers with a choice to opt-in or opt-out of third party disclosure 
(O’Connor, 2007, p. 195).  Furthermore, consumers’ ability to control third party 
communications was 62%, compared to 49% for the originating company 
communications (O’Connor, 2007, p. 195).  This implied that the originating company 
provided less control over consumer communications (O’Connor, 2007).  In this 
situation, consumers could be more at risk for personal information violations by the 
originating company than by third parties.  Even though consumers are concerned about 
secondary use, their concern is not only applicable to external use but internal use as 
well.  
Ford (2005) noted that it has been estimated that “more than 13 billion spam 
messages are sent per day” (p. 355), which cost U.S. companies approximately 10 billion 
dollars a year.  Spam can be very frustrating and trigger consumer reactions such as 
distrust and ceasing further interaction with that company.  Because spam was recognized 
as a significant problem and efforts to control it have been ineffective, in 2003, Congress 
passed the CAN-SPAM Act, which provides legislation for email regulations.  It is 
important to note that this law does not prohibit spam, but provides content specifications 
and supports the opt-out approach (Clarke et al., 2005).  
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Table 4 
Summary of Consumer Control Literature 
 
Study Methodology Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Belanger & 
Crossler, 2011 
Literature 
review and 
analysis 
142 journal 
articles, 102 
conference 
proceedings 
Information privacy Summarizes the 
current state of 
information privacy 
research and provides 
recommendations for 
future research.  
 
Clarke et al., 
2005 
Literature 
review and 
synthesis 
 CAN-SPAM Act Summarizes the CAN-
SPAM Act law and 
the sales implications. 
 
Cromer, 2010 Empirical 
study via 
secondary 
data and 
survey 
2,126 online 
consumers, 
482 online 
consumers 
Adaptive behavior, 
Internet experience,  
risk concern 
Consumers use self-
efficacy to regulate 
Internet use and 
adaptive behaviors to 
mitigate online risk 
concerns. 
 
Culnan & 
Armstrong, 
1999 
Empirical 
study via 
secondary 
data analysis  
1,000 U.S. 
adults 18 
years or 
older 
Information privacy 
concerns, 
procedural fairness, 
impersonal trust  
Companies can 
increase customer 
retention by 
recognizing 
procedural fairness. 
 
Ford, 2005 Literature 
review and 
analysis 
 CAN-SPAM Act Summarizes the 
preemption of the state 
spam laws by the 
CAN-SPAM Act. 
 
Hough, 2009 Literature 
review and 
analysis 
 Loss of control Summarizes the facets 
of privacy, control 
preservation, and how 
technology contributes 
to a loss of consumer 
control. 
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Table 4  
 
Summary of Consumer Control Literature (continued) 
 
Study Methodology Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Lai & Hui, 
2006 
Empirical 
study via 
experiment 
68 under-
graduate 
students 
120 under-
graduate 
student 
 
Frames, defaults, 
privacy concern 
Different phrasing of 
consumer choice and 
default preferences for 
opt-in or opt-out 
influences consumer 
participation. 
Milne & 
Rohm, 2000 
Empirical 
study via 
survey 
1508 
adults 
Awareness of 
information 
capture, knowledge 
of name removal 
mechanisms 
 
Consumers are 
unaware of data 
collection practices 
and name removal 
mechanisms. 
 
O’Connor, 
2007 
Empirical 
study via 
experiment 
97 hotel 
Websites 
Fair Information 
Practices 
No website fully 
complies with the Fair 
Information Practices. 
 
Poddar et al., 
2009 
Empirical 
study via 
interviews 
21 
Internet 
users 
Information 
exchange 
Consumers are 
challenged with 
maintaining control of 
their online identities 
and lacked trust of 
how their information 
is being managed 
online. 
  
Zuo & 
O’Keefe, 
2007 
Literature 
review and 
analysis 
 Information Privacy 
Protection 
 
Introduced a set of 
information privacy 
protection models to 
reduce the information 
flow to provide 
consumers with 
greater control of 
information 
disclosure. 
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Social Exchange Theory  
 The theoretical foundation for this research draws on the social exchange theory 
(SET).  The context of the SET is that there is a voluntary exchange between multiple 
parties. Homans (1958) noted that “persons that give much to others try to get much from 
them, and persons that get much from others are under pressure to give much to them” (p. 
606).  This theory posits that consumers engage in a “privacy calculus” where they assess 
information disclosure against the expected benefits (Emerson, 1976).  During the 
assessment, consumers evaluate if their information will be used ethically and if they will 
not suffer negative consequences from information disclosure (Culnan & Armstrong, 
1999; Xu, 2009).  Yang and Wang (2009) used the SET to examine cost-benefit effects 
on privacy concern and behavioral intention.  Yang and Wang (2009) found that privacy 
concern has a negative effect on information disclosure but a positive effect on privacy 
intention.  In order to make an informed decision, the consumer should have prior 
knowledge of companies’ information practices (Milne & Rohm, 2000; Xu, 2009).  
 
 
Table 5  
 
Summary of Social Exchange Theory Literature 
 
Study Methodology  Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Homans, 1958 Theoretical  Social Behavior Describes the concept 
of social behavior as 
an exchange of goods. 
 
Emerson, 
1976 
Theoretical  Social Exchange 
Theory 
Provides an overview 
of the Social 
Exchange Theory. 
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Table 5  
 
Summary of Social Exchange Theory Literature (continued) 
 
Study Methodology  Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Culnan & 
Armstrong, 
1999 
Empirical 
study via 
secondary 
data analysis  
1000 U.S. 
adults 18 
years or 
older 
Information privacy 
concerns, 
procedural fairness, 
impersonal trust  
Companies can 
increase customer 
retention by 
recognizing 
procedural fairness. 
 
Milne & 
Rohm, 2000 
Empirical 
study via 
survey 
1508 
adults 
Awareness of 
information 
capture, knowledge 
of name removal 
mechanisms 
 
Consumers are 
unaware of data 
collection practices 
and name removal 
mechanisms. 
Xu, 2009 Theoretical  Information 
exchange, social 
contract, 
information control 
 
Privacy concerns 
influence information 
disclosure behavior. 
Yang &Wang, 
2009 
Empirical 
study via 
experiment 
238 
Taiwan 
undergrad
uate and 
graduate 
students 
Shopping Website 
ethical 
performance, 
perceived ethical 
performance of the 
site, trusting belief, 
trusting intention 
Consumers can 
distinguish between 
good and bad ethical 
websites.  
Perceived ethical 
performance may 
increase consumer 
trust in the website. 
 
 
  
Composite Indices 
There are certain phenomena that are too multifarious to express with an 
individual indicator.  According to Latuszynka (2012), the reputation of composite 
indices has increased over the years, and researchers have begun to use composite indices 
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to measure complex phenomena with multiple dimensions.  Srebotnjak (2007) wrote, 
“composite indicators are designed to measure a state, trend, or process that is the scope 
of policy decisions” (p. 14).  Latuszynka (2012) noted that “the most common application 
of composite indices are currently classifications (primarily rankings of countries 
performance) and forecasting (estimating market trends)” (p. 68).  Saisana, Saltelli, and 
Tarantola (2005) noted that the pros of composite indices are as follows; 
§ Composite indicators can be used to summarize complex or multi-dimensional 
issues, in view of supporting decision-makers.  
§ Composite indicators provide the big picture.  They can be easier to interpret 
than trying to find a trend in many separate indicators.  They facilitate the task 
of ranking countries on complex issues.  
§ Composite indicators can help attracting public interest by providing a 
summary figure with which to compare the performance across countries and 
their progress over time.  
§ Composite indicators could help to reduce the size of a list of indicators or to 
include more information within the existing size limit. (p. 307) 
Saisana et al. (2005) further noted that the cons of composite indices are as follows: 
§ Composite indicators may send misleading, non-robust policy messages if 
they are poorly constructed or misinterpreted.  Sensitivity analysis can be used 
to test composite indicators for robustness. 
§ The simple "big picture" results which composite indicators show may invite 
politicians to draw simplistic policy conclusions.  Composite indicators should 
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be used in combination with the sub-indicators to draw sophisticated policy 
conclusions. 
§ The construction of composite indicators involves stages where judgment has 
to be made: the selection of sub-indicators, choice of model, weighting 
indicators, and treatment of missing scores, etc.  These judgments should be 
transparent and based on sound statistical principles.  
§ There could be more scope for Member States about composite indicators 
than on individual indicators.  The selection of sub-indicators and weights 
could be the target of political challenge.  
§ The composite indicators increase the quantity of data needed because data 
are required for all the sub-indicators and for a statistically significant 
analysis. (p. 308) 
 In order to derive a composite index, the following four steps are required: (a) 
variables that are correlated with the phenomenon must be selected, (b) variables must be 
normalized and standardized, (c) weights must be assigned to each variable, and (d) 
aggregation of information (Latuszynka, 2012; Muro, Mazziotta, & Paretto, 2011). 
“Indicators should be aggregated and weighted according to the underlying theoretical 
framework” (OECD/JRC, 2008, p. 15).  Muro et al. (2011) noted that there are three 
ways to aggregate the information: arithmetic mean, factorial analysis, and power mean 
or adjusted mean.  The arithmetic mean approach is “that the weights of the components 
are completely arbitrary” (Muro et al., 2011, p. 5).  Arithmetic mean has two approaches: 
simple (non-weighted) mean and weighted mean.  The simple mean approach “implies 
that all the weights are equal and that all components (dimensions) are perfectly suitable” 
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(Muro et al., 2011, p. 5).  OECD/JRC (2008) noted that this approach could “disguise the 
absence of a statistical or an empirical basis, e.g. when there is insufficient knowledge of 
casual relationships or a lack of consensus on the alternative” (p. 31).  In addition, 
OECD/JRC (2008) contended that caution should be taken when variables are grouped in 
dimensions, because some groupings “could result in an unbalanced structure in the 
composite index” (p. 31).  Moreover, OECD/JRC (2008) argued that an element of 
double counting could be introduced when highly correlated variables are combined.  
With the weighted mean, “the weights are not equal, this implies that the substitutability 
between components is not perfect” (Muro et al., 2011, p. 5).  Next, the factorial analysis 
uses a statistical technique to assign the weights, rather than the researcher (Muro et al., 
2011). OECD/JRC (2008) noted that that this approach can be used to group indicators 
based upon the extent of their correlation.  Muro et al. (2011) stated that the factorial 
analysis has two limitations.  The first limitation is that because the weights are acquired 
based upon the data, they are not stable over time and space, which can make it difficult 
to compare results (Muro et al., 2011).  Likewise, OECD/JRC (2008) stated that with 
correlated based indicators, the estimation of the weights cannot occur if there is no 
correlation.  The second limitation is that weights are assigned “to the original variables 
on the basis of their variance and covariance” (Muro et al., 2011, p. 5).  The last approach 
to aggregate information is the power mean, which assigns greater weight on the lower 
developed dimensions (Muro et al., 2011).  Likewise, the adjusted mean “adjusts the 
arithmetic mean by using a penalty coefficient or function” (Muro et al., 2011, p. 5). 
This research study will create the PIPVI composite index based upon indicators 
identified from a review of literature that will also be validated by an expert panel.  Next, 
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the weight assignment approach was used and based upon the mean response from the 
expert panel.  Finally, the aggregation was also conducted using the weighted mean 
approach.  
 
Table 6 
Summary of Composite Indices Literature  
 
Study Methodology Sample Instrument or 
Construct 
Main Finding or 
Contribution 
Latuszynka, 
2012 
Literature 
review and 
analysis 
 Composite indices Provides an overview of 
incorporating dynamic 
rankings of measured 
items and using 
composite indices to 
measure the complex 
phenomena. 
 
Muro et al., 
2011 
Literature 
review and 
proposal 
 
 Composite indices Provides a proposal for a 
new composite index.  
 
OECD/JRC, 
2008 
standard  Composite 
indicators 
construction guide 
Provides an overview of 
constructing and using 
composite indicators. 
 
Saisana et 
al., 2005 
  Composite 
indicators 
Provides an overview of 
composite indicators 
advantages and 
disadvantages along 
with using uncertainty 
and sensitivity analysis 
to assess composite 
indicators. 
Srebotnjak, 
2007 
Literature 
review and 
synthesis 
 Composite 
indicators 
Composite indicators 
provide a useful tool to 
aggregate data for policy 
considerations. 
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Delphi Expert Methodology 
The Delphi expert methodology was “devised in order to obtain the most reliable 
opinion consensus of a group of experts by subjecting them to a series of questionnaires 
in depth interspersed with controlled opinion feedback” (Dalkey & Helmer, 1963, p. 
458).  Because the expert panel feedback is not elicited face to face, this eliminates direct 
disagreement among the expert panel (Dalkey & Helmer, 1963; Jain, 1985).  Dalkey and 
Helmer (1963) noted that the Delphi expert methodology’s objective is “to obtain the 
most reliable consensus of opinion of a group of experts” (p. 458).  Ramim and Lichvar 
(2014) indicated that “the Delphi methodology is mainly used in the situation where 
accurate information is unavailable and human judgment input is crucial” (p. 127).  
Sarlak and Aliahmadi (2008) further stated that “the notion is that well informed 
individuals, calling on their insights and experience, are better equipped to predict the 
future than theoretical approaches or extrapolation of trends” (p. 1468).  McCubbrey and 
Taylor (2005) contended that the Delphi expert methodology includes the following nine 
steps:  
1. Define the problem – what is to be forecast and how will the results be used when 
available. 
2. Select knowledgeable and willing participants as a panel to respond to a 
questionnaire. The participants do not know one another and never meet face to 
face. 
3. Structure the questionnaire. 
4. Select the medium to be used to contact participants. 
5. Send the questionnaire (Round 1). 
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6. Compute the simple average of the results. 
7. Send a 2nd questionnaire (Round 2). 
8. Compute the average from the 2nd round results. 
Send a 3rd round questionnaire (Round 3). (p. 476) 
McFadzean, Ezingeard, and Birchall (2011) stated that the Delphi expert 
methodology “ensures that the data collection process is both reliable and valid because it 
exposes the investigation to differing, and often divergent, opinions and seeks 
convergence through structured feedback” (p. 108). 
 
Table 7 
Summary of Delphi Expert Methodology Literature 
 
Study Methodology Sample Instruments or 
Constructs 
Main Finding or 
Contribution 
Dalkey & 
Helmer, 
1963 
Empirical 
study via 
survey using 
the Delphi 
7 panel 
experts 
Factors that 
influence judgment 
The Delphi export 
methodology is beneficial 
in providing preliminary. 
 Expert 
methodology 
  Insights even though 
predictions derived by 
opinion consensus 
may lack reliability. 
 
Jain, 1985 Standard  Forecasting 
methods 
Provides a summary 
of the Delphi expert 
methodology process. 
 
 
 
 
  
 
63 
Table 7 
Summary of Delphi Expert Methodology Literature (continued) 
 
Study Methodology Sample Instruments or 
Constructs 
Main Finding or 
Contribution 
McCubbrey & 
Taylor, 2005 
Empirical 
study via 
survey using 
the Delphi 
expert 
methodology 
17 panel 
experts 
Effects of 
electronic 
commerce 
technology 
Delphi expert 
methodology was 
successful in 
predicting the effects 
that EC-enabled 
disintermediation and 
reintermediation 
would have on 
traditional travel 
agents in the US. 
 
McFadzean et 
al., 2011 
Empirical 
study via 
interviews and 
the Delphi 
expert 
methodology 
43 senior 
managers,  
36 
academics 
Information 
assurance, 
information 
systems, 
corporate 
strategy 
Information assurance, 
information systems, 
and corporate strategy 
alignment is essential 
to organizational 
success. 
 
Sarlak & 
Aliahmadi,  
(2008) 
Empirical 
study via 
survey using 
the Delphi 
expert 
methodology 
 
25 panel 
experts 
Trust factors Online and virtual 
universities must 
recognize factors 
effecting student trust. 
 
 
Summary of What is Known and Unknown 
A review of various aspects of personal information privacy was conducted to 
provide the foundation for this research study.  Through this review of the literature, the 
constructs of privacy policy, information sharing, and consumer control were identified 
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as they relate to personal information privacy violations. The literature review provides a 
description of what is known and unknown about the constructs in this research study.  
Research regarding personal information privacy extended across fields including IS, 
marketing, and business.  
Companies have benefited tremendously from the progression of technology by 
being able to easily integrate and aggregate information to create consumer profiles for 
targeting marketing (Jaisingh et al., 2008; Lanier & Saini, 2008; Rapp et al., 2009; Xu, 
2009).  However, this capability has also facilitated the growth of PIPV.  Belanger and 
Crossler (2011), as well as Vlasic (2006), stated that consumers are not aware of the 
various information collection practices of companies.  Due to continued media attention 
regarding personal information privacy violations and consumers’ perceptions of identity 
theft and spam, consumers are concerned about information management and use by 
companies (Roberts, 2009; Zimmer et al., 2010). 
Based upon studies by the FTC (1998, 2000) and the lack of privacy policies on 
Websites, the FTC recommended that companies adhere to the FIPs.  However, research 
continued to illustrate that companies were still not adhering to this recommendation 
(O’Connor, 2007; Sheehan, 2005; Storey et al., 2009).  It is important to note that the 
self-regulation instead of the legislative approach could be seen as a contributor since the 
adherence and monitoring is voluntary.  Storey et al. (2009) noted companies are aware 
that they cannot be held accountable for privacy practices that have not been stated. 
Furthermore, even though some companies have implemented privacy policies and 
adhere to the FIPs, this does not guarantee the actual practices will align with the stated 
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practices (Schwaig et al., 2005; Sheehan, 2005).  In this respect, there is limited empirical 
research that has examined the stated practices against the actual practices. 
Two of the top consumer concerns are loss of information control (Cromer, 2010; 
Hough, 2009; Poddar et al., 2009) and the information sharing practices of companies 
(Anton et al., 2010; Lanier & Saini, 2008; Pollach, 2007).  Consumers have continued to 
express that they have lost control when interacting with Websites.  Even though 
companies have attempted to address this concern by providing opt-out and opt-in 
capabilities, these options are not always easily accessible (Milne &Rohm, 2000).  Most 
companies implement the opt-out approach because the consumer will remain on the 
email list and information can be shared until a request for removal is initiated. 
Otherwise, with the opt-in approach, the company cannot send communications or share 
information until the consumer provides consent.  Spam statistics continued to 
demonstrate that companies’ participation in information sharing remained persistent 
(Bhuleskar et al., 2009; Ford, 2005).  However, there are limited empirical studies that 
have examined the magnitude of information sharing practices.  Pratt and Conger (2009) 
noted that it is essential to understand the information sharing practices of companies.  
The constructs of privacy policy (O’Conner, 2007), information sharing (Jafarr & 
Abdullat, 2009), and consumer control (Pollach, 2007) have been found to be 
contributors of PIPV.  Very limited empirical studies have been located with a 
comprehensive view of these constructs in a single study.  Therefore, more research is 
warranted to examine privacy policies, information sharing, and consumer control to 
determine their contribution to PIPV. 
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To assess the constructs above, this research study will focus on pharmaceutical 
companies’ Websites.  Consumers have begun to take a more active role in their 
healthcare and have increased their use of the Internet to obtain information.  In 
particular, the use of pharmaceutical websites has significantly increased over the years 
(Hoy & Park, 2014; W. J. Kim & King, 2009).  Because of this phenomenon, consumers 
are exposed to potential personal information violations when interacting with these 
Websites.  These Websites offer registration for newsletters, rebates, discount cards, and 
drug samples, which are all beneficial to consumers.  In order to obtain these benefits, 
consumers must disclose information.  However, consumers concerns are heightened 
when interacting with health related Websites due to the sensitivity of the information.  In 
addition, it is believed that potential inferences could be made based upon information 
disclosed and possibly used against the consumer for other purposes, such as employment 
or health care coverage decisions (Bansal et al., 2010).  Therefore, assessing the privacy 
policy, information sharing, and consumer control of pharmaceutical companies may 
provide a better understanding of their contribution to PIPV.  
 
Contributions of Research Study 
This research study made several contributions to the information privacy domain 
and body of knowledge.  The main contribution of this research study was to advance the 
awareness of PIPV.  First, empirical evidence was provided regarding the magnitude of 
voluntary adherence to the Fair Information Practices by pharmaceutical companies.  
This evidence is important to regulators and associations to assist with understanding the 
effectiveness of self-regulation.  Second, this research study provided insight into the 
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documented and actual online practices of pharmaceutical companies that contribute to 
personal information privacy violations.  Assessment of the documented and online 
practices in one study validated whether companies are actually adhering to their 
documented practices.  Differences based upon condition type, registration type, 
headquarters country/region, company size, annual revenue, years in service, and PII 
collection was also examined.  Third, companies can use the PIPVI benchmarking 
instrument to perform a self-assessment of their Website documented and online 
practices.  Last, given the heightened concerns of consumers regarding personal 
information privacy, the results of this research study provided consumers with empirical 
evidence of how their information is managed and used by pharmaceutical companies.  A 
high magnitude of personal information privacy violations could negatively impact 
consumers’ trust, concerns, and interactions with the Websites, which could continue to 
constrain the growth of e-commerce.  
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Chapter 3 
Methodology 
Overview  
Research Design 
     This research study was conducted in three phases, as shown in Figure 2.  The first 
phase developed the PIPVI benchmarking instrument that was used to assess the 
documented and online practices of Websites.  Ellis and Levy (2009) noted that 
“developmental research attempts to answer the question: How can researchers build a 
‘thing’ to address the problem?” (p. 326).  Developmental research should include three 
critical components (Ellis & Levy, 2009).  First, “establishing and validating criteria the 
product must meet” (Ellis & Levy, 2009, p. 326).  Reviewing and establishing the criteria 
of DPPP, OPIS, and OPCC from literature on this topic met this critical component. 
Second, “follow a formalized, accepted process for developing the product” (Ellis & 
Levy, 2009, p. 326).  This second component was met by creating a set of questions from 
literature that was used to develop the PIPVI benchmarking instrument.  In phase one, an 
expert panel using the Delphi expert methodology evaluated the draft of the PIPVI 
benchmarking instrument.  For this expert panel, at least 35 individuals from academia 
and practitioners in the field of information security and privacy, as well as corporate 
social responsibility, were solicited to participate from professional contacts with those 
associated to this project and membership in professional societies.  In addition, a 
message was posted to LinkedIn contacts and Information Security Groups.  After 
consensus was achieved through several iterations with the expert panel, the feedback 
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was incorporated to create the final PIPVI benchmarking instrument. The last component 
is “subjecting the product to a formalized, accepted process to determine if it satisfies the 
criteria” (Ellis & Levy, 2009, p. 326).  To satisfy this component, the expert panel was 
requested to evaluate the documented and online practices criteria, as well as assess the 
relative importance of each criterion in DPPP, OPIS, and OPCC. The relative importance 
of each criterion within each measure (DPPPM, OPISM, & OPCCM), along with the 
relative importance of the measures, was aggregated to develop the PIPVI. 
 
                
                 Figure 2: Research Methodology 
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In phase two of this research study, the final PIPVI benchmarking instrument was 
used to collect data from pharmaceutical Websites that market chronic and non-chronic 
prescription medications directly to consumers.  This research study occurred over a five-
month time period with no interventions. The time delay is necessary to observe and 
collect data from the companies’ practices over a period of five months to enable the 
assessment of spam, secondary use, and information sharing. O’Connor (2007) and White 
(2010) used a time delay.  For example, O’Connor (2007) collected data for one year to 
assess secondary use of information by registering for newsletters, competitions, and 
loyalty programs on 97 hotel Websites.  
To assess the pharmaceutical company’s DPPP, a copy of the privacy policy was 
downloaded and analyzed against the FIPs using assessments by Culnan (2000), FTC 
(2000), O’Connor (2007), Schwaig et al. (2005, 2006), Sheehan (2005), and Storey et al. 
(2009) as the foundation for development of the PIPVI benchmarking instrument.  The 
aforementioned studies used a survey instrument with a binary coding scheme that was 
used in this research study to represent the presence or absence of each criterion with 
levels: no (0) and yes (1).  It is important to note that the questions for this research study 
for these criteria were structured such that a response of yes indicated a violation.  
Registration for a newsletter, update, discount, or support program was initiated 
with a unique name and email address for each Website to assess the types of PII 
collected, OPIS, and OPCC.  It is important to note that where applicable, multiple 
registrations per Website were initiated with a unique name and email address if the 
Website allowed registration for different activities. For example, some Websites allowed 
registrations for both updates and discounts.  In addition, multiple Website registrations 
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occurred with different selections for opt-in/opt-out selections for secondary use and third 
party sharing, as well as the patient or caregiver.  The use of a unique name and email 
address for each registration maintained data integrity to facilitate accurate descriptive 
metrics for each pharmaceutical company Website.  Otherwise, it would have been a 
potential challenge to determine accurate metrics for the origination of emails to assess 
OPIS for each pharmaceutical company Website.  To assess OPIS, the number of emails 
received from the originating company, third parties, phone calls, and text messages were 
aggregated.  The Website registrations provided empirical evidence of the actual OPIS.  
The assessment criteria by O’Connor (2007) assessed the consumer’s ability to 
access, modify, and delete his or her information.  For example, an attempt was made to 
view, modify, and delete the information provided during the Website registration 
process.  This validation provided evidence of the actual OPCC that was used to validate 
against the DPPP.  Because pharmaceutical companies required a request by email, 
phone, or mail to delete personal information, this validation was beyond the scope of 
this research study. Similar to the assessment of the DPPP, a binary response will be 
recorded for each criterion with levels: no (0) and yes (1).  It is important to note that the 
questions for this research study for these criteria were structured such that a response of 
yes indicated a violation.  
To validate the documented practices against the actual online practices, the 
choice and access criteria from the DPPP and OPCC were assessed.  These criterions 
were evaluated to determine if pharmaceutical companies are actually adhering to their 
documented practices.  Given the nature of security and the inability to assess, the actual 
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practices for security are beyond the scope of this research study.   Therefore, security 
will only be assessed within the DPPP and not the actual online practices.   
Phase three of this research study included both the pre-analysis data screening 
and data analysis from the data collected using the PIPVI benchmarking instrument.  The 
results of the data analysis were used to develop the comparison reports to address the 
eight research questions and three null hypotheses.  The comparison report also included 
a graphical representation where appropriate. 
This research study required approval from the Institutional Review Board (IRB) 
because human subjects were involved for the expert panel.  The PIPVI benchmarking 
instrument elicited general demographics from the respondents.  However, the responses 
were anonymous to ensure that no PII was collected.   
 
Instruments and Measures 
Instrument Development 
Two instruments were developed for this research study.  The first instrument was 
developed to elicit responses from the expert panel.  This instrument elicited responses to 
assess the validity of the content for the criteria and measures identified, provide weight 
allocations of the relative importance for the criteria within DPPP, OPIS, OPCC, and the 
weight allocation of the relative importance for the DPPP, OPIS, and OPCC measures 
themselves that were used to develop the PIPVI.  The second instrument developed was 
the PIPVI benchmarking instrument that was used to collect data about the documented 
and online practices of the pharmaceutical companies’ Websites.  This instrument was 
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developed based upon the feedback from the expert panel using the Delphi expert 
methodology. 
The Personal Information Privacy Violations Index Expert Panel Instrument in 
Appendix B was administered using SurveyMonkey®, which is a web-based tool that 
collects anonymous responses from the expert panel.  The respondents of the expert panel 
received a message with the details of the research study and an invitation to participate. 
In an effort to elicit additional respondents, a message was also posted to LinkedIn 
contacts and Information Security groups. 
The PIPVI benchmarking instrument, as depicted in Appendix A, was developed 
to collect data from pharmaceutical companies’ Websites to measure the contribution of 
DPPP, OPIS, and OPCC on personal information privacy violations.  This instrument 
was also created using Microsoft Word® to facilitate data collection from the 
pharmaceutical companies’ Websites.  The items for measurement in the PIPVI 
benchmarking instrument were a minimally modified version derived from prior pertinent 
studies (Culnan, 2000; FTC, 2000; O’Connor, 2007; Schwaig et al., 2005, 2006; 
Sheehan, 2005; Storey et al., 2009) along with feedback from the expert panel using the 
Delphi expert methodology.  The instruments used in those studies included as many as 
31 items with a nominal scale, which was the approach that was adopted for this research 
study.  Inter-rater reliability was used by the aforementioned studies to evaluate the 
reliability and validity of the instruments with estimates between .89 and 1, which is 
considered to be reliable.  According to Creswell (2002), inter-rater reliability means that 
“two or more individuals observe an individual’s behavior and record scores, and then the 
scores of the observers are compared to determine whether they are similar” (p. 182).  
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Documented Practices of the Privacy Policy Measure 
The DPPP construct was measured using items to assess the pharmaceutical 
company’s privacy policy adherence to the FIPs.  Notice, choice, security, and access are 
the four principles by which the privacy policy was assessed using a nominal scale with 
levels: no (0) and yes (1).  The questions were structured such that a yes response 
indicated a violation.  The items used to measure DPPP were derived from FTC (2000), 
O’Connor (2007), Schwaig et al. (2006), Sheehan (2005), and Storey et al. (2009), whose 
items were structured such that a yes response indicated the presence of the item.  First, 
notice was measured using five items to assess the communication of the pharmaceutical 
company’s Website information collection practices.  Second, choice was measured using 
four items to assess the pharmaceutical company’s Website practice for consumer’s 
ability to control future communications and information disclosure to third parties. 
Third, access was measured using three items to assess the pharmaceutical company’s 
Website ability to enable consumers to retrieve and modify their information.  Last, 
security was measured using two items to assess the pharmaceutical company’s 
information protection practices. 
Online Practices of Information Sharing Measure 
The OPIS construct was measured using items to assess the pharmaceutical 
company’s Website actual practices for information sharing using a ratio scale to capture 
the actual volume of emails and postal mail received.  According to Sekaran (2003), ratio 
scale is “a scale that has an absolute zero origin, and hence indicates not only magnitude, 
but also the proportion of the differences” (p. 422).  The items used to measure OPIS 
were derived from O’Connor (2007), whose items to measure the actual online practices 
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were structured such that a yes response indicated the presence of the item.  To the 
contrary, instead of assessing the presence of information sharing, this research study will 
assess the actual volume of data received online, through postal mail, phone calls, and 
text messages from the pharmaceutical company, as well as third parties.  The volume of 
additional communications from the pharmaceutical company unrelated to the original 
request to represent internal information sharing or secondary use of information was 
measured with two items.  Similarly, two additional items were used to measure the 
volume for actual receipt of communications from third parties. 
Online Practices of Consumer Control Measure 
The OPCC construct was measured using items to assess the pharmaceutical 
company’s actual practices for allowing the consumer to control receipt of future 
communications from the original company and third parties.  Choice and access were 
assessed using a nominal scale with levels: no (0) and yes (1).  The questions were 
structured such that a yes response indicated a violation.  FTC (2000), O’Connor (2007), 
Schwaig et al. (2006), Sheehan (2005), and Storey et al. (2009) included items in the 
DPPP construct to measure the pharmaceutical company’s stated policies for choice and 
access, which represents the consumer’s ability to control distribution and access to their 
information.  For this research study, the items were slightly modified to capture 
responses for the actual consumer control practices of choice and access.  O’Connor 
(2007) measured the actual practices of choice and access of hotel Websites such that a 
yes response indicated the presence of the item.  This research study followed the same 
approach for consumer control that was measured using four items to assess the 
pharmaceutical company’s actual practice for allowing consumers to control receipt of 
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future communications from original company and third parties. In addition, three items 
were used to measure the consumer’s ability to access their personal information.  
Documented Practices versus Actual Online Practices 
The documented versus the actual OPCC was measured using items from the 
DPPP to assess the pharmaceutical company’s adherence to their stated practices.  Choice 
and access were assessed using a nominal scale with levels: no (0) and yes (1).  The 
questions were structured such that a yes response indicated a violation.  Choice was 
measured using four items to assess the pharmaceutical company’s Website practice for 
the consumer’s ability to control future communications and information disclosure to 
third parties.  Last, access was measured using three items to assess the pharmaceutical 
company’s Website ability to enable consumers to view, modify, or delete their 
information.  
Pharmaceutical Company Demographics 
 This research study collected demographics about each pharmaceutical 
company’s Website.  Consistent with Sheehan (2005) and Macias and Lewis (2003), the 
pharmaceutical company demographics included the pharmaceutical company name, 
headquarters country/region, company size, annual revenue, years in existence.  The 
demographics were used for descriptive statistics, such as frequencies and measures of 
central tendencies.  The pharmaceutical company demographic information was used to 
demonstrate that the sample is representative of the population.  Furthermore, the 
demographics were used as control variables for the comparison reports. 
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Reliability and Validity 
 Creswell (2002) stated that the reliability and validity of an instrument should 
provide “an accurate assessment of the variable and enable the researcher to draw 
inferences to a sample or population” (p. 180).  The reliability and validity of a 
measurement instrument is vital and is the first line of defense against inaccurate 
conclusions (Salkind, 2006).  Salkind (2006) further contended that “if the instrument 
fails, then everything else down the lines fails, as well” (p. 106).  McFadzean et al. 
(2011) noted that the Delphi expert methodology “ensures that the data collection process 
is both reliable and valid because it exposes the investigation to differing, and often 
divergent, opinions and seeks convergence through structured feedback” (p. 108). 
Therefore, to ensure validity and reliability, this research study elicited feedback from the 
expert panel to verify that the criteria used to generate the measures were appropriate to 
assess the documented and online practices. 
Instrument Reliability 
Creswell (2002) defined reliability as, “individual scores from and instrument 
should be nearly the same or stable on repeated administrations of the instrument, they 
should be free from sources of measurement error, and they should be consistent” (p. 
180).  Sekaran (2003) contended that reliability is important because it indicates the 
extent of un-bias and is an indication of stability and consistency.  
Validity 
 Validity is described as the ability to draw significant and valuable 
generalizations from the survey scores (Creswell, 2002).  Similarly, Salkind (2006) 
asserted that validity indicated that the test or instrument measures correspond to the 
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research intentions.  Creswell (2002) defined validity as the researcher’s ability to “draw 
meaningful and justifiable inferences from scores about a sample or population” (p. 185). 
Sekaran (2003) also noted that “validity ensures the ability of a scale to measure the 
intended concept” (p. 206).  Creswell (2002) further contended that five factors can 
hinder validity and the ability to draw valid conclusions: “(a) poorly designed studies; (b) 
participant fatigue, stress, and misunderstanding of question on the instrument; (c) 
inability to make useful predictions from scores; (d) poorly designed questions or 
measures of variables; and (e) information that has little use and application” (p. 185).  
Using previously validated instruments with minimal changes diminished the threat to 
validity for this research study.  According to Creswell (2002), there are three types of 
threats to validity: internal, external, and construct.  
Internal Validity 
 According to Straub (1989), “internal validity raises the question of whether the 
observed effects could have been caused by or correlated with a set of unhypothesized 
and/or unmeasured variables” (p. 151).  In other words, Sekaran (2003) referred to 
internal validity as “the confidence we place in the cause-and-effect relationship” (p. 
149).  Creswell (2002) and Sekaran (2003) noted that history, maturation, regression, 
selection, mortality, testing, and instrumentation are seven major threats to internal 
validity.  History, maturation, regression, selection, and mortality are related to 
participants in the study, while testing and instrumentation are related to the procedures 
of the study (Creswell, 2002).  
 Both the history and maturation threats involve uncontrollable changes during the 
length of the study that could influence the outcome (Creswell, 2002; Sekaran, 2003). 
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The limited duration of five months for this research study will alleviate history and 
maturation threats that could occur during a more elongated study.  Regression and 
selection entail researcher bias for participant selection that could influence the outcome 
(Creswell, 2002; Sekaran, 2003).  Creswell (2002) and Salkind (2006) agreed that 
random selection of participants would increase internal validity.  Therefore, regression 
and selection were prevented by randomly selecting pharmaceutical companies’ Websites 
that meet specific criteria.  Mortality is the attrition of participants during the research 
study (Creswell, 2002; Salkind, 2006; Sekaran, 2003).  Because this research study 
involves an expert panel using the Delphi expert methodology, mortality is a threat. 
While it was not expected that 100% participation would be maintained through the 
entire process, at least 25 respondents were expected.  
 As previously mentioned, testing and instrumentation are threats to internal 
validity related to procedures of the research study.  Testing poses a threat to internal 
validity when participants are exposed to a pretest that could later influence the outcome 
of the posttest (Creswell, 2002; Salkind, 2006; Sekaran, 2003).  Testing was not a threat 
for this research study because a pretest was not administered.  Next, Salkind (2006) 
stated that instrumentation is a threat because “when the scoring of an instrument itself is 
affected, any change in the scores might be caused by the scoring procedure, rather than 
the effects of the treatment” (p. 224).  Therefore, this research study used the expert panel 
survey for all iterations of the Delphi expert methodology to ensure consistency in 
responses and standardization.  This approach is supported by Creswell (2002), who 
noted that “procedures should be standardized so that the same observational scales or 
instrument is used throughout the experiment” (p. 327). 
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External Validity 
 “Threats to external validity are problems that threaten drawing correct inferences 
from the sample data to other persons, settings, and past and future situations” (Creswell, 
2002, p. 327).  Sekaran (2003) noted that eternal validity can be maximized by ensuring 
experiment conditions are compatible to the situations targeted for generalizations.  The 
generalization of this research study was expected to increase because the study took 
place in a non-contrived setting.  For instance, registrations were initiated on the actual 
pharmaceutical companies’ Websites to evaluate their documented and actual online 
practices, thereby reducing the threat to external validity.  
Instrument Validity 
 Straub (1989) contended that it is important to show evidence that the instrument 
is measuring what it intends to measure.  Straub (1989) added that an unrepresentative 
instrument would yield uncertain results.  There are two types of validation used to 
establish credibility of results: content and construct (Creswell, 2002; Salkind, 2006; 
Sekaran, 2003; Straub, 1989).  According to Creswell (2002), “content validity is the 
extent to which the questions on the instrument and the scores from the questions are 
representative of all the possible questions that could be asked about the content or skills” 
(p. 184).  Creswell (2002), Sekaran (2003), and Straub (1989) indicated that a panel of 
judges or experts could be used to validate the instrument content.  Hence, this research 
study solicited feedback from an expert panel using the Delphi expert methodology to 
validate the instrument content.  
 Construct validity is considered by Creswell (2002) as “a determination of the 
significance, meaning, purpose, and use of scores from an instrument” (p. 184).  Straub 
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(1989) contended that construct validity “asks whether the measures chosen are true 
constructs describing the event or merely artifacts of the methodology itself (p. 150). 
Straub (1989) recommended that “researchers should use previously validated 
instruments wherever possible, being careful not to make significant alterations in the 
validated instrument without revalidating the instrument content, constructs, and 
reliability” (p. 161).  Therefore, where appropriate, this research study used previously 
validated constructs from prior research (Culnan, 2000; FTC, 2000; O’Connor, 2007; 
Schwaig et al., 2005, 2006; Sheehan, 2005; Storey et al., 2009).  
 
Population and Sample 
The unit of analysis for this research study was the assessment results from the 
pharmaceutical companies’ Website registrations.  The sample population included 
pharmaceutical companies Websites headquartered in and outside of the US that provide 
information about prescription drugs.  The sample included Websites for prescription 
medications to treat the following chronic and non-chronic conditions: allergies, birth 
control, blood pressure, cholesterol, diabetes, erectile dysfunction, estrogen, frequent 
urination, infertility, menopause, peyronie’s disease, prostate, and testosterone.  A total of 
100 Website registrations across 53 Websites of 25 pharmaceutical companies were used 
for this research study using a convenience sampling.  Creswell (2002) noted that “in 
convenience sampling the researcher selects participants because they are willing and 
available to be studied” (p. 167).  In this research study, the 100 Website registrations of 
pharmaceutical companies were selected based upon an extensive Internet search of 
available Websites.  Sekaran (2003) indicated that “ample sizes larger than 30 and less 
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than 500 are appropriate for most research” (p. 295).  Sekaran (2003) further noted that 
“in multivariate research (including multiple regression analyses), the sample size should 
be several times (preferably 10 times or more) as large as the number of variables in the 
study” (p. 295).  Based upon Sekaran’s (2003) recommendation, a minimum sample size 
of 30 may be sufficient for a study with three independent variables.   
The pharmaceutical companies Websites sample was derived from Marcias and 
Lewis (2003) and Sheehan (2005) samples, supplemented with randomly selected 
Websites.  To be selected, the pharmaceutical company’s Website must have met the 
following criteria: (a) advertise pharmaceutical drugs in the US; (b) present information 
for a prescription drug; (c) have the capability to register for a newsletter, rebate, discount 
card, drug sample or support program; and (d) not provide the ability to purchase the 
prescription drug such as an online pharmacy.  Table 8 represents the pharmaceutical 
companies Website registration demographics by headquarters country/region.   
Table 8 
Pharmaceutical Companies Website Registrations by Headquarters Country/Region 
 Company Website Registration 
Headquarters 
Country/Region 
n % N % n % 
Asia 2 8% 5 9% 8 8% 
Europe 6 24% 17 32% 37 37% 
United Kingdom 1 4% 4 8% 5 5% 
United States 16 64% 27 51% 50 59% 
Totals 25 100% 53 100% 100 100% 
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Pharmaceutical Company Demographics 
Twenty-five pharmaceutical companies were examined.  The 
pharmaceutical companies were headquartered in Asia, Europe, UK, and the US.  
The revenue for the companies ranged from less than $1 million (2, 8%) all the 
way to $51 - $100 billion (4, 16%), and ranged in employees from less than 100 
(2, 8%) to over 100,000 (4, 16%).  The most common headquarters 
country/region was the US (16, 64%).  Table 9 presents frequencies and 
percentages for demographics for the pharmaceutical companies. 
 
Table 9 
Pharmaceutical Companies Demographics 
Demographic n % 
Annual Revenue 
  
 
Less than 1 million 2 8% 
 
1 - 50 million 6 24% 
 
51 - 100 million 3 12% 
 
101 - 500 million 2 8% 
 
501 - 999 million 2 8% 
 
1 - 50 billion 6 24% 
 
51 - 100 billion 4 16% 
Note. n=25. 
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Table 9 
Pharmaceutical Companies Demographics (continued) 
Demographic n % 
Company Size   
 Less than 100 2 8% 
 100 – 1000 8 32% 
 1001 - 25,000 7 28% 
 25,001 - 50,000 2 8% 
 75,001 - 100,000 2 8% 
 Over 100,000 4 16% 
Note. n=25. 
 
Pre-Analysis Data Screening  
Mertler and Vannatta (2010) contended that pre-analysis data screening is 
necessary and must be addressed prior to the statistical analysis.  Levy (2006) noted that 
“pre-analysis data preparation deals with the process of detecting irregularities or 
problems with the collected data” (p. 150).  Levy (2006) asserted that there are four 
primary purposes for pre-analysis data screening: data collection accuracy, response set, 
missing data, and outliers.  After these issues have been addressed, “the researcher can be 
confident that the main analysis will be an honest one, which will ultimately result in 
valid conclusions being drawn from the data” (Mertler & Vannatta, 2010, p. 25).  This 
research study used SurveyMonkey®, a Web-based tool, to facilitate data collection 
accuracy for the expert panel survey and Microsoft Word® for the PIPVI data collection 
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form.  The expert panel survey and the PIPVI data collection form elicited binary and 
minimal continuous responses to prevent inconsistent responses. 
Because this empirical developmental study examined several aspects of 
documented and online practices, it is imperative that the data collection is accurate.  
Inaccurate data collection can result from date entry or script errors (Levy, 2006).  
Mertler and Vannatta (2010) noted that “the results of any statistical analysis are only as 
good as the data analyzed” (p. 25).  If the data collection is inaccurate, the results will be 
misrepresented because it is difficult to discern if the results are invalid since results will 
appear to be legitimate (Mertler & Vannatta, 2010). Therefore, the results collected were 
reviewed several times to validate data collection and accuracy.  In addition, to determine 
the data accuracy, the data collected was examined using data frequency distributions, 
and descriptive statistics using Statistical Package for the Social Sciences (SPSS®), as 
recommended by Mertler and Vannatta (2010). 
Another issue that may have arisen during data collection was response set.  Levy 
(2006) defined response set as, “cases where respondents submitted the same score for all 
items” (p. 151).  Because this research study involved an expert panel, response set is 
valid for this research study.  If response set was detected, the data was examined to 
validate the responses and take the appropriate action, which may include excluding the 
response set from the sample.  
Missing data is another issue that must be addressed during data collection.  The 
data collected from the expert panel survey and PIPVI data collection form was examined 
for missing responses to ensure that each question had been completed.  Levy (2006) 
noted that “the amount of missing data can significantly affect the validity of the data 
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collected and the results drawn from it” (p. 151).  Because a Web-based tool was used to 
capture responses from the expert panel survey and PIPVI data collection form, missing 
scores are not expected.  
Identifying outliers during data collection was another issue that was addressed 
during pre-analysis data screening to prevent cases that would potentially distort results 
(Levy, 2006; Mertler & Vanata, 2010).  Mertler and Vannatta (2010) defined outliers as 
“cases with unusual or extreme values at one or both ends of a sample distribution” (p. 
27).  Because the responses were binary and open-ended, outliers for both the expert 
panel survey and PIPVI data collection form are not expected. 
 
Data Analysis 
Data analysis was conducted on two data sets.  The first data set represents data 
collection from the phase one expert panel survey responses.  The second data set from 
the PIPVI data collection form represents scores collected from 100 Website registrations 
that market chronic and non-chronic companies prescription medications.  As previously 
mentioned, the expert panel survey was completed using the Web-based tool 
SurveyMonkey® and Microsoft Word® for the PIPVI data collection form. 
Six types of analyses were conducted to assess the eight research questions and 
three hypotheses: frequencies and percentages, factorial analysis of variance (ANOVA), 
factorial analysis of covariance (ANCOVA), chi-square tests of independence, Pearson 
correlation, and Spearman correlation.  Mertler and Vannatta (2010) noted that the 
purpose of factorial ANOVA is “to determine group differences when two or more 
factors create these groups” (p. 90).  In order to conduct a factorial ANOVA, there must 
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be one dependent variable and more than one independent variable (Mertler & Vanatta, 
2010; Pallant, 2010; Terrell, 2012).  Terrell (2012) noted that there are four major 
assumptions for using the ANOVA.  First, the sample for the dependent variable should 
be random.  Second, “the scores must be independent of one another” (Terrell, 2012, p. 
245).  Third, the sample or population should be normally distributed (Terrell, 2012).  
Last, there must be homogeneity of variance; Terrell (2012) qualified that “the degree of 
variance within each of the samples should be about the same” (p. 245).  Mertler and 
Vannatta (2010) noted that ANCOVA is an extension of ANOVA in that it “adjusts the 
effects of variables that are related to the dependent variables” (p. 93).  With the 
ANCOVA, the effects of concomitant variables can be controlled for or partialed out of 
the results (Mertler & Vanatta, 2010).  Mertler and Vanatta (2010) stated that 
concomitant variables are variables considered to have an effect on the dependent 
variable; the variable that is partialed out is called the covariate.  Terrell (2012) noted that 
chi-square test of independence is similar to ANOVA except that this method involves 
counts of values.  Pallant (2010) further noted that this test involves categorical data.  The 
Spearman Correlation is valid for ordinal data or ranked data (Mertler & Vanatta, 2010; 
Pallant, 2010; Terrell, 2012).  This method is used to “explore the strength of the 
relationship between two continuous variables” (Pallant, 2010, p. 103).  Moreover, the 
Pearson correlation is appropriate for quantitative data, such as interval or ratio data 
(Mertler & Vanatta, 2010; Terrell, 2012). 
The first data set from the expert panel instrument was tabulated in the data 
screening process.  Those scores were placed into a table with responses from each expert 
panelist that represented their opinion regarding the criteria to measure personal 
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information privacy violations, as well as their weight recommendations for the criteria 
and measures for DPPP, OPIS, and OPCC.  Afterwards, the mean was computed for each 
criteria and measure.  It is important to note that the combined weights must total 100%, 
as the focus of the index is to evaluate the distribution of importance across all criteria 
measured.   
The second data set from the PIPVI benchmarking instrument was collected from 
100 Website registrations that market chronic and non-chronic prescription medications. 
Those scores were placed into a table with responses for each pharmaceutical company 
Website registration.  Once observed scores were tabulated and divided by the total 
criterion and multiplied by the Delphi expert panel mean weight for each criterion to 
compute the measures DPPPM, OPISM, and OPCCM.  These calculated measures were 
multiplied by the mean scores for the expert panel weights and combined to derive the 
PIPVI for the sample of pharmaceutical company Websites.  Figure 3 depicts how the 
index score was derived from the three measures and the germane criteria for each 
measure.  The calculated PIPVI was used to sort the data and compute the standard 
deviation (SD), which was used to develop the comparison report to address the research 
goals (See Eq. 1, 2, 3, & 4).  In addition, the table included responses that were translated 
into binary responses to represent the documented and the actual online practices of 
consumer control for choice and access.  Similarly, the table included responses that were 
translated to a binary response to represent the pharmaceutical company’s demographics, 
such as condition type (chronic or non-chronic), registration type (update or discount), 
headquarters country/region (Asia, Europe, United Kingdom, & United States), PII, size, 
annual revenue, and years in existence.  Mertler and Vannatta (2010) noted that data 
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analysis should include a more advanced technique if appropriate.  Upon completion of 
this data set, it was appropriate to conduct a factorial ANOVA, factorial ANCOVA, chi-
square test of independence, and Spearman correlations for further comparisons of the 
data based upon the pharmaceutical company’s condition type, registration type, 
headquarters country/region, PII collection, size, annual revenue, and years in existence 
to assess any significant differences in the DPPPM, OPISM, OPCCM, PIPVI, and the 
documented OPCC versus actual OPCC practices.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 
                       Figure 3: Hierarchical View of the Index, Measures, and Criteria of PIPVI 
 
Eq. 1: 𝐷𝑃𝑃𝑃𝑀 = 𝑤! ∙ !"#$%&!"#$%  !"#$%"#& + 𝑤! ∙ !!!"#$!"#$%  !"#$%"#& + 𝑤! ∙ !""#$$!"#$%  !"#$%"#& +𝑤! ∙ !"#$%&'(!"#$%  !"#$%"#&  
Eq. 2:  𝑂𝑃𝐼𝑆𝑀 = 𝑤!" ∙ !"#$%&'()  !"#!"#  !"  !"#$%& + 𝑤!" ∙ !!!"#  !"#$%!"#  !"  !"#$%&  
Eq. 3: 𝑂𝑃𝐶𝐶𝑀 = 𝑤! ∙ !!!"#$!"#$%  !"#$%"#& + 𝑤! ∙ !""#$$!"#$%  !"#$%"#&  
Eq. 4: 𝑃𝐼𝑃𝑉𝐼 =𝑊!"""! ∙ 𝐷𝑃𝑃𝑃𝑀 +𝑊!"#$% ∙ 𝑂𝑃𝐼𝑆𝑀 +𝑊!"##$ ∙ 𝑂𝑃𝐶𝐶𝑀 
First, to assess the fifth, sixth, and seventh research question, frequencies and 
percentages were calculated for the DPPPM, OPISM, OPCCM, and PIPVI between 
pharmaceutical companies that market chronic and those that market non-chronic 
prescription medications.  In addition, a factorial ANOVA and chi-square tests of 
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independence were conducted to assess the statistical significance mean differences for 
DPPPM, OPISM, OPCCM, and PIPVI between pharmaceutical companies that market 
chronic and those that market non-chronic prescription medications.  
RQ5: Are there any statistical significance mean differences for DPPM between 
pharmaceutical companies that headquarters are based in United States 
versus Asia, Europe, or United Kingdom? 
RQ6: Are there any statistical significance mean differences for OPISM, OPCCM, 
and PIPVI between pharmaceutical companies that: (a) market chronic 
versus non-chronic prescription medications; (b) market registrations for 
prescription medication discounts versus updates; (c) their headquarters are 
based in United States, versus Asia, Europe, or United Kingdom?  
RQ7: Are there any significant differences between the documented and the 
actual online practices for choice, and access of pharmaceutical companies 
that: (a) market chronic versus non-chronic prescription medications; (b) 
market registrations for prescription medication discounts versus updates; 
(c) their headquarters are based in United States, versus Asia, Europe, or 
United Kingdom? 
 To assess the eighth research question, frequencies and percentages were 
conducted on the types of PII that are collected by pharmaceutical companies’ Websites 
over a five-month period.  As previously noted, PII is represented by information such as 
name, postal address, email address, phone or fax number, SSN, or credit card number 
(FTC, 2000).  In particular, for this research study, the capturing of name, postal address, 
email address, phone number, and SSN were assessed. Frequencies and percentage were 
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calculated to assess which PII are the most common among the pharmaceutical 
companies.  In addition, a factorial ANOVA and chi-square tests of independence were 
conducted to assess the statistical significance mean differences for OPISM, OPCCM, 
and PIPVI between pharmaceutical companies that collect a limited amount of PII and 
those that collect a high amount of PII. 
RQ8: Are there any statistical significance mean differences for OPISM, 
OPCCM, and PIPVI between pharmaceutical companies that collect a 
limited amount of PII and those that collect a high amount of PII? 
To assess the following three null hypotheses, a factorial ANCOVA, and 
Spearman correlations were conducted to assess the statistical significant difference for 
DPPPM, OPISM, OPCCM, and PIPVI when controlling for companies’ size, annual 
revenue, and years in existence. 
H1: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will 
not be significantly different when controlling for company size. 
H2: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will 
not be significantly different when controlling for annual revenue. 
H3: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will 
not be significantly different when controlling for years in existence. 
 
Resources 
The following resources were required for this research study: computer, Internet 
access, Microsoft Word®, Microsoft Excel®, SPSS®, post office box, and email accounts. 
Access to a computer, Internet, Microsoft Word®, Microsoft Excel®, and post office box 
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are currently available.  Statistical services were contracted prior to data analysis.  Email 
accounts were set up on a new domain that was purchased to accommodate the volume of 
emails and to maintain separation from personal email accounts.  Because this research 
study involved an expert panel, access to human subjects was required.  As a result, this 
research study required approval from the Institutional Review Board (IRB). 
 
Summary 
 Chapter three provided the methodology overview that was used in this research 
study.  This research study was considered developmental in nature and used qualitative 
methods to develop and validate the reliability of the PIPVI benchmarking instrument.  A 
discussion of methods that were used to answer the eight research questions and three 
hypotheses was presented.  The PIPVI benchmarking instrument was developed to assess 
the documented and online practices criteria using a literature review, in addition to 
feedback by an expert panel.  This process was initiated by identifying the assessment 
criteria from literature.  Next, an expert panel evaluated the questions used in the 
instrument and the feedback was used to revise the PIPVI benchmarking instrument until 
consensus was reached using the Delphi expert Methodology.  According to McFadzean 
et al. (2011), this methodology is acceptable to assess the reliability and validity of the 
PIPVI benchmarking instrument.  Issues pertaining to reliability and validity were 
discussed along with how they were mitigated.  
 Next, the population and sample for this research study were presented, which 
included the selection criteria for the Websites.  Furthermore, the pre-screening data 
analysis, along with the data analysis that was used to address the research questions and 
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hypothesis, were discussed.  Pre-screening data analysis is used to “detect irregularities or 
problems with the collected data” (Levy, 2006, p. 150).  Frequencies and percentages, 
factorial analysis of variance (ANOVA), and factorial analysis of covariance 
(ANCOVA), chi-square tests of independence, and Spearman correlations were used to 
assess the statistical significance mean differences for DPPPM, OPISM, OPCCM, and 
PIPVI.  Last, the chapter concluded with the resources that were used to conduct this 
research study.  
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 Chapter 4  
Results 
 
Overview 
 The results of this research study are presented in this chapter.  The analysis of the 
processes used for data collection, in addition to the method of statistical analysis used to 
initiate the data analysis, is included.  In phase one, the data collection for the expert 
panel using the Delphi Method and results will be presented. This will be followed by 
phase two – a data collection process used to attain the PIPVI data along with the pre-
analysis data screening of that data.  The conclusion of the chapter will include phase 
three, the results summary using the PIPVI benchmarking instrument, and the data 
analysis processes used.  
 
Expert Panel 
 The data initially collected for this research study was derived from an expert 
panel survey in the area of information privacy, information security, and corporate social 
responsibility.  For this phase of the research study, round I was conducted using the 
Delphi Method in early June 2014 and concluded late July 2014.  The following sections 
document the evolution of the PIPVI.   
Round I - Data Collection and Analysis 
 During this phase of the study, the goal of the first round for the expert panel was 
to corroborate the proposed measures and criteria, in addition to eliciting their 
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recommendation for the weight assignments.  The expert panel was comprised of 35 
individuals known to the researcher, including individuals in academia and individuals 
from professional society mailing lists.  The individuals were selected as described in 
Chapter 3.  An email that contained a link to a Web-based survey tool was used to record 
the opinions of the expert panel using the survey instrument shown in Appendix B and as 
explained in Chapter 3.  Twenty-five participants completed the survey.  It is important to 
note that because the survey was anonymous, it is not known how many respondents 
were from the email or professional society mailing group lists.  After tabulation of the 
survey responses, no responses were omitted.  Based upon the 35 individuals explicitly 
solicited, the survey response rate was 70% and a survey completion rate of 100%.  The 
survey results were examined in three segments. The first segment of analysis included 
the expert panel’s level of agreement regarding the proposed measures and criteria.  The 
second segment of analysis included the expert panel’s recommendations for the weight 
allocations to support the PIPVI measures and criteria.  Finally, an analysis of the 
respondent’s background and opinion of future Personal Information Privacy practices 
implemented on Websites are presented.  
Round I - Pre-Analysis Data Screening 
 Prior to data analysis for the data collected from the expert panel, pre-analysis 
data screening was conducted.  As previously noted, the four primary purposes for pre-
analysis data screening are to assess the data collected for accuracy, response set, missing 
data, and outliers (Levy, 2006).  After the expert panel completed the first round of the 
survey, pre-analysis data screening was conducted on the responses.  Because the survey 
was conducted using SurveyMonkey®, a Web-based tool, the responses were recorded, 
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tabulated, and assessed to ensure their completeness.  The survey design mitigated the 
submission of incomplete responses by ensuring that all questions required a response.  
Because the survey design used a Likert Scale to indicate level of agreement, there was 
opportunity for response set, but none was identified for exclusion.  If there were 
incomplete responses, they would have been excluded for the particular measure or 
criteria, instead of excluding the entire survey.  Again, none were identified for 
exclusion.  Last, no outliers were identified or excluded.  Therefore, after the four-step 
assessment, all 25 responses were complete and included in the data analysis.  
Expert Panel Characteristics 
The expert panel was solicited by email and professional society mailing lists. 
The invitation included a link to the survey.  Twenty-five respondents completed all 
aspects of the survey.  The survey included questions about the respondents’ opinions 
regarding the future of Website practices to address personal information privacy as 
presented in Table 10.  
 
Table 10  
Opinion of Future Personal Information Privacy Practices Implemented on Websites 
 
Opinion n % 
Personal Information Privacy practices implemented on Websites are 
adequate and companies will continue to adequately self-regulate over the 
next 10 years 
0 0% 
Personal Information Privacy practices implemented on Websites are 
adequate but companies need additional enforcement over the next 10 
years 
6 24% 
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Table 10  
Opinion of Future Personal Information Privacy Practices Implemented on Websites 
(continued) 
 
Opinion n % 
Personal Information Privacy practices implemented on Websites are 
inadequate and companies need additional enforcement over the next 10 
years 
15 60% 
None of the choices adequately capture my opinion. 4 16% 
 
Next, to obtain additional information about the expert panel, they were requested 
to provide information to describe additional characteristics about their background.  
They were requested to classify themselves as an academic, practitioner, or both.  Table 
11 represents their responses.  
 
Table 11 
Expert’s Self-Perception of Background 
Self-Perception n % 
I consider myself to be an academic 6 24% 
I am both an academic and a practitioner but am mostly focused on 
academics 
0 0% 
I consider myself to be an practitioner 12 48% 
I am both a practitioner and academic, but am mostly focused on the 
practitioner 
4 16% 
I consider myself to be evenly balanced as both a practitioner 
and academic 
3 12% 
 
Based upon their responses of their perceived roles of academic or practitioner, 
the respondents were questioned to acquire information regarding their experience.  The 
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subject matter experts who responded to the survey have taught for an average of five 
years and have published an average of two peer-reviewed journal articles in the area of 
information security/information privacy.  The expert panel had experience supervising 
students with a thesis or dissertation related to information security/information privacy.  
In addition, some experts have published non-peer-reviewed journal articles, books, or 
book chapters in the area of information security/information privacy.  They also have an 
average of six or more years of experience in multiple subject areas regarding 
information security/information privacy.  The mean responses are presented in Tables 12 
and 13. 
 
Table 12 
Academic Information Security/Information Privacy Experience 
Academic Experience  
Mean 
Years 
How many years have you taught undergraduate or Masters level students 
in courses that have included topics in Information Security/Information 
Privacy? 
5.36 
How may Doctoral students have you supervised with Information 
Security/Information Privacy-related theses or dissertations? 
0.18 
How many peer-reviewed journal articles have you published in the area 
of Information Security/Information Privacy? 
1.55 
How many other periodical articles (not PRJ) have you published in the 
area of Information Security/Information Privacy? 
0.64 
How many books or invited book chapters have you published in the area 
of Information Security/Information Privacy?  
0.45 
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Table 13 
Practitioner Information Security/Information Privacy Experience 
Practitioner Experience 
Mean 
Years 
Systems design which have involved at least some aspects of Information 
Security/Information Privacy 
8.47 
Systems development which has involved at least some aspects of 
Information Security/Information Privacy 
8.42 
Systems implementation which has involved at least some aspects of 
Information Security/Information Privacy 
10.74 
Project management or supervisory management which have involved at 
least some aspects of Information Security/Information Privacy 
9.63 
Employment or consulting engagement assignments have focused on 
building or improving Information Security/Information Privacy 
6.00 
Employment or consulting engagement have focused on evaluating 
Information Security/Information Privacy 
6.17 
Management assignments which have involved governance and/or policy 
creation related to Information Security/Information Privacy 
6.11 
 
 
Round I - PIPVI Measures and Criteria Validation  
The first round of the survey was for the expert panel to validate that the proposed 
measures and criteria were sufficient to measure personal information privacy violations.  
The expert panel was requested to specify their level of agreement for the questions 
regarding each of the measures and criteria.  Participants rated each question on a Likert 
scale from 1 = strongly disagree to 7 = strongly agree.  The highest level of agreement 
was for “access is an accurate component of Consumer Control to assess” with 96% of 
the respondents specifying at least somewhat agree (5) or above.  Between 17 (68%) and 
22 (88%) of the respondents at least somewhat agreed (5) or above to the remaining 
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criteria.  Hsu and Sanford (2007) recommended that the level agreement should be at 
least 70%.  Table 14 represents the percentage of the responses for those that specified 
“somewhat agree (5)” or above. 
 
Table 14 
Round I - Level of Agreement with Criteria  
Question n % 
DPPP-Notice   
 Notice is an accurate component of the Privacy Policy to assess 21 84% 
 The Privacy Policy components regarding personal information, 
collected along with secondary and third party use described 
above, provide an accurate assessment of notice violations 
19 76% 
DPPP-Choice   
 Choice is an accurate component of the Privacy Policy to assess 19 76% 
 The Privacy Policy components regarding opt-in/opt-out for secondary 
use and third party communications described above provide an 
accurate assessment of choice violations 
17    68% 
DPPP-Access   
 Access is an accurate component of the Privacy Policy to assess 19 76% 
 The Privacy Policy components to review, modify, and 
delete personal information collected described above provide an 
accurate assessment of Access violations 
18 72% 
DPPP-Security   
 Security is an accurate component of the Privacy Policy to assess 22 88% 
 The Privacy Policy components regarding the steps taken to provide 
security for information collected described above provide an accurate 
assessment of Security violations 
17 68% 
Note. n and % refer to those that specified “somewhat agree (5)” or above. 
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Table 14 
Round I - Level of Agreement with Criteria (continued) 
Question n % 
OPIS-Secondary Use   
 Secondary Use is an accurate component of Information Sharing to 
assess 
21 84% 
 The number of emails and regular mail received described 
above provide an accurate assessment of Secondary Use for 
Information Sharing 
18 72% 
OPIS-Third Party for the Choice   
 Third Party is an accurate component of Information Sharing to 
assess 
17 68% 
 The number of emails and regular mail received described 
above provide an accurate assessment of Third Party Use for 
Information Sharing 
17 68% 
OPCC-Secondary Use for the Choice   
 Secondary Use is an accurate component of Consumer Control to 
assess 
22 88% 
 The components to opt-in/opt-out of Secondary Use described 
above provide an accurate assessment of Secondary Use for 
Consumer Control violations 
20 80% 
OPCC-Third Party   
 Third Party component is an accurate component of Consumer 
Control to assess 
21 84% 
 The components to opt-in/opt-out of Third Party described 
above provide an accurate assessment of Third Party for Consumer 
Control violations 
20 80% 
OPCC-Access   
 Access is an accurate component of Consumer Control to assess 24 96% 
 The components to review, modify, and delete personal information 
collected described above provide an accurate assessment of Access 
for consumer control violations 
20 80% 
Note. n and % refer to those that specified “somewhat agree (5)” or above. 
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Table 14 
Round I - Level of Agreement with Criteria (continued) 
Question n % 
Personal Identifiable Information   
     Name 20 80% 
     Postal address 18 72% 
     Telephone number 20 80% 
     Social Security Number 20 80% 
Note. n and % refer to those that specified “somewhat agree (5)” or above. 
 
Round I - PIPVI Comments 
 All 25 respondents completed the survey with no exclusions identified.  After 
assessment of the data, including the comments from the expert panel, capturing the 
volume of phone calls/text messages was added to the criteria for OPIS to assess 
secondary and third party use.  Overall, the comments were general in nature, pertaining 
to the measures, criteria, and practices and did not warrant any further additions.  
Round I - PIPVI Weight Elicitation for Measures and Criteria 
In addition to requesting the experts to corroborate on the measures and criteria, 
they were requested to allocate the relative weights for the three measures DPPP, OPIS, 
and OPCC that will contribute to the PIPVI.  For DPPP, the experts were requested to 
allocate 100 points across the criteria of notice, choice, access, and security.  For OPIS, 
the experts were requested to allocate 100 points across the criteria of secondary and third 
party use.  For OPCC, the experts were requested to allocate 100 points across the criteria 
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of choice and access.  Table 15 represents the expert panel’s recommendation for the 
criteria mean weight allocations. 
 
Table 15 
Round I - PIPVI Criteria and Mean Weight Allocations  
 
Criteria Mean 
Weight 
Documented Practices of the Privacy Policy Criteria - DPPP  
   Notice 25% 
   Choice 22% 
   Access 20% 
   Security 33% 
Online Practices of Information Sharing criteria – OPIS  
   Choice: Secondary Use 55% 
   Choice: Third Party  45% 
Online Practices of Consumer Control Criteria – OPCC  
   Choice  58% 
   Access 42% 
Note. The mean weight allocations must total 100 for each criteria group. 
After the expert panel was requested to assign relative weights to the criteria, they 
were requested to provide relative weights to the overall measures (DPPPM, OPISM, 
OPCCM) that would contribute to personal information privacy violations.  Likewise, the 
experts were requested to allocate 100 points across the DPPPM, OPISM, and OPCCM 
measures within the PIPVI.  Table 16 represents the mean weight allocations suggested 
by the expert panel for the measures.      
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Table 16 
Round I - PIPVI Measures and Mean Weight Allocations 
Measure Mean 
Weight 
Personal Information Privacy Violations Index - PIPVI  
   Documented Practices of the Privacy Policy Measure - DPPPM 35% 
   Online Practices of Information Sharing Measure - OPISM 33% 
   Online Practices of Consumer Control Measure - OPCCM 32% 
Note. The mean weight allocations must total 100. 
 
Round II - PIPVI Measures and Criteria Weight Validation 
During this phase of the study, the goal of the second round of questioning was to 
obtain consensus from the expert panel regarding the mean weight assignments attained 
from the first round.  Twenty-three participants completed the survey.  It is assumed that 
these participants also participated in the first survey.  After tabulation of the survey 
responses, two responses regarding the weights for DPPPM were omitted because the 
recommended weight distribution did not total 100.  Based upon the 35 individuals 
explicitly solicited, the survey response rate was 66% and a survey completion rate 
between 91% and 100%.  Similar to round I, all respondents cannot be assumed from the 
email solicitation.  Because the survey was anonymous, it is not known how many 
respondents were from the professional group’s mailing lists.  The data analysis for this 
round was conducted on the expert panel’s opinions regarding the weight allocations for 
the measures and criteria.  
 The data initially collected for this research study was derived from same expert 
panel as round I survey.  This phase of the research study was conducted using the Delphi 
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Method in early August 2014 and concluded late September 2014.  The following 
sections presented further documents the evolution of the PIPVI.   
Round II - Data Analysis and Collection  
During this phase of the study, the goal of the second round of questioning was to 
obtain consensus from the expert panel regarding the mean weight assignments attained 
from the first round.  Twenty-three participants completed the survey.  This represents 
92% of the respondents from the first survey.  After tabulation of the survey responses, 
two responses regarding the weights for DPPPM were omitted.  Based upon the 35 
individuals explicitly solicited, the survey response rate was 66%, but also represents a 
response rate of 92% of the first respondents from the first survey.  The completion rate 
was between 91% and 100%.  The survey results were examined to analyze the expert 
panel’s opinion regarding the weight allocations for the measures and criteria.  Table 17 
presents the level of agreement with the criteria and measures weight allocations. 
 
Table 17 
Round II - Level of Agreement with Measure and Criteria Weight Allocations 
Measures and Criteria n % 
Documented Practices of the Privacy Policy Criteria - DPPP   
   Notice 16 70% 
   Choice 11 48% 
   Access 15 65% 
   Security 12 52% 
Note. n and % refer to those that specified “somewhat agree (5)” or above. 
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Table 17 
Round II - Level of Agreement with Measure and Criteria Weight Allocations (continued) 
Measures and Criteria n % 
Online Practices of Information Sharing criteria - OPIS   
   Choice: Secondary Use 17 74% 
   Choice: Third Party Use  17 74% 
Online Practices of Consumer Control criteria - OPCC   
   Choice  14 61% 
   Access 14 61% 
Personal Information Privacy Violations Index - PIPVI   
   Documented Practices of the Privacy Policy Measure - DPPPM 17 74% 
   Online Practices of Information Sharing Measure - OPISM 17 78% 
   Online Practices of Consumer Control Measure - OPCCM 17 78% 
Note. n and % refer to those that specified “somewhat agree (5)” or above. 
Round II - Pre-Analysis Data Screening 
 A second survey was distributed to the subject matter experts and 
professional mailing group lists to corroborate the percentage weights for each of 
the criteria and measures.  A total of 23 participants responded to the survey. 
However, it is important to note that due to the anonymous survey, it is assumed 
that the respondents participated in the first survey.  For this survey, the level of 
agreement ranged from 48% to 78%.  For the level of agreement between 48% 
and 65%, the mean weights for those who did not agree were within 5% of the 
proposed weight.  Therefore, the proposed weight was determined to be sufficient 
as indicated in the aforementioned Table 15 and Table 16. As a result, no 
additional rounds with the expert panel were required. 
 
  
 
107 
PIPVI  
 Phase two of the study encompassed data collection from the Website 
registrations using the final PIPVI benchmarking instrument.  The Website registrations 
occurred over a two-week period.  The first group of registrations who did not require a 
phone number occurred May 18 through May 23.  The next group of Website 
registrations occurred from June 8 through June 9 because a mobile phone was purchased 
to establish a unique phone number for this research study.  The data collection occurred 
over a period of late June 2014 to late October 2014.  The following sections will 
describe the process.  
Data Collection and Analysis 
 In phase two, the Website the PIPVI data collection was derived from several 
sources to examine the documented and online practices.  First, to examine the DPPP, 
data was collected from the downloaded privacy policy of each pharmaceutical company 
Website to provide response to the specified criteria as denoted in the final PIPVI 
benchmarking instrument.  The main DPPP data collection was conducted over four 
weeks from mid June to mid July.  Second, to examine the OPIS, the volume of emails, 
postal mail, phone calls, and text messages were calculated from each Website 
registration. The main OPIS data collection was conducted over one week in late 
October.  Third, to examine the OPCC, data from the Website registrations were 
collected based upon the availability of selections to opt-in/opt-out of secondary and third 
party use for both initial and after Website registration.  The main OPCC data collection 
was conducted over six weeks in early August 2014 to mid September 2014. In addition, 
data were collected based upon the ability to review, modify, and delete personal 
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information disclosed during the Website registration.  Based upon the availability of 
selections for opt-in/opt-out and the ability to review, modify, and delete personal 
information the response was recorded. Fourth, to examine the PII required for 
disclosure, data were collected from the Website registrations based upon registration 
type and the response was recorded.  
Pre-Analysis Data Screening 
 Although the data collection from phase three involved a manual effort instead of 
survey respondents, pre-analysis data screening was still required.  The pre-analysis data 
screening was performed on the data collected from the Website registrations.  First, the 
recorded responses were converted to binary responses, reviewed, tabulated in a 
spreadsheet, and assessed for accuracy.  Afterwards, the data was evaluated for a 
response set – none was identified.  Then, data was evaluated for omitted responses.  If 
responses were omitted, they were completed using the documented sources for the 
specific criteria.  Last, because the data was binary, no outliers were identified or 
expected.  If there were outliers, the response would have been completed using the 
documented sources for the specific criteria.  
Data Analysis 
  After the pre-data analysis screening was performed, the descriptive analysis was 
prepared. Descriptive statistics were calculated for the DPPPM, OPISM, OPCCM, and 
PIPVI to describe any significant differences as stated in the research questions and 
hypotheses.  Table 18 presents the summary of Website registrations by condition type, 
registration type, and headquarters country/region.  The findings are presented in the 
subsequent sections. 
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Table 18 
Pharmaceutical Company Website Registrations by Condition Type, Registration Type, 
and Headquarters Country/Region 
 
   Condition Type Registration Type 
Headquarters 
Country/Region 
Pharmaceutical 
Company  
Website 
Registrations 
Chronic Non-
Chronic 
Discount Update 
 
Asia 2 8 6 2 6 2 
Europe 6 37 24 13 15 22 
United Kingdom 1 5 0 5 3 2 
United States 16 50 19 31 24 26 
Totals 25 100 49 51 48 52 
 
Documented Practices of the Privacy Policy (DPPP) 
 Twenty-five different pharmaceutical companies were examined for their 
documented practices of the privacy policy (DPPP).  These were the same 25 
pharmaceutical companies from above.  The valid range for DPPPM scores were 
0.00 to 1.00, with 0.00 representing no violations and 1.00 representing 
violations.  The higher the score, the more DPPP violations occurred.  Based upon 
the assessment of DPPP, the DPPM scores ranged from 0.00 to 0.85, with a mean 
of 0.39 (SD = 0.24).  Both the lowest and highest score for DPPPM was for 
pharmaceutical companies that headquarters country/region are in the US. A 
Pearson correlation conducted between the last time their privacy policy was 
updated and the measure for DPPP was not significant (r = -0.13, p = 0.687).  
These scores suggest that there was no difference between how long it’s been 
since the privacy policy has been updated and the DPPPM. 
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 Next, ANOVAs were conducted to assess if there were differences between the 
DPPPM by condition type, registration type, and headquarters country/region.  Results of 
the ANOVA by condition type (chronic and non-chronic) were not significant, F(1, 98) = 
3.11, p = 0.081, partial η2 = 0.03, suggesting there were no differences in the DPPPM by 
condition type.  Results were similar for registration type (update and discount), F(1, 98) 
= 2.54, p = 0.114, partial η2 = 0.03, suggesting there were no differences in the DPPPM 
by registration type.  The ANOVA conducted for headquarters country/region was also 
not significant, F(3, 21) = 1.86, p = 0.168, partial η2 = 0.21, suggesting there were no 
differences in the DPPPM by headquarters country/region.  Table 19 presents the 
ANOVA results by condition type, registration type, and headquarters country/region. 
 
Table 19  
ANOVA Results for DPPPM by Condition Type, Registration Type, and Headquarters 
Country/Region 
 
Control Variable SS df MS F p Partial η2 
Condition Type 0.02 1 0.02 3.11 0.081 0.03 
Error 0.63 98 0.01    
Registration Type 0.02 1 0.02 2.54 0.114 0.03 
Error 0.63 98 0.01    
Headquarters Country/Region 0.28 3 0.09 1.86 0.168 0.21 
Error 1.06 21 0.05    
 
 Spearman correlations were conducted to assess the difference between company 
size, annual revenue, and years in existence with DPPPM.  Results of the correlations 
were all not significant.  Results of the correlations are presented in Table 20. 
  
 
111 
Table 20 
Spearman Correlations between Company Size, Annual Revenue, Years in Existence, and 
DPPPM 
 
Control Variable DPPPM 
Company Size -0.28 
Annual Revenue  0.03 
Years in Existence  0.14 
Note. All p > .050. 
Because adherence with the FIPs is self-regulated, it is important to have insight 
into pharmaceutical companies’ compliance.  Both Europe and UK demonstrated higher 
overall adherence to the FIPs than Asia or US.  Table 21 presents the percentage 
compliant with all aspects of the FIPs criteria by headquarters country/region.   
 
Table 21 
Pharmaceutical Company Adherence to FIPs 
 
Headquarters 
Country/Region 
Notice Choice Access Security 
Asia 100% 0% 0% 0% 
Europe 83% 17% 67% 67% 
United Kingdom 100% 0% 100% 100% 
United States 75% 13% 25% 38% 
 
Online Practices of Information Sharing (OPIS) 
 The data collected from the 100 Website registrations examined for online 
practices of information sharing (OPIS).   The Website registration data was comprised of 
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49 chronic and 51 non-chronic conditions and registration types of 48 as discounts and 52 
as updates.  The headquarters country/region for the Websites were primarily from the 
US.  The number of emails received from the Website registrations ranged from 0 to 36. 
Surprisingly, no emails were received from 34 Website registrations across 21 unique 
Websites.  Pharmaceutical companies with headquarters country/region in the US and 
Europe were respectively the top two that received no emails from Website registrations. 
The summary of emails received from the Website registrations are presented in Table 
22. 
 
Table 22 
Summary of OPIS Emails Received from Website Registrations 
 
Emails Received n % 
     0 34 34% 
     1 18 18% 
     2 – 5 24 24% 
     6 – 10 14 14% 
     11 - 36 10 10% 
 
 ANOVAs were conducted to assess if there were differences in OPISM scores by 
condition type, registration type, and headquarters country/region.  The valid OPISM 
scores range from 0.00 to 1.00, with 0.00 representing no violations and 1.00 representing 
violations.  The higher the score, the more OPIS violations occurred.  Based upon the 
assessment of OPIS, the OPISM scores ranged from 0.00 to 0.55, with a mean of 0.03 
(SD = 0.12).  The highest score was from a pharmaceutical company that headquarters 
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country/region is the US.  Results of all the ANOVAs were not significant, p > .050 for 
all, suggesting that there were no differences found.  Table 23 presents the results of the 
ANOVAs. 
 
Table 23 
ANOVA Results for OPISM by Condition Type, Registration Type, and Headquarters 
Country/Region 
 
Control Variable SS Df MS F P Partial η2 
Condition Type 0.00 1 0.00 0.16 0.691 0.00 
Error 1.32 98 0.01    
Registration Type 0.00 1 0.00 0.16 0.689 0.00 
Error 1.32 98 0.01    
Headquarters Country/Region 0.10 3 0.03 2.55 0.600 0.07 
Error 1.22 96 0.01    
Note. p > 0.050. 
 Spearman correlations were also conducted to assess the differences between 
emails, company size, annual revenue, and years in existence with OPISM scores.  
Results of the correlations showed that emails, r = 0.37, p < .001, annual revenue, r = -
0.27, p = 0.006, and years in existence were all correlated to OPISM scores.  As the 
volume of emails and years in existence increased, OPISM scores also tended to increase.  
These scores suggest that the longer the company is in existence and the more emails are 
distributed, the risk is greater for companies to share information.  Additionally, as the 
annual revenue of the company increased, OPISM scores tended to decrease.  To the 
contrary, these scores suggest that as the company’s annual revenue increases, the risk is 
less for sharing information.  Results of the correlations are presented in Table 24. 
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Table 24  
Spearman Correlations between Emails Received, Company Size, Annual Revenue, and 
Years in Existence, and OPISM 
 
Control Variable OPISM 
Emails Received    0.37** 
Annual Revenue   -0.27** 
Company Size 0.09 
Years in Existence     0.35** 
Note.  * p ≤ .050.  ** p ≤ .010.  Otherwise p > .050. 
Online Practices of Consumer Control (OPCC) 
 The online practices of consumer control (OPCC) scores were examined next.  A 
total of 60 registration types were examined.  This measure was based upon the 
registration types of discount and update.  While there were 100 Website registrations, 
each registration was initiated for a discount or update even though multiple Website 
registrations occurred for a particular registration type for each Website.  For example, 
two Website registrations could have been initiated for a discount for the same Website, 
but the difference was the selections for opt-in/opt-out.  Because the criteria for consumer 
control would be the same for both registrations, this was considered one registration type 
for the particular Website instead of two when measuring consumer control.  Details were 
similar to the previous OPISM registrations.  Table 25 presents the descriptive statistics 
for the details for OPPCM Website registration types. 
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Table 25  
Summary of OPCCM by Condition Type, Registration Type, and Headquarters 
Country/Region  
 
Control Variable n % 
Condition Type   
     Chronic 30 50% 
     Non-Chronic 30 50% 
Registration Type   
     Discount 27 45% 
     Update 33 55% 
Headquarters Country/Region   
     Asia 5 8% 
     Europe 16 27% 
     United Kingdom 4 7% 
     United States 35 58% 
Note. n=60 for each control variable. 
 ANOVAs were conducted to assess if there were differences in OPCCM scores 
by condition type, registration type, and headquarters country/region.  The valid OPCCM 
scores range from 0.00 to 1.00, with 0.00 representing no violations and 1.00 representing 
violations.  The higher the score, the more OPCC violations occurred.  Based upon the 
assessment of OPCC, the OPCCM scores ranged from 0.15 to 1.00, with a mean of 0.73 
(SD = 0.25).  The lowest score was from a pharmaceutical company that headquarters 
country/region is Europe.  Results of the ANOVAs showed significant differences in 
OPCCM scores by condition type, F(1, 58) = 5.25, p =  0.026, partial η2 = 0.08.  OPCCM 
scores for chronic conditions tended to be significantly lower than scores for non-chronic 
conditions.  These scores suggest that consumers appear to have more control over their 
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data for chronic conditions than for non-chronic conditions.  The ANOVAs by 
registration type and headquarters country/region were not significant, p > .050 for both.  
Table 26 presents the results of the ANOVAs. 
 
Table 26 
ANOVA Results for OPCCM by Condition Type, Registration Type, and Headquarters 
Country/Region 
 
Control Variable SS df MS F P Partial η2 
Condition Type 0.31 1 0.31 5.25 0.026 0.08 
Error 3.37 58 0.06    
Registration Type 0.21 1 0.21 3.45 0.068 0.06 
Error 3.47 58 0.06    
Headquarters Country/Region 0.44 3 0.15 2.54 0.066 0.12 
Error 3.24 56 0.06    
 
Spearman correlations were also conducted to assess the differences between 
company size, annual revenue, and years in existence with OPCCM scores.  Results of 
the Spearman correlations were not significant for all correlations, p > .050 for all.  
Results of the correlations are presented in Table 27. 
Table 27 
Spearman Correlations between Company Size, Annual Revenue, Years in Existence, and 
OPCCM 
 
Control Variable OPCCM 
Company Size -0.22 
Annual Revenue -0.04 
Years in Existence -0.01 
Note.  All p > .050. 
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Personal Information Privacy Violations Index (PIPVI) 
 The personal information privacy index (PIPVI) scores were examined next.  A 
total of 100 Website registrations were examined.  See Table 18 above for summary by 
condition type, registration type, and headquarters country/region.  ANOVAs were 
conducted to assess if there were differences in PIPVI scores by condition type, 
registration type, and headquarters country/region.  The valid PIPVI scores range from 
0.00 to 1.00, with 0.00 representing no violations and 1.00 representing violations. The 
higher the score, the more PIPVI violations occurred.  PIPVI scores ranged from 0.06 to 
0.62, with a mean of 0.34 (SD = 0.12).   The lowest score was for a pharmaceutical 
company that headquarters country/region is in Europe and the highest score was in the 
US. Results of the ANOVAs showed significant differences in PIPVI scores by condition 
type, F(1, 98) = 11.76, p = 0.001, partial η2 = 0.11.  PIPVI scores for chronic conditions 
tended to be significantly lower than scores for non-chronic conditions.  These scores 
appear to suggest that fewer personal information privacy violations occur for chronic 
conditions than for non-chronic conditions. The ANOVA for PIPVI scores by registration 
type was also significant, F(1, 98) = 5.12, p = 0.026, partial η2 = 0.05.  PIPVI scores for 
discount registration types tended to be significantly higher than update PIPVI scores.  
These scores appear to suggest that more violations occur with Website registrations for 
discounts than for updates.  Finally, PIPVI scores were significantly different by 
headquarters country/region, F(3, 96) = 6.48, p < .001, partial η2 = 0.17.  Post hoc 
pairwise comparisons showed that European PIPVI scores tended to be significantly 
lower compared to US PIPVI scores.  These results appear to suggest that European 
countries might be more responsible with management and use of consumer personal 
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information.  Table 28 presents the results of the ANOVAs, and Table 29 represents the 
mean and standard deviations.  Figure 4 represents the measures contributions to PIPVI 
by headquarters country/region. 
 
Table 28 
ANOVA Results for PIPVI by Condition Type, Registration Type, and Headquarters 
Country/Region 
 
Control Variable SS df MS F p Partial η2 
Condition Type 0.16 1 0.16 11.76 0.001 0.11 
Error 1.34 98 0.01    
Registration Type 0.07 1 0.07 5.12 0.026 0.05 
Error 1.42 98 0.02    
Headquarters Country/Region 0.25 3 0.10 6.48 0.001 0.21 
Error 1.24 96 0.01    
 
 
Table 29 
Means and Standard Deviations for PIPVI Scores by Condition Type, Registration Type, 
and Headquarters Country/Region 
 
Control Variable M SD 
Condition Type   
 Chronic 0.30 0.13 
 Non-Chronic 0.38 0.10 
Registration Type   
 Discount 0.37 0.12 
 Update 0.32 0.12 
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Table 29 
Means and Standard Deviations for PIPVI Scores by Condition Type, Registration Type, 
and Headquarters Country/Region (continued) 
 
Control Variable M SD 
Headquarters Country/Region   
   Asia 0.40 0.07 
   Europe 0.28 0.14 
   United Kingdom 0.29 0.07 
   United States 0.38 0.10 
Total 0.34 0.12 
 
 
Figure 4: Measures Contributions to PIPVI by Headquarters Country/Region 
  Spearman correlations were also conducted to assess the differences between 
company size, annual revenue, and years in existence with PIPVI scores.  Results showed 
significance for annual revenue, r = -0.21, p = 0.036, and for company size, r = -0.29, p < 
.001.  These scores suggest that as the pharmaceutical company size and annual revenue 
increased, PIPVI scores tended to decrease.  This implies that as companies’ revenue and 
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employees increase, they are more responsible with managing consumer information.  
Table 30 presents the results of the Spearman correlations. 
 
Table 30 
Spearman Correlations between Company Size, Annual Revenue, Years in Existence, and 
PIPVI 
 
Control Variable PIPVI 
Company Size    -0.29** 
Annual Revenue -0.21* 
Years in Existence 0.02 
Note.  * p ≤ .050.  ** p ≤ .010.  Otherwise p > .050. 
Documented and Actual OPCC Practices for Choice and Access 
 To determine if companies are adhering to their documented practices, the OPCC 
of choice and access criteria were selected for assessment.  A series of chi-square tests of 
independence were conducted to examine the differences in documented versus actual 
opt-in/opt-out practices for Website registrations by condition type, registration type, and 
headquarters country or region.  The differences were examined for the consumer’s 
ability to opt-in/opt-out of secondary and third party use during and after initial 
registration and the ability to review, modify or delete personal information.  Differences 
in the ability to opt-in/opt-out of secondary use during initial Website registration were 
examined first.  Results of the chi-squares showed no difference between the documented 
and actual practices by condition type, registration type, or headquarters country/region 
(p > .050 for all).  Table 31 presents the chi-squares for differences in the documented 
and actual practices to opt-in/opt-out of secondary use during initial Website registration.  
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Table 31 
Chi-squares for Documented versus Actual Practices for Opt-in/Opt-out of Secondary 
Use During Initial Website Registration 
 
  Difference    
Control Variable DV/ANV D/A DNV/AV χ2 df p 
Condition Type    1.04 2 0.595 
 Chronic 10 13 7    
 Non-Chronic 12 14 4    
Registration Type    0.56 2 0.757 
 Discount 9 12 6    
 Update 13 15 5    
Headquarters Country/Region    11.56 6 0.073 
 Asia 4 0 1    
 Europe 5 11 5    
 United Kingdom 0 2 2    
 United States 13 14 3    
Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and 
Actual in agreement for Violation or No Violation; DNV/AV = Documented No 
Violation/Actual Violation. 
 
 Second, differences in the ability to opt-in/opt-out of secondary user after initial 
Website registration were examined.  Results of the chi-squares showed a significant 
difference between documented versus actual practices to opt-in/opt-out of secondary use 
and headquarters country/region, χ2(6) = 20.20, p = 0.003.  Further examination showed 
that Europe had a higher level of agreement between the documented and actual 
practices, with the US close behind.  This confirms that the documented/undocumented 
practices (violations) and actual practices are in agreement.  No other large differences 
between the actual and documented practices were found in the chi-square.  The chi-
squares for condition type and registration type were both not significant (p > .050 for 
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both).  Table 32 presents the chi-squares for the differences in the documented versus 
actual practices for the consumer to opt-in/opt-out of secondary use after initial Website 
registration. 
 
Table 32 
Chi-squares for Documented versus Actual Opt-in/Opt-Out of Secondary Use after Initial 
Website Registration  
 
  Difference    
Control Variable DV/ANV D/A DNV/AV χ2 df p 
Condition Type    1.93 2 0.381 
 Chronic 7 17 6    
 Non-Chronic 8 12 10    
Registration Type    5.89 2 0.053 
 Discount 3 14 10    
 Update 12 15 6    
Headquarters Country/Region    20.20 6 0.003 
 Asia 3 2 0    
 Europe 3 15 3    
 United Kingdom 0 0 4    
 United States 9 12 9    
Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and 
Actual in agreement for Violation or No Violation; DNV/AV = Documented No 
Violation/Actual Violation. 
 
Third, differences in the ability to opt-in/opt-out of third party use during initial 
Website registration were examined.  Results of the chi-squares showed a significant 
difference between documented versus actual practices to opt-in/opt-out of third party use 
during initial Website registration and headquarters country/region, χ2(6) = 14.19, p = 
0.028.  However, the documented values were found to be below 1.00, and thus caution 
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should be taken in the interpretation and generalization of the chi-square results.  
Although significance was found, no large differences between the actual and 
documented practices were found in the chi-square.  This suggests that there were slight 
differences between documented and actual practices for all headquarters 
countries/regions, but no major differences.  Thus, no definite interpretation could be 
made for the chi-square.  The chi-squares for condition type and registration type were 
both not significant (p > .050 for both).  Table 33 presents the chi-squares for 
documented versus actual practices for the consumer to opt-in/opt-out of third party use 
after initial Website registration. 
Table 33 
Chi-squares for Documented versus Actual Practices for Opt-in/Opt-out of Third Party 
Use During Initial Website Registration 
 
  Difference    
Control Variable DV/ANV D/A DNV/AV χ2 df P 
Condition Type    1.78 2 0.411 
 Chronic 5 21 4    
 Non-chronic 2 25 3    
Registration Type    3.15 2 0.207 
 Discount 1 23 3    
 Update 6 23 4    
Headquarters Country/region    14.19 6 0.028 
 Asia 3 2 0    
 Europe 2 17 2    
 United Kingdom 0 4 0    
 United States 2 23 5    
Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and 
Actual in agreement for Violation or No Violation; DNV/AV = Documented No 
Violation/Actual Violation. 
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 Fourth, differences in the ability to opt-in/opt-out of third party use after initial 
Website registration were examined.  Results of the chi-squares showed no difference 
between the documented and actual practices to opt-in/opt-out of third party use after 
initial Website registration by condition type, registration type, or headquarters 
country/region (p > .050 for all).  Table 34 presents the chi-squares for differences in the 
documented versus actual practices to opt-in/opt-out of third party use after initial 
Website registration.   
 
Table 34 
Chi-squares for Documented versus Actual Practices for Opt-in/Opt-out of Third Party 
Use After Initial Website Registration 
 
  Difference    
Control Variable DV/ANV D/A DNV/AV χ2 Df p 
Condition Type    1.02 2 0.601 
 Chronic 1 26 3    
 Non-chronic 0 27 3    
Registration Type    1.25 2 0.536 
 Discount 0 25 2    
 Update 1 28 4    
Headquarters Country/Region    4.30 6 0.636 
 Asia 0 5 0    
 Europe 0 20 1    
 United Kingdom 0 4 0    
 United States 1 24 5    
Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and 
Actual in agreement for Violation or No Violation; DNV/AV = Documented No 
Violation/Actual Violation. 
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 Fifth, differences in the ability to review personal information disclosed during 
the Website registrations were examined.  Results of the chi-squares showed a significant 
difference between the documented versus actual practices to review personal 
information and headquarters country/region, χ2(6) = 17.84, p = 0.007.  However, the 
documented practices were found to be below 1.00, and thus caution should be taken in 
the interpretation and generalization of the chi-square results.  Although significance was 
found, no large differences between actual and documented practices were found in the 
chi-square.  This suggests that there were slight differences between documented and 
actual practices for all headquarters countries/regions, but no major differences.  Thus, no 
definite interpretation could be made for the chi-square.  The chi-squares for condition 
type and registration type were both not significant (p > .050 for both).  Table 35 presents 
the chi-squares for the differences in the documented versus actual practices for the 
ability to review personal information.   
 
Table 35 
Chi-squares for Documented versus Actual Practices for the Ability to Review Personal 
Information 
 
  Difference    
Control Variable DV/ANV D/A DNV/AV χ2 df p 
Condition Type    0.67 2 0.715 
 Chronic 3 13 14    
 Non-Chronic 3 16 11    
Registration Type    2.16 2 0.339 
 Discount 1 14 12    
 Update 5 15 13    
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Table 35 
Chi-squares for Documented versus Actual Practices for the Ability to Review Personal 
Information (continued) 
 
  Difference    
Control Variable DV/ANV D/A DNV/AV χ2 df p 
Headquarters Country/Region    17.84 6 0.007 
 Asia 3 2 0    
 Europe 1 10 10    
 United Kingdom 0 1 3    
 United States 2 16 12    
Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and 
Actual in agreement for Violation or No Violation; DNV/AV = Documented No 
Violation/Actual Violation. 
 
 
 Sixth, differences in the ability to modify personal information disclosed during 
the Website registration were examined.  Results of the chi-squares showed a significant 
difference between the documented versus actual practices for the ability to modify 
personal information disclosed during the Website registration and headquarters 
country/region, χ2(6) = 20.46, p = 0.002.  However, documented practices were found to 
be below 1.00, and thus caution should be taken in the interpretation and generalization 
of the chi-square results.  There were more European companies with agreement between 
the documented and actual practices for the ability to modify personal information 
disclosed during the Website registration.  Finally, there were more US pharmaceutical 
companies with differences between the documented and actual practices, particularly for 
the actual practices not in accordance with the documented practices for the ability to 
modify personal information disclosed during the Website registration.  The chi-squares 
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for condition type and registration type were both not significant (p > .050 for both).  
Table 36 presents the chi-squares for the differences in the documented versus actual 
practices for the ability to modify personal information disclosed during the Website 
registration.   
 
Table 36 
Chi-squares for Documented versus Actual Practices for the Ability to Modify Personal 
Information 
 
  Difference    
Control Variable DV/ANV D/A DNV/AV χ2 df p 
Condition Type    0.32 2 0.853 
 Chronic 3 11 16    
 Non-Chronic 3 9 18    
Registration Type    2.29 2 0.318 
 Discount 1 9 17    
 Update 5 11 17    
Headquarters Country/Region    20.46 6 0.002 
 Asia 3 2 0    
 Europe 1 10 10    
 United Kingdom 0 1 3    
 United States 2 7 21    
Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and 
Actual in agreement for Violation or No Violation; DNV/AV = Documented No 
Violation/Actual Violation. 
 
Last, differences in the ability to delete personal information disclosed during the 
Website registration were examined.  Results of the chi-squares analysis showed a 
significant difference between the documented versus actual practices for the ability to 
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delete personal information disclosed during the Website registration and headquarters 
country/region, χ2(3) = 9.35, p = 0.025.  The Asian pharmaceutical companies in this 
research study did not have documented practices to delete nor did they provide the 
ability to delete personal information.  Therefore, there were more Asian pharmaceutical 
companies with agreement between documented and actual PIPV to delete, while there 
were fewer undocumented violations for the ability to delete personal information 
disclosed during the Website registration.  The chi-squares analysis for condition type 
and registration type were both not significant (p > .050 for both).  Table 37 presents the 
chi-squares for the differences in the documented versus actual practices for the ability to 
delete personal information disclosed during the Website registration.  
Table 37 
Chi-squares for Documented versus Actual Practices for the Ability to Delete Personal 
Information 
 
  Difference    
Control Variable DV/ANV D/A DNV/AV χ2 df p 
Condition Type    0.27 1 0.602 
 Chronic - 18 12    
 Non-Chronic - 16 14    
Registration Type    0.46 1 0.496 
 Discount - 14 13    
 Update - 20 13    
Headquarters Country/Region    9.35 3 0.025 
 Asia - 5 0    
 Europe - 11 10    
 United Kingdom - 0 4    
 United States - 18 12    
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Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and 
Actual in agreement for Violation or No Violation; DNV/AV = Documented No 
Violation/Actual Violation. 
 
Personal Identifiable Information (PII) 
 The data to support the transactions for the 60 Website registration types 
previously mentioned to measure the online practices of consumer control were also used 
to examine the personal identifiable information (PII) scores.  For instance, the data 
collection for an update or discount are the same regardless of other selections used to 
differentiate the particular Website registration.  Table 38 presents the PII characteristics 
of the Website registrations. 
 
Table 38 
 
Summary of PII Data Collection  
 
PII Level n % 
Low (1 – 2) 11 18% 
Medium (3) 19 32% 
High (4 -6) 30 50% 
Note. n=60. 
Chi-square tests of independence were conducted to assess if there was a 
difference between company size, annual revenue, condition type, registration type, and 
headquarters country/region with total PII level.  The results of the chi-squares showed 
significance for annual revenue, χ2(4) = 15.95, p = 0.003, employees, χ2(4) = 11.09, p 
= 0.026, and for headquarters country/region, χ2(6) = 12.65, p = 0.049.  However, the 
expected values for headquarters country/region were below 1.00 in some cases, and thus 
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caution should be taken in the interpretation and generalization of the results.  There were 
a larger number of high PII level Website registrations from pharmaceutical companies 
with greater than $1 billion in revenue.  Next, there were a larger number of high PII 
level Website registrations from companies with 1,001 to 50,000 employees.  Last, there 
were fewer high PII level Website registrations from US pharmaceutical companies.  
Table 39 presents the results for the chi-squares. 
 
Table 39 
Chi-squares between Company Size, Annual Revenue, Condition Type, Registration Type, 
Headquarters Country/Region, and Total PII Level 
 
  Total PII Level    
Control Variable Low Medium High χ2 df P 
Company Size    11.09 4 0.026 
 Less than 1,000 3 8 6    
 1,001 to 50,000 6 1 13    
 Greater than 50,000 2 10 11    
Annual Revenue    15.95 4 0.003 
 Less than 50 million 2 10 5    
 51 – 999 million 5 3 3    
 Greater than 1 billion 4 6 22    
Condition Type    5.47 2 0.065 
 Chronic 4 6 19    
 Non-Chronic 7 13 11    
Registration Type    5.74 2 0.057 
 Discount 4 5 18    
 Update 7 14 12    
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Table 39 
Chi-squares between Company Size, Annual Revenue, Condition Type, Registration Type, 
Headquarters Country/Region, and Total PII Level (continued) 
 
  Total PII Level    
Control Variable Low Medium High χ2 df P 
Headquarters Country/Region    12.65 6 0.049 
Asia 1 0 4    
Europe 1 6 14    
United Kingdom 2 0 2    
United States 7 13 10    
 
Additional ANOVAs were conducted to assess if there were differences in 
OPISM, OPCCM, and PIPVI by PII (low versus high).  Results of the ANOVA for 
OPISM by PII were not significant, F(1, 58) = 0.42, p = 0.517, partial η2 = 0.01.  
Results of the ANOVA for OPCCM by PII were also not significant, F(1, 58) = 0.68, p = 
0.412, partial η2 = 0.01.  Finally, results of the ANOVA for PIPVI by PII were not 
significant, F(1, 58) = 0.05, p = 0.819, partial η2 = 0.00.  This suggests that no 
significant differences were found in OPISM, OPCCM, and PIPVI by PII.  Results of the 
ANOVAs are presented in Table 40. 
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Table 40 
ANOVAs for OPISM, OPCCM, and PIPVI by PII 
Measure SS df MS F p Partial η2 
OPISM 0.00 1 0.00 0.42 0.517 0.01 
Error 0.02 58 0.00    
OCCM 0.01 1 0.01 0.68 0.412 0.01 
Error 0.43 58 0.01    
PIPVI 0.00 1 0.00 0.05 0.819 0.00 
Error 0.74 58 0.01    
 
Controlling for Company Size, Annual Revenue, and Years in Existence 
The Spearman correlations and non-parametric measures were used to examine 
the differences between DPPM, OPISM, OPCCM, and PIPVI with company size, annual 
revenue, and years in existence.  OPISM scores were significantly negatively related to 
annual revenue and positively related to years in existence (see Table 24).  PIPVI scores 
were significantly negatively related to company size and annual revenue (see Table 30).  
No other significant differences were found.  Based upon the results, hypothesis one can 
be accepted, because no significance was found with company size.  However, because of 
the significant differences with annual revenue and years in existence, the ANOVAs for 
OPISM and PIPVI were re-conducted as ANCOVAs to assess if controlling for annual 
revenue and years in existence affects the outcome of the comparisons. 
 The results of the ANCOVA for OPISM scores by condition type after controlling 
for annual revenue and years in existence were significant, F(1, 96) = 5.74, p = 0.019, 
partial η2 = 0.06.  This is a change from the original ANOVA conducted.  Based upon 
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the results, hypotheses two and three were rejected, because significance was found with 
annual revenue and years in existence.   In addition, the mean for chronic conditions was 
significantly higher than the mean for non-chronic conditions.  The results of the 
ANCOVA for OPISM scores by registration type were not significant, F(1, 96) = 0.26, p 
= 0.611, partial η2 = 0.00, which is similar to the previous results.  The results for the 
ANCOVA for OPISM scores by headquarters country/region were not significant, F(3, 
94) = 0.24, p = 0.865, partial η2 = 0.01, mirroring what was previously found.  Results 
of the new ANCOVAs for OPISM scores are presented in Table 41. 
 
Table 41 
ANCOVA Results for OPISM Scores by Condition Type, Registration Type, and 
Headquarters Country/Region Controlling for Annual Revenue and Years in Existence 
 
Source SS df MS F p Partial η2 
Condition Type 0.01 1 0.01 5.74 0.019 0.06 
Annual Revenue 0.02 1 0.02 17.37 0.001 0.15 
Years in Existence 0.03 1 0.03 25.11 0.001 0.21 
Error 0.10 96 0.00    
Registration Type 0.00 1 0.00 0.26 0.611 0.00 
Annual Revenue 0.01 1 0.01 11.47 0.001 0.11 
Years in Existence 0.02 1 0.02 21.32 0.001 0.18 
Error 0.11 96 0.00    
Headquarters 
Country/Region 
0.00 3 0.00 0.24 0.865 0.01 
Annual Revenue 0.01 1 0.01 10.77 0.001 0.10 
Years in Existence 0.02 1 0.02 18.86 0.001 0.17 
Error 0.11 94 0.00    
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 The results of the ANCOVA for PIPVI scores by condition type while controlling 
for annual revenue showed significance, F(1, 97) = 7.79, p = 0.006, partial η2 = 0.07, 
suggesting that the PIPVI scores for chronic conditions were significantly lower than the 
PIPVI scores for non-chronic conditions.  The results suggest that fewer violations occur 
with chronic conditions than for non-chronic.  This is similar to the results found in the 
original ANOVA.  Significance was also found by registration type, F(1, 97) = 4.64, p = 
0.034, partial η2 = 0.05, also mirroring the results found in the previous ANOVA.  
Finally, the results for differences by headquarters country/region were also similar to the 
previous ANOVA, F(3, 95) = 6.87, p < .001, partial η2 = 0.18. Results of the new 
ANCOVAs for PIPVI scores are presented in Table 42. 
 
Table 42 
ANCOVA Results for PIPVI Scores by Condition Type, Registration Type, and 
Headquarters Country/Region Controlling for Annual Revenue 
 
Control Variable  SS df MS F p Partial η2 
Condition Type 0.11 1 0.11 7.79 0.006 0.07 
Annual Revenue 0.02 1 0.02 1.21 0.275 0.01 
Error 1.32 97 0.01    
Registration Type 0.07 1 0.07 4.64 0.034 0.05 
Annual Revenue 0.06 1 0.06 4.39 0.039 0.04 
Error 1.36 97 0.01    
Headquarters Country/Region 0.25 3 0.09 6.87 0.000 0.18 
Annual Revenue 0.01 1 0.01 1.12 0.293 0.01 
Error 1.17 95 0.01    
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 Thus, from the results of the ANCOVAs, the only change that was made by 
controlling for the relevant covariates was the ANCOVA for OPISM scores by condition 
type.  Previously, the ANOVA results were not significant, but after controlling for 
registration type and annual revenue, significant differences in OPISM scores were found 
by condition type.  
Validity Analysis 
 According to Pallant (2010), “the validity of a scale refers to the degree to which 
it measures what it is suppose to measure” (p. 7). She further noted that because there is 
no clear indicator of a scale’s validity, the validation encompasses a “collection of 
empirical evidence concerning its use” (p. 7).  The two main threats to validity in this 
research were construct and content. To ensure constructs of this research were valid, this 
research study used previously validated constructs from prior research.  Another main 
threat to validity was the content validity.  Once the constructs were gleaned from the 
literature review and the draft instrument was developed, an anonymous expert panel was 
solicited to elicit feedback on the proposed criteria and measures.  The expert panel was 
solicited based upon their experience and knowledge of information privacy or 
information security from both the academic and corporate sectors to establish a qualified 
group of subject matter experts.  The expert panel was requested to review the proposed 
criteria and indicate their level of agreement and provide additional comments if they 
disagreed.  Once the first round of the Delphi Method was completed, responses were 
reviewed for applicable revisions to the benchmarking instrument.      
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Reliability Analysis 
 Pallant (2010) noted that “the reliability of a scale indicates how free it is from 
random error” (p. 6).  To ensure reliability, this research used the aforementioned expert 
panel to validate the proposed criteria and measures.  In addition, another researcher 
reviewed the data to ensure accuracy.  Special attentiveness and concentration was taken 
during the data collection phases to ensure responses were complete and correct to 
achieve an accurate assessment of the practices for the Website registrations.  The 
Cronbach alpha values are noted in Table 43.  While it is recommended that the alpha 
values be above .7 (Pallant, 2010; Sekaran, 2003), Pallant (2010) noted that the alpha 
value could be fairly low if there are fewer than 10 scales.  Therefore, because the PIPVI 
instrument meets this criterion, the alpha values were expected to be low.   
 
Table 43 
Reliability of Scales 
Scale Item α  
DPPP Notice, Choice, Access, Security .59 
OPIS Secondary Use, Third Party Use* -.04 
OPCC Choice, Access .46 
PIPVI DPPPM, OPISM, OPCCM .00 
Note. * Measurement was constant except for one company. 
 
Summary of the Results 
 This chapter presented the results of the study.  First, the chapter began with 
phase one of the research study, which involved engaging the expert panel.  The 
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demographics of the expert panel and the results of both surveys using the Delphi Method 
were discussed.  The discussion encompassed the elicitation of an expert panel to confirm 
the criteria and measures that contribute to personal information privacy violations, along 
with the weight allocations that were used to calculate the PIPVI.  Next, phase two of the 
study was discussed that described the data collection for the 100 Website registrations.  
The chapter concluded with phase three that presented the data analysis and results of the 
PIPVI.   
 The nine goals of this research study were achieved using a three-phased 
approach: the first specific goal of this research study was to develop and assess the 
experts’ approved components and weights for the DPPP implemented by pharmaceutical 
companies using the Delphi expert methodology.  The second specific goal of this 
research study was to develop and assess the experts’ approved components and weights 
for the OPIS implemented by pharmaceutical companies using the Delphi expert 
methodology.  The third specific goal of this research study was to develop and assess the 
experts’ approved components and weights for the OPCC implemented by 
pharmaceutical companies using the Delphi expert methodology.  The fourth specific 
goal of this research study was to develop the components of the single, integrated 
measure of PIPVI and assess the DPPP, OPIS, and the OPCC implemented by 
pharmaceutical companies using the Delphi expert methodology.  The first four goals 
were met with the development of the DPPPM, OPISM, OPCCM, PIPVI, which included 
the criteria and weight allocations.  The fifth specific goal was to assess and compare the 
DPPPM of pharmaceutical companies that headquarters are based in United States versus 
Europe, Asia, or United Kingdom.  This goal was met as presented in Table 19.  The 
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sixth specific goal was to assess and compare the OPISM, OPCCM, and PIPVI for 100 
Website registrations of pharmaceutical companies that a) market chronic versus non-
chronic prescription medications, b) market registrations for prescription medication 
discounts versus updates, c) their headquarters are based in United States versus Europe, 
Asia, or United Kingdom.  This goal was met as presented in Table 22, Table 25, and 
Table 27.  The seventh specific goal was to assess and compare the differences for 100 
Website registrations between the documented and actual online practices of consumer 
control for choice and access of pharmaceutical companies that a) market chronic versus 
non-chronic prescription medications, b) market registrations for prescription medication 
discounts versus updates, c) their headquarters are based in United States, versus Europe, 
Asia, or United Kingdom. This goal was met as presented in Table 33, Table 34, Table 
35, Table 36, Table 37 and Table 38.  The eighth specific goal of this research study was 
to assess and compare the OPISM, OPCCM, and PIPVI between pharmaceutical 
companies that collect a limited amount of PII and those that collect a high amount of 
PII.  This goal was met as presented in Table 31.  The last and ninth goal was to measure 
if there were any significant differences in the pharmaceutical companies’ DPPPM, 
OPISM, OPCCM, and PIPVI based on their size, reported annual revenues, and years in 
existence.  This goal was met as presented in Table 32.     
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Chapter 5 
Conclusions, Implications, Recommendations, and Summary 
 
Conclusions 
Because incidents continue to rise due to companies’ misuse of consumer 
information (Anton et al., 2010; Lanier & Saini, 2008; Pollach, 2007), this research study 
attempted to address the proliferation of online privacy violations by companies.  This 
was conducted by developing a PIPVI benchmarking instrument, including its essential 
hierarchical components, to assess documented and online practices implemented on 
Websites.  This research study achieved the nine goals with a three-phased approach. 
First, an expert panel using the Delphi expert methodology was used to develop relative 
weights for the criteria, documented practices of the privacy policy measure (DPPPM), 
online practices of information sharing measure (OPISM), online practices of consumer 
control measure (OPCCM), and the Personal Information Privacy Violations Index 
(PIPVI).  Second, the PIPVI benchmarking instrument was used to assess the 
documented and online practices implemented for 100 pharmaceutical companies’ 
Website registrations.  Last, a comparison report was developed for 100 Website 
registrations of pharmaceutical companies.  
 
Discussion  
Overall, the results indicated that pharmaceutical companies with headquarters in 
Europe had fewer personal information privacy violations than the US.  In addition, the 
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results suggested that as the annual revenue of the pharmaceutical company increased, 
fewer OPIS violations occurred.  Second, as years in existence increased, the more OPIS 
personal information privacy violations occurred.  Third, the results suggested 
pharmaceutical companies were more responsible with managing personal information 
for chronic conditions than for non-chronic conditions.  Fourth, fewer violations occurred 
with Website registrations for updates than for discounts.  Fifth, as company size and 
annual revenue increased, the PIPVI scores tended to decrease, which insinuates 
companies are more responsible when they have higher revenue and a larger volume of 
employees.  Finally, both Europe and UK demonstrated more overall adherence to FIPs 
than the US and Asia.  This suggests that self-regulation may not be sufficient, while 
more enforcement may be necessary to decrease personal information privacy violations.   
 
Implications 
 This research study has some implications for the existing body of knowledge in 
the area of information privacy and information security.  Companies are continuing to 
use the Internet as a source for engaging customers. This research study demonstrated 
that the PIPVI benchmarking instrument could be used to assess the documented and 
actual practices implemented on Websites. Because companies can revise their privacy 
policies or Website registrations at any time, there is risk of revisions that can alter the 
results.  Therefore, it is important to ensure that when assessing documented Website 
practices, the researcher must be very meticulous and organized to capture data at that 
point in time for comparison to validate any changes.  During this research study, there 
were no updates to any of the documented practices of the privacy policy.  In addition to 
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revisions to the documented practices of the privacy policy, there is also risk to revisions 
for registration types.  For example, the information required for disclosure to register for 
updates or discounts could be revised or no longer available.  During this research study, 
this was also not experienced.   
 In this research study, the expert panel phase occurred over approximately16 
weeks.  This time period was required to allow for sufficient participation.  Hsu and 
Sanford (2007) recommended a minimum of 45 days for administering a Delphi study.  It 
is important to note that the survey method is one of the drawbacks of using the Delphi 
method because it could delay other processes.  They further noted that it is crucial for 
the researcher to encourage the expert panel to respond to ensure a sufficient response 
rate.  Because phase two for the Website registrations could be initiated simultaneously 
with phase one, the expert panel phase did not cause a delay in the other proceeding 
phases.  
 This research study provides a PIPVI benchmarking instrument that can be used 
to assess the documented and actual Website practices of companies.  This benchmarking 
instrument could assist companies with assessing their practices to provide insight into 
what the company can do to further encourage adherence with the FIPs.  
 
Study Limitations 
As with any research study, this one also had some limitations.  One of the main 
significant limitations of our study is the generalizable of the specific index values (not 
the weights) due to the sample used.  It is expected that the Delphi compositions of the 
hierarchical weights will indeed be generalized in the future, but as time progresses, the 
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use of the benchmarking index on different companies may yield different values.  While 
the sample size of 100 Website registrations is valid, further studies can use a larger 
sample size to increase validation of the results and generalizability.  Next, there was not 
an equal distribution of pharmaceutical company Website registrations across each 
headquarters country/region.  Furthermore, because some of the Website registrations did 
not receive any emails, OPIS could not be truly assessed for all pharmaceutical 
companies Website registrations.  Finally, because most pharmaceutical companies 
documented practices specified to submit request to delete personal information through 
email, phone, or mail, the delete practices could not be assessed.  
 
Recommendations and Future Research 
This research study outlined the research plan to develop a set of measures and a 
single composite index based upon hierarchical criteria identified by current US laws and 
regulations recommended for ethical business practices for online transactions.  The 
weights of the hierarchical criteria and composite index were developed using a Delphi 
approach.  Followed by the development of the PIPVI, along with the data collection and 
analysis using the research outline plan discussed here.  The findings and the results of 
the statistical analyses were reported.  
Future studies are warranted to increase the validity of the instrument.  In 
addition, more research will be needed to expand the sample size and the use of other 
industries to increase the generalizability.  While our work concentrated on the 
pharmaceutical market, future research could include assessing other industries.  
Moreover, future work can assess the opt-out practices against the Controlling the 
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Assault of Non-Solicited Pornography and Marketing Act (CAN-SPAM Act).  An 
extension of assessing the opt-out practices could include examining the differences 
based upon the type of request such as Website or email.  Another area of future research 
includes selection of a population with criteria specifically for males and females or age 
to determine if the documented and online practices of companies differ by gender or 
age.  Another area of future research includes having an equal distribution of Website 
registrations across each headquarters country/region.  Finally, because the privacy 
policies stated that requests to delete information must be submitted by phone, email, or 
mail, future research could include assessing the delete practices of pharmaceutical 
companies or other industries. 
 
Summary 
This research study addressed the proliferation of online privacy violations by 
companies (Anton, Earp, & Young, 2010; Kim & Byramjee, 2014; Li, Sarathy, & Xu, 
2011; Nam et al., 2006; Nhan, Kinkade, & Burns, 2009; Peltier et al., 2009).   Personal 
information privacy violations using the Internet continue to receive media attention and 
continue to be a growing concern for consumers (K. Kim & Kim, 2011; Koorzaan & 
Boswell, 2008; Li et al., 2011).  Because of the consistent occurrence of personal 
information violations, the growth of e-commerce is at risk (Kim & Byramjee, 2014; K. 
Kim & Kim, 2011; Li et al., 2011).  The information privacy and information security 
literature present substantial evidence that consumers continue to be concerned about 
how their information is managed, used, and distributed by companies, especially if 
accessed via the Web.  While the advancement of technology has provided significant 
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benefits to companies and consumers, the proliferation of personal information privacy 
violations demonstrates that it has also had an adverse effect.  Because of technological 
advancements of the Internet, companies are able to collect, store, transfer, sell, and 
analyze consumer information (Kim & Byramjee, 2014).  Companies leverage the 
Internet as a source of communication to engage and establish relationships with 
customers.  However, in order to establish the relationship, the consumer voluntarily and 
involuntarily discloses information. Through both voluntary and involuntary methods, 
companies are able to collect and aggregate consumer information. As a result of the 
continued proliferation of personal information privacy violations, consumers continue to 
be concerned how companies manage their information.  As previously noted, consumers 
expect companies to have an ethical responsibility to engage in practices that maintain 
information integrity and protect consumer information from unauthorized disclosure, 
access, use, or loss (Kelly & Rowland, 2000; Peltier, Milne, & Phelps, 2009).  
Consumers have an even greater expectation for financial, medical, and health 
information (Gupta, Iyer, & Weisskirch, 2010; Yang & Wang 2009).  Literature 
presented significant evidence that the documented practices of the privacy policy 
(DPPP), online practices of information sharing (OPIS), and online practices of consumer 
control (OPCC) are three practices that contribute to personal information privacy 
violations by companies.  The literature further noted that there is little research in studies 
that assesses both the documented and online practices contributing to the proliferation of 
personal information privacy violations.  Given the significant rise in the use of 
healthcare Websites (Davis, 2012; Kim & King, 2009) and the sensitivity of consumers 
to information privacy, pharmaceutical companies’ Websites are the focus of this 
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research study.  Therefore, the main goal of this research study was to develop the 
Personal PIPVI benchmarking instrument that can be used to assess the DPPP, OPIS, 
OPCC, and compute PIPVI while using it to compare 100 registrations initiated through 
53 Websites of 25 pharmaceutical companies that market chronic and non-chronic 
prescription medications.  This was achieved using three phases to answer eight research 
questions and three hypotheses.  
In phase one, an expert panel from academia and practitioners in the field of 
information security and privacy, as well as corporate social responsibility were engaged 
to answer the first four research questions.  The expert panel survey was conducted using 
the Delphi Method.  The survey requested the expert panel to indicate their level of 
agreement with the criteria, measures, along with their recommendation for the relative 
weight allocations.  The outcome of the two survey rounds was the development of and 
the relative weight allocations for the documented practice of the privacy policy measure 
(DPPPM), online practices of information sharing (OPISM), online practices of consumer 
control (OPCCM), and the personal information privacy violations index (PIPVI).     
RQ1a: What are the experts’ approved components of the DPPP implemented by 
pharmaceutical companies using a Delphi expert methodology?   
RQ1b: What are the experts’ approved weights of the DPPP’s components 
implemented by pharmaceutical companies using a Delphi expert 
methodology?   
RQ2a: What are the experts’ approved components of the OPIS implemented by 
pharmaceutical companies using a Delphi expert methodology?   
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RQ2b: What are the experts’ approved weights of the OPIS’s components 
implemented by pharmaceutical companies using a Delphi expert 
methodology? 
RQ3a: What are the experts’ approved components of the OPCC implemented by 
pharmaceutical companies using a Delphi expert methodology?   
RQ3b: What are the experts’ approved weights of the OPCC’s components 
implemented by pharmaceutical companies using a Delphi expert 
methodology? 
RQ4: What are the experts’ approved weights of the single, integrated measure of 
PIPVI’s components of DPPP, OPIS, and the OPCC implemented by 
pharmaceutical companies using a Delphi expert methodology? 
In phase two, the privacy policy of the pharmaceutical companies was 
downloaded to assess the documented practices of the privacy policy (DPPP).  In 
addition, 100 Website registrations were initiated across 53 Websites of 25 
pharmaceutical companies. The pharmaceutical companies were headquartered in Asia, 
Europe, UK, and the US.  The Website registrations were initiated for prescription 
medications that marketed chronic and non-chronic conditions with registration types of 
update and discount.  It is important to note that Websites that sold prescription 
medications were excluded from the sample.  Data was collected, analyzed, and 
calculated to derive the values for the DPPPM, OPISM, OPCCM, and PIPVI.    
The remaining research questions and hypotheses were achieved in phase three. 
First, there were no significant differences for DPPM, OPISM, and OPCCM between 
pharmaceutical companies that a) market chronic versus non-chronic prescription 
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medications, b) market registrations for prescription medication discounts versus updates, 
c) their headquarters are based in United States, versus Europe, Asia, or United Kingdom.  
Second, there were no significant differences for OPCCM between pharmaceutical 
companies that a) market registrations for prescription medication discounts versus 
updates and b) their headquarters country/region are based in US, Europe, Asia, or UK.  
Differing from DPPPM and OPISM, there was a significant difference for OPCCM 
between pharmaceutical companies that market chronic versus non-chronic prescription 
medications.  The results suggest that consumers had more control over their data for 
chronic conditions than for non-chronic conditions.  Third, there was a significant 
difference for PIPVI between pharmaceutical companies that a) market chronic versus 
non-chronic prescription medications, b) market registrations for prescription medication 
discounts versus updates, c) their headquarters are based in United States, versus Europe, 
Asia, or United Kingdom.  The results suggest that fewer personal information privacy 
violations occur for chronic conditions, update registrations, and for pharmaceutical 
companies that are headquartered in Europe.  Overall, Europe was more responsible with 
managing consumer information compared to the US, Asia, or UK. Finally, both Europe 
and UK demonstrated a higher adherence to the FIPs than the US and Asia. 
RQ5: Are there any statistical significance mean differences for DPPM between 
pharmaceutical companies that headquarters are based in United States 
versus Europe, Asia, or United Kingdom? 
RQ6: Are there any statistical significance mean differences for OPISM, OPCCM, 
and PIPVI between pharmaceutical companies that a) market chronic versus 
non-chronic prescription medications, b) market registrations for 
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prescription medication discounts versus updates, c) their headquarters are 
based in United States, versus Europe, Asia, or United Kingdom?  
Fourth, there were no significant differences in the documented versus actual 
practices for choice (opt-in/opt-out) between pharmaceutical companies that a) market 
chronic versus non-chronic prescription medications, b) market registrations for 
prescription medication discounts versus updates.  However, for pharmaceutical 
companies headquarters country/region, there was a significant difference for opt-in/opt-
out of secondary use after initial Website registration and opt-in/opt-out of third party use 
during initial Website registration.  Once again Europe had a higher level of agreement 
for the ability to opt-in/opt-out of secondary use after initial Website registration.  Fifth, 
there were no significant differences in the documented versus actual practices for access 
(review, modify, delete) between pharmaceutical companies that a) market chronic versus 
non-chronic prescription medications or b) market registrations for prescription 
medication discounts versus updates.  On the other hand, there was a significant 
difference for access between pharmaceutical companies that their headquarters are based 
in United States, versus Europe, Asia, or United Kingdom.  The results suggest that the 
US pharmaceutical companies had a higher disagreement between the documented and 
actual practices for the ability to modify personal information.  
RQ7: Are there any significant differences between the documented and the 
actual online practices for choice, and access of pharmaceutical companies 
that a) market chronic versus non-chronic prescription medications, b) 
market registrations for prescription medication discounts versus updates, c) 
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their headquarters are based in United States, versus Europe, Asia, or United 
Kingdom? 
Sixth, there were no significant mean differences for OPISM, OPCCM, and 
PIPVI between pharmaceutical companies that collect a limited amount of PII and those 
that collect a high amount of PII.  Pharmaceutical companies with annual revenue greater 
than 1 billion dollars and pharmaceutical companies with a company size of 1,001 to 
50,000 employees had a higher volume of Website registrations that collected a high 
level of PII.  However, the US had fewer Website registrations that collected a high level 
of PII.  
RQ8: Are there any statistical significance mean differences for OPISM, OPCCM 
and PIPVI between pharmaceutical companies that collect a limited amount 
of PII and those that collect a high amount of PII?  
Last, unlike OPISM and PIPVI, there were no significant mean differences for the 
pharmaceutical company’s DPPPM and OPCCM when controlling for company size, 
annual revenue, and years in existence.  Because there was no significant difference 
found for DPPPM, IPOSM, OPCC, or PIPVI, hypothesis one was accepted.  A significant 
difference was found for OPISM and PIPVI when controlling for annual revenue and 
years in existence.  Therefore, both hypotheses two and three were rejected.  
H1: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will 
not be significantly different when controlling for company size.  
H2: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will 
not be significantly different when controlling for annual revenue. 
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H3: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will 
not be significantly different when controlling for years in existence. 
Like any study, this research study had four main limitations.  The first limitation 
was the set of measures combined to form the PIPVI.  The second limitation was that the 
reliability and validation of the instrument relied on an expert panel.   The expert panel, 
the relative weights, criteria, and measures may not be representative of the broader 
population.  For these reasons, generalization of the results from this research study was 
cautioned.  Future studies are required with other populations to increase generalizability 
of the results and improve the validity of the instrument. The third limitation was the 
inability to assess certain practices, such as security and the ability to delete personal 
information disclosed during the Website registration.  In addition, because some of the 
Website registrations did not produce any emails, the OPIS measure could not be fully 
assessed for all Website registrations.  The last limitation is that the results represent data 
at a point in time.   
This research study made several contributions to the information privacy domain 
and body of knowledge.  The study provided empirical evidence regarding the magnitude 
of voluntary adherence to the Fair Information Practices by pharmaceutical companies. 
This evidence is important to regulators and associations to assist with understanding the 
effectiveness of self-regulation.  This research study provided insight into the 
documented and actual online practices of pharmaceutical companies that contribute to 
personal information privacy violations.  Given the heightened concerns of consumers 
regarding personal information privacy, the results of this research study provided 
consumers with empirical evidence of how their information is managed and used by 
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pharmaceutical companies.  A high magnitude of personal information privacy violations 
could negatively impact consumers’ trust, concerns, and interactions with the Websites, 
which could continue to constrain the growth of e-commerce.  
In conclusion, other researchers can use the PIPVI benchmarking instrument to 
assess Websites for new populations.  The PIPVI benchmarking instrument can be used 
as a tool by researchers and corporations to assess and provide awareness regarding the 
documented and actual online practices of Websites.  In addition, regulators and 
advocacy groups can use this type of evidence to assess and aide in determining if 
companies can be trusted with self-regulation and if more stringent laws and regulations 
or enforcement are necessary. 
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 Appendix A 
PIPVI Data Collection Form 
 
PHARMACEUTICAL COMPANY DEMOGRAPHICS 
Pharmaceutical Company  
Website URL   
Headquarters Country/Region  
Company Size  
Annual Revenue  
Years in Existence  
Condition Type  
Registration Type  
Name  
Email Address  
 
The questions below are represented such that a response of YES will be an 
indication of a violation. An “X” will be placed in the space to indicate a response of 
YES or NO for each question. A response will be indicated for all questions. 
 
PART 1 – DOCUMENTED PRACTICES OF THE PRIVACY POLICY 
 
NOTICE 
    YES   NO 
DPPP-N1 The Privacy Policy contains a declaration that the Website 
does NOT collect any personal information from 
consumers 
 
  
DPPP-N2 The Privacy Policy does NOT contain a declaration about 
the specific personal information the Website collects from 
consumers 
 
  
DPPP-N3 The Privacy Policy does NOT contain a declaration that the 
Website may use personal information it collects for 
internal purposes 
 
  
DPPP-N4 The Privacy Policy does NOT contain a declaration about 
whether the Website uses personal information it collects to 
send communications to the consumer 
 
  
DPPP-N5 The Privacy Policy does NOT contain a declaration about 
whether the Website discloses personal information it 
collects to third parties 
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CHOICE 
  YES NO 
DPPP-C1 The Privacy Policy does NOT contain a declaration that 
the Website provides the choice to opt-in/opt-out of 
future communications from the company other than 
those directly related to a transaction originated by the 
consumer 
 
  
DPPP-C2 The Privacy Policy does NOT contain a declaration that 
the Website provides the choice to opt-out of future 
communications at a later date after receipt of 
communications 
 
  
DPPP-C3 The Privacy Policy does NOT contain a declaration that 
the Website provides the choice to opt-in/opt-out of 
information disclosure to third parties 
 
  
DPPP-C4 The Privacy Policy does NOT contain a declaration that 
the Website provides the choice to opt-out of future 
communications from third parties at a later date after 
receipt of communications 
 
  
ACCESS 
  YES NO 
DPPP-A1 The Privacy Policy does NOT contain a declaration that 
the Website allows consumers to review personal 
information previously collected 
 
  
DPPP-A2 The Privacy Policy does NOT contain a declaration that 
the Website allows consumers to modify personal 
information previously collected 
 
  
DPPP-A3 The Privacy Policy does NOT contain a declaration that 
the Website allows consumers to delete personal 
information previously collected 
  
 
SECURITY 
  YES NO 
DPPP-S1 The Privacy Policy does NOT contain a declaration that 
the Website takes any steps to provide security of the 
personal information collected  
 
  
DPPP-S2 The Privacy Policy does NOT contain a declaration that 
the Website takes steps to provide security for personal 
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PART 2 – ONLINE PRACTICES OF INFORMATION SHARING 
SECONDARY USE 
  YES NO 
OPIS-SU1 Received emails or regular mail, text, or phone calls for 
other purposes from the pharmaceutical company 
 
  
  Total 
OPIS-SU2 How many emails, text, or phone calls were received for 
other purposes from the pharmaceutical company 
 
 
OPIS-SU3 How many pieces of regular mail, text, or phone calls 
were received for other purposes from the 
pharmaceutical company 
 
 
THIRD PARTY  
  YES NO 
OPIS-TP1 Received emails or regular mail, text, or phone calls for 
other purposes from the third parties 
  
   
  Total 
OPIS-TP2 How many emails were received from third parties 
 
 
OPIS-TP3 How many pieces of regular mail, text, or phone calls 
were received for other purposes from third parties 
 
 
PART 3 – ONLINE PRACTICES OF CONSUMER CONTROL 
 
CHOICE: SECONDARY USE 
  YES NO 
OPCC-SU1 Consumers do NOT have the option to opt-in/opt-out to 
receive future communications from the Website (other 
than those directly related to processing an order or 
responding to a consumer’s question) 
 
  
OPCC-SU2 Consumers do NOT have the option to opt-out of 
receiving future communications from the Website at a 
later date after receipt of communications (other than 
those directly related to processing an order or 
responding to a consumer’s question) 
  
 
information the Website collects, during transmission of 
the information from the consumer to the Website  
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CHOICE: THIRD PARTY 
  YES NO 
OPCC-TP3 Consumers do NOT have the option to opt-in/opt-out of 
disclosure of personal identifying information to third 
parties 
 
  
OPCC-TP4 Consumers do NOT have the option to opt-out of 
disclosure of personal identifying information to third 
parties at a later date after receipt of communications 
  
    
ACCESS 
  YES NO 
OPCC-A1 The Website does NOT allow consumers to review 
personal information previously collected about them 
 
  
OPCC-A2 The Website does NOT allow consumers to modify 
personal information previously collected about them 
 
  
OPCC-A3 The Website does NOT allow consumers to delete 
personal information previously collected about them 
  
 
 
PART 4 – DOCUMENTED VERSUS ACTUAL PRACTICES 
Compare the documented practices against the actual online practices of consumer 
control for choice and access. 
 
CHOICE: SECONDARY USE 
  Documented Actual 
OPCC-SU1 Consumers do NOT have the option to opt-in/opt-
out to receive future communications from the 
Website (other than those directly related to 
processing an order or responding to a consumer’s 
question)  
 
  
OPCC-SU2 Consumers do NOT have the option to opt-out of 
receiving future communications from the Website 
at a later date after receipt of communications 
(other than those directly related to processing an 
order or responding to a consumer’s question)  
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CHOICE: THIRD PARTY 
  Documented Actual 
OPCC-TP3 Consumers do NOT have the option to opt-in/opt-
out of disclosure of personal identifying 
information to third parties  
 
  
OPCC-TP4 Consumers do NOT have the option to opt-out of 
disclosure of personal identifying information to 
third parties at a later date after receipt of 
communications  
  
    
ACCESS  
  Documented Actual 
OPCC-A1 The Website does NOT allow consumers to review 
personal information previously collected about 
them 
 
  
OPCC-A2 The Website does NOT allow consumers to modify 
personal information previously collected about 
them 
 
  
OPCC-A3 The Website does NOT allow consumers to delete 
personal information previously collected about 
them 
  
 
PART 5 – PERSONAL IDENTIFYING INFORMATION 
The Website collects the following personal identifying information 
  YES NO 
PII1 Name 
 
  
PII2 Postal Address 
 
  
PII3 Telephone Number 
 
  
PII4 Social Security Number   
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Appendix B 
Round I Expert Panel Survey 
 
 
Thank you for taking the time to participate in this expert panel survey on the 
documented and online practices of Websites. I need your help to review the proposed 
measurement criteria and provide your expert opinion regarding their relative importance. 
Finally, you will be asked a few questions about your background and experience. 
This expert panel survey is part of a PhD doctoral dissertation research study, which 
seeks to develop the Personal Information Privacy Violation Index (PIPVI) 
benchmarking instrument that can be used to assess the documented and actual online 
practices of Websites. Your assistance and expertise as an expert is being solicited to 
review the initial instrument and perform a qualitative evaluation of the instrument's 
validity by answering questions pertaining to the criteria being measured, which are as 
follows: 
1. Document Practices of the Privacy Policy (Notice, Choice, Access, Security)  
2. Online Practices of Information Sharing (Choice, Access)  
3. Online Practices of Consumer Control (Choice, Access) 
 
PART 1 – DOCUMENTED PRACTICES OF THE PRIVACY POLICY 
Personal Information Privacy Violations will be assessed by the Documented 
Practices of the Privacy Policy (DPPP) of Websites. The criteria are written such 
that a yes response will indicate a violation. Please read the criteria for assessment 
and provide response to the questions below. 
NOTICE 
DPPP-N1 The Privacy Policy contains a declaration that the Website does NOT collect 
any personal information from consumers 
DPPP-N2 The Privacy Policy does NOT contain a declaration about the specific personal 
information the Website collects from consumers 
DPPP-N3 The Privacy Policy does NOT contain a declaration that the Website may use 
personal information it collects for secondary purposes 
DPPP-N4 The Privacy Policy does NOT contain a declaration about whether the Website 
uses personal information it collects to send communications to the consumer 
DPPP-N5 The Privacy Policy does NOT contain a declaration about whether the Website 
discloses personal information it collects to third parties 
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1. Violation of the Notice component of the Documented Practices of the Privacy 
Policy will be assessed using the data collected from the questions above. Please 
evaluate the following statements. 
 Strongly 
Disagree 
(1) 
Somewhat 
Disagree 
(2) 
Disagree 
(3) 
Neither 
Agree or 
Disagree 
(4) 
Somewhat 
Agree (5) 
Agree 
(6) 
Strongly 
Agree 
(7) 
Notice is an accurate 
component of the 
Privacy Policy to 
assess 
 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
The Privacy Policy 
components 
regarding personal 
information 
collected along with 
secondary and third 
party use described 
above provide an 
accurate assessment 
of Notice violations 
 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
Additional Comments 
 
 
 
CHOICE 
 
DPPP-C1     The Privacy Policy does NOT contain a declaration that the Website 
provides the choice to opt-in/opt-out of future communications from the company other 
than those directly related to a transaction originated by the consumer 
DPPP-C2     The Privacy Policy does NOT contain a declaration that the Website 
provides the choice to opt-out of future communications at a later date after receipt of 
communications 
DPPP-C3     The Privacy Policy does NOT contain a declaration that the Website 
provides the choice to opt-in/opt-out of information disclosure to third parties 
DPPP-C4     The Privacy Policy does NOT contain a declaration that the Website 
provides the choice to opt-out of future communications from third parties at a later date 
after receipt of communications 
 
2. Violation of the Choice component of the Documented Practices of the Privacy 
Policy will be assessed using the data collected from the questions above.  Please 
evaluate the following statements. 
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 Strongly 
Disagree 
(1) 
Somewhat 
Disagree 
(2) 
Disagree 
(3) 
Neither 
Agree or 
Disagree 
(4) 
Somewhat 
Agree (5) 
Agree 
(6) 
Strongly 
Agree 
(7) 
Choice is an 
accurate component 
of the Privacy 
Policy to assess 
 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
The Privacy Policy 
components 
regarding personal 
information 
collected along with 
secondary and third 
party use described 
above provide an 
accurate assessment 
of Choice violations 
 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
Additional Comments 
 
 
 
ACCESS 
DPPP-A1 The Privacy Policy does NOT contain a declaration that the Website allows 
consumers to review personal information previously collected 
DPPP-A2 The Privacy Policy does NOT contain a declaration that the Website allows 
consumers to modify personal information previously collected 
DPPP-A3 The Privacy Policy does NOT contain a declaration that the Website allows 
consumers to delete personal information previously collected 
 
3. Violation of the Access component of the Documented Practices of the Privacy 
Policy will be assessed using the data collected from the questions above. Please 
evaluate the following statements. 
 Strongly 
Disagree 
(1) 
Somewhat 
Disagree 
(2) 
Disagree 
(3) 
Neither 
Agree or 
Disagree 
(4) 
Somewhat 
Agree (5) 
Agree 
(6) 
Strongly 
Agree 
(7) 
Access is an 
accurate component 
of the Privacy 
Policy to assess 
 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
The Privacy Policy 
components to 
review, modify, and 
delete personal 
information 
collected described 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
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above provide an 
accurate assessment 
of Access violations 
 
Additional Comments 
 
 
SECURITY 
 
DPPP-S1 The Privacy Policy does NOT contain a declaration that the Website takes any 
steps to provide security of the personal information collected 
DPPP-S2 The Privacy Policy does NOT contain a declaration that the Website takes 
steps to provide security for personal information the Website collects during 
transmission of the information from the consumer to the Website 
4. Violation of the Security component of the Documented Practices of the Privacy 
Policy will be assessed using the data collected from the questions above. Please 
evaluate the following statements. 
 Strongly 
Disagree 
(1) 
Somewhat 
Disagree 
(2) 
Disagree 
(3) 
Neither 
Agree or 
Disagree 
(4) 
Somewhat 
Agree (5) 
Agree 
(6) 
Strongly 
Agree 
(7) 
Security is an 
accurate component 
of the Privacy 
Policy to assess 
 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
The Privacy Policy 
components 
regarding the steps 
taken to provide 
security for 
information 
collected described 
above provide an 
accurate assessment 
of Security 
violations 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
Additional Comments 
 
PART 2 – ONLINE PRACTICES OF INFORMATION SHARING 
Personal Information Privacy Violations will be assessed by the Online Practices of the 
Information Sharing (OPIS) of Websites. Please read the criteria for assessment and 
provide response to the questions below. 
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SECONDARY USE 
OPIS-SU1 How many emails were received for other purposes from the company  
OPIS-SU2 How many pieces of regular mail were received for other purposes from the 
company 
 Strongly 
Disagree 
(1) 
Somewhat 
Disagree 
(2) 
Disagree 
(3) 
Neither 
Agree or 
Disagree 
(4) 
Somewhat 
Agree (5) 
Agree 
(6) 
Strongly 
Agree 
(7) 
Secondary Use is an 
accurate component 
of the Information 
Sharing to assess 
 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
The number of 
emails and 
regular mail 
received described 
above provide an 
accurate assessment 
of Secondary Use 
for Information 
Sharing violations 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
Additional Comments 
 
THIRD PARTY 
OPIS-TP1 How many emails were received from third parties  
OPIS-TP2 How many pieces of regular mail were received for other purposes from third 
parties 
 Strongly 
Disagree 
(1) 
Somewhat 
Disagree 
(2) 
Disagree 
(3) 
Neither 
Agree or 
Disagree 
(4) 
Somewhat 
Agree (5) 
Agree 
(6) 
Strongly 
Agree 
(7) 
Third Party Use is 
an accurate 
component of the 
Information Sharing 
to assess 
 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
The number of 
emails and 
regular mail 
received described 
above provide an 
accurate assessment 
of Third Party Use 
for Information 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
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Sharing violations 
Additional Comments 
 
PART 3 - ONLINE PRACTICES OF CONSUMER CONTROL 
Personal Information Privacy Violations will be assessed by the Online Practices of 
Consumer Control (OPCC) by Websites. The criteria are written such that a yes response 
will indicate a violation. Please read the criteria to allow consumers to opt-in/out of 
Secondary Use and information disclosure to Third Parties along with the ability to 
Access their information and provide response to the questions below. 
CHOICE: SECONDARY USE 
OPCC-SU1 Consumers do NOT have the option to opt-in/opt-out to receive future 
communications from the Website (other than those directly related to processing an 
order or responding to a consumer’s question) 
OPCC-SU2 Consumers do NOT have the option to opt-out of receiving future 
communications from the Website at a later date after receipt of communications (other 
than those directly related to processing an order or responding to a consumer’s question) 
7. Violation of Secondary Use for the Choice component of Online Practices of 
Consumer Control will be assessed using the data collected from the questions 
above. Please evaluate the following statements. 
 Strongly 
Disagree 
(1) 
Somewhat 
Disagree 
(2) 
Disagree 
(3) 
Neither 
Agree or 
Disagree 
(4) 
Somewhat 
Agree (5) 
Agree 
(6) 
Strongly 
Agree 
(7) 
Secondary Use is an 
accurate component 
of Consumer 
Control to assess 
 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
The number of 
emails and 
regular mail 
received described 
above provide an 
accurate assessment 
of Secondary Use 
for Consumer 
Control violations 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
Additional Comments 
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CHOICE: THIRD PARTY 
OPCC-TP1 Consumers do NOT have the option to opt-in/opt-out of disclosure of 
personal identifying information to third parties 
OPCC-TP2 Consumers do NOT have the option to opt-out of disclosure of personal 
identifying information to third parties at a later date after receipt of communications 
8. Violation of the Third Party component of Online Practices of Consumer Control 
will be assessed using the data collected from the questions above. Please evaluate 
the following statements. 
 Strongly 
Disagree 
(1) 
Somewhat 
Disagree 
(2) 
Disagree 
(3) 
Neither 
Agree or 
Disagree 
(4) 
Somewhat 
Agree (5) 
Agree 
(6) 
Strongly 
Agree 
(7) 
Third Party Use is 
an accurate 
component of 
Consumer Control 
to assess 
 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
The number of 
emails and 
regular mail 
received described 
above provide an 
accurate assessment 
of Third Party Use 
for Consumer 
Control violations 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
Additional Comments 
 
ACCESS 
OPCC-A1  The Website does NOT allow consumers to review personal information 
previously collected about them  
OPCC-A2  The Website does NOT allow consumers to modify personal information 
previously collected about them  
OPCC-A3  The Website does NOT allow consumers to delete personal information 
previously collected about them 
9. Violation of the Access component of Online Practices of Consumer Control will 
be assessed using the data collected from the questions above. Please evaluate the 
following statements. 
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 Strongly 
Disagree 
(1) 
Somewhat 
Disagree 
(2) 
Disagree 
(3) 
Neither 
Agree or 
Disagree 
(4) 
Somewhat 
Agree (5) 
Agree 
(6) 
Strongly 
Agree 
(7) 
Access is an 
accurate component 
of Consumer 
Control to assess 
 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
The Privacy Policy 
components to 
review, modify, and 
delete personal 
information 
collected described 
above provide an 
accurate assessment 
of Access for 
Consumer Control 
violations 
 
 ¢  ¢  ¢  ¢  ¢  ¢  ¢ 
Additional Comments 
 
PART 4 - PERSONAL INDENTIFYING INFORMATION 
10. Some Websites collect Personal Identifying Information (PII). Please review the 
suggested PII information for assessment and provide response if they represent 
PII. 
 Strongly 
Disagree 
(1) 
Somewhat 
Disagree 
(2) 
Disagree 
(3) 
Neither 
Agree or 
Disagree 
(4) 
Somewhat 
Agree (5) 
Agree 
(6) 
Strongly 
Agree 
(7) 
Name ¢ ¢ ¢ ¢ ¢ ¢ ¢ 
Postal Address ¢ ¢ ¢ ¢ ¢ ¢ ¢ 
Telephone Number ¢ ¢ ¢ ¢ ¢ ¢ ¢ 
Social Security 
Number 
 
¢ ¢ ¢ ¢ ¢ ¢ ¢ 
Additional Comments 
 
PART 5 - WEIGHT ASSSIGNMENT 
11. Each of these criteria will be assessed against a consensus of documented 
industry practices. If each measured criteria is assumed to meet industry practice 
guidance, what should the relative importance of each of the Documented Practices 
of the Privacy Policy (DPPP) criteria be relative to one another? 
Please allocate 100 points among the Documented Practices of the Privacy Policy 
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criteria listed. 
[DPPP-N] Notice  
[DPPP-C] Choice  
DPPP-A] Access  
[DPPP-S] Security  
 
12. Each of these criteria will be assessed against a consensus of documented 
industry practices. If each measured criteria is assumed to meet industry practice 
guidance, what should the relative importance of each of the Online Practices of 
Information Sharing (OPIS) criteria be relative to one another? 
Please allocate 100 points among the Online Practices of Information Sharing 
criteria listed 
[OPIS-SU] Secondary Use  
[OPIS-TP] Third Party  
13. Each of these criteria will be assessed against a consensus of documented 
industry practices. If each measured criteria is assumed to meet industry practice 
guidance, what should the relative importance of each of the Online Practices of 
Consumer Control (OPCC) criteria be relative to one another? 
[OPCC-C] Choice  
[OPCC-A] Access  
14. The three proposed measures described above will be assessed based on the 
clusters of criteria described above. These are to be combined into a single index. 
Please indicate the relative importance of each of the Personal Information Privacy 
Violations Index (PIPVI) criteria by assigning weights. 
Please allocate 100 points among the Personal Information Privacy Violations Index 
(PIPVI) criteria listed. 
DPPP - Documented 
Practices of the Privacy 
Policy 
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OPIS - Online Practices of 
Information Sharing 
 
OPCC - Online Practices of 
Consumer Control 
 
PART 6 - DEMOGRAPHICS 
15. Which of the following statements best describes your opinion about the future 
of Personal Information Privacy practices implemented on Websites? 
¢    Personal Information Privacy practices implemented on Websites are adequate and 
companies will continue to adequately self regulate over the next 10 years 
 ¢   Personal Information Privacy practices implemented on Websites are adequate but 
companies need additional enforcement over the next 10 years 
 ¢   Personal Information Privacy practices implemented on Websites are inadequate and 
companies need additional enforcement over the next 10 years 
 ¢  None of the choices adequately capture my opinion. My opinion is: 
 
16. Please provide a general estimate of your background to the following questions: 
Would you classify yourself as an ‘academic’ or ‘practitioner’ in regards to your 
involvement with Information Security/Information Privacy? 
  ¢  I consider myself to be an academic  
  ¢  I am both an academic and a practitioner but am mostly focused on academics n 
  ¢  I consider myself to be a practitioner  
  ¢  I am both a practitioner and academic, but am mostly focused on the practitioner  
  ¢  I consider myself to be evenly balanced as both a practitioner and academic 
17. If you consider yourself an academic, what is your experience with the subject 
area of Information Security/Information Privacy? 
How many years have you taught undergraduate or Masters 
level students in courses that have included topics in 
Information Security/Information Privacy?  
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How may Doctoral students have you supervised with 
Information Security/Information Privacy related thesis or 
dissertations?  
How many peer-reviewed journal articles have you published 
in the area of Information Security/Information Privacy? 
 
How many other periodical articles (not PRJ) have you 
published in the area of Information Security/Information 
Privacy? 
 
How many books or invited book chapters have you published 
in the area of Information Security/Information Privacy? 
 
18. If you consider yourself to be a practitioner, what is your experience with the 
subject area of Information Security/Information Privacy (years in each answer 
need not be mutually exclusive)? 
How many years of systems design which have involved at 
least some aspects of Information Security/Information 
Privacy?  
How many years of systems development which have involved 
at least some aspects of Information Security/Information 
Privacy?  
How many years of systems implementation which has 
involved at least some aspects of Information 
Security/Information Privacy?  
How many years of project management or supervisory 
management which have involved at least some aspects of 
Information Security/Information Privacy?  
How many years of employment or consulting engagement 
assignments have focused on building or improving 
Information Security/Information Privacy? 
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Appendix C 
Round I Email to Expert Panel 
 
Dear Privacy, Security, HR, Medical, and Pharmaceutical Experts, 
  
We need your help in providing expert feedback on a framework for an upcoming 
doctoral research study. I am a PhD Candidate in Information Systems with a 
concentration in Information Security at the Graduate School of Computer and 
Information Sciences, Nova Southeastern University. My research is seeking to develop 
an index to measure if there are (or to what extent the magnitude exists) personal 
information privacy violations by companies' Websites. To develop the index, I need 
assistance from those that have knowledge in Information Security/Information 
Privacy/Human Resources/Medical/Pharmaceutical to review the proposed measurement 
criteria for the documented and online practices of Websites and provide your expert 
opinion regarding their relative importance by assigning weights to help me develop the 
novel benchmarking instrument of the Personal Information Privacy Violations Index 
(PIPVI).  
  
This survey response will be used to develop the Personal Information Privacy Violation 
Index (PIPVI) benchmarking instrument that will help organizations as well as industry 
entities to assess the documented and actual online practices of Websites, especially in 
the medical and/or pharmaceutical field. Your assistance and expertise is being solicited 
to review the initial instrument and perform an evaluation of the criteria's validity by 
answering questions pertaining to the criteria being measured, which are as follows; 
      1. Document Practices of the Privacy Policy (Notice, Choice, Access, Security) 
      2. Online Practices of Information Sharing (Choice, Access) 
      3. Online Practices of Consumer Control (Choice, Access) 
  
The information provided will be used only for this research study and in aggregated 
form. No personal identifiable information (PII) will be collected. If you are willing to 
participate, please click on the link below for access and completion by Friday, June 13. 
  
https://www.surveymonkey.com/s/PIPVI_ExpertPanelSurvey 
  
Thank you in advance for your consideration. I appreciate your assistance and 
contribution to this research study. 
  
Should you wish to receive the findings of the study, please send me an email and I will 
be happy to provide you with information about the academic research publication(s) 
resulting from this study. 
  
Regards, 
Shonda Brown, PhD Candidate  
E-mail: bshonda@nova.edu 
Information Systems with a concentration in Information Security  
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Graduate School of Computer and Information Sciences  
Nova Southeastern University 
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Appendix D 
Round II Expert Panel Survey 
 
Thank you for taking the time to participate in this final phase of the expert panel survey 
on the documented and online practices of Websites. I need your help to review the 
aggregated results from the first phase that represent the percentages for the proposed 
measurement criteria and provide your expert opinion regarding their relative importance. 
The survey has four questions that should take approximately less than 10 minutes to 
complete. Finally, you will be asked a few questions about your background and 
experience if you did not participate in the first phase of the survey. 
  
This expert panel survey is part of a PhD doctoral dissertation research study which seeks 
to develop the Personal Information Privacy Violation Index (PIPVI) benchmarking 
instrument that can be used to assess the documented and actual online practices of 
Websites. Your assistance and expertise is being solicited as an expert to review the 
aggregated results by answering questions pertaining to the percentages assigned to the 
criteria being measured, which are as follows;  
      1. Document Practices of the Privacy Policy (Notice, Choice, Access, and Security) 
      2. Online Practices of Information Sharing (Choice and Access) 
      3. Online Practices of Consumer Control (Choice and Access) 
  
PART 1 – CONCEPTUAL MODEL 
 
The conceptual model is displayed to provide insight into the research study and the 
criteria that will contribute to the development of the Personal Information 
Privacy Violation Index.  
 
PART 2 - WEIGHT ASSIGNMENT 
 
1. DOCUMENTED PRACTICES OF THE PRIVACY POLICY  
 
Each of these criteria will be assessed against a consensus of documented industry 
practices. The aggregated responses from the first phase of the survey are indicated below 
as percentages in red that represents the relative importance of each of the Documented 
Practices of the Privacy Policy (DPPP) criteria. Please indicate your opinion regarding 
the validity of the aggregated results. If new weights are provided, the allocation must 
equal 100 points. 
 
DOCUMENTED PRACTICES OF THE PRIVACY POLICY are the documented 
practices of the company that is represented in the Privacy Policy. The criteria for the 
Privacy Policy represent the following. 
 
Notice provides consumers clear and conspicuous notice of the company's information 
practices, including what information they collect, how they collect it, how it is used, 
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how they provide Choice, Access, and Security to consumers, and whether they disclose 
the information collected to other entities 
Choice - documented practices on whether the company allows customers to opt-in/opt-
out of information sharing within and outside of the company 
 
Access - documented practices on whether the company allows customers to access and 
modify information provided during the transaction 
 
Security - documented practices about the company's security of the information they 
collect from consumers 
 
 YES the % appears valid 
as the relative weight 
NO the % does not appear valid 
as the relative weight 
 
[DPPP-N] Notice 
25% 
 
 ¢  ¢  
[DPPP-C] Choice 
22% 
 
 ¢  ¢  
DPPP-A] Access 
20% 
 
 ¢  ¢  
[DPPP-S] Security 
33% 
 ¢  ¢  
 
Other Percentage (please specify) 
 
 
 
2. ONLINE PRACTICES OF INFORMATION SHARING  
 
Each of these criteria will be assessed against a consensus of documented industry 
practices. The aggregated responses from the first phase of the survey are indicated below 
as percentages in red that represent the relative importance of each of the Online 
Practices of Information Sharing (OPIS) criteria. Please indicate your opinion regarding 
the validity of the aggregated results. If new weights are provided, the allocation must 
equal 100 points.  
 
ONLINE PRACTICES OF INFORMATION SHARING are the actual practices of 
the company regarding sharing information within or outside of the company 
Secondary Use is information shared within the company and used for purposes other 
than original transaction 
 
Third Party Use is information shared outside of the company 
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 YES the % appears valid 
as the relative weight 
NO the % does not appear valid 
as the relative weight 
 
[OPIS-SU] 
SECONDARY 
USE 
55% 
 
 ¢  ¢  
[OPIS-TP] THIRD 
PARTY 
45% 
 
 ¢  ¢  
Other Percentage (please specify 
 
 
 
3. ONLINE PRACTICES OF CONSUMER CONTROL  
 
Each of these criteria will be assessed against a consensus of documented industry 
practices. The aggregated responses from the first phase of the survey are indicated below 
as percentages in red that represent the relative importance of each of Consumer Control 
(OPCC) criteria. Please indicate your opinion regarding the validity of the aggregated 
results. If new weights are provided, the allocation must equal 100 points.  
 
ONLINE PRACTICES OF CONSUMER CONTROL are the actual practices of the 
company regarding the consumer's ability to control their information 
 
Choice is the ability to opt-in/opt-out of information sharing within and outside of the 
company 
 
Access is the ability to access and modify information provided during the transaction 
 
 YES the % appears valid 
as the relative weight 
NO the % does not appears 
valid as the relative weight 
 
[OPCC] CHOICE 
58% 
 
 ¢  ¢  
[OPCC] ACCESS 
42% 
 
 ¢  ¢  
Other Percentage (please specify 
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4. PERSONAL INFORMATION PRIVACY VIOATIONS INDEX 
 
The three proposed measures described below will be combined to create the Personal 
Information Privacy Violations Index (PIPVI). The aggregated responses from the first 
phase of the survey are indicated below as percentages in red that represent the relative 
importance of each of measure. Please indicate your opinion regarding the validity of the 
aggregated results. If new weights are provided, the allocation must equal 100 points.  
 
DOCUMENTED PRACTICES OF THE PRIVACY POLICY are the documented 
practices of the company that are represented in the Privacy Policy       
                    
ONLINE PRACTICES OF INFORMATION SHARING are the actual practices of 
the company for sharing information within or outside of the company  
 
ONLINE PRACTICES OF CONSUMER CONTROL are the actual practices of the 
company regarding the consumers' ability to control their information 
 
 YES the % appears valid 
as the relative weight 
NO the % does not appear valid 
as the relative weight 
 
[DPPP] DOCUMENTED 
PRACTICES OF THE 
PRIVACY POLICY 
35% 
 
 ¢  ¢  
Other Percentage (please specify) 
 
[OPIS] ONLINE PRACTICES 
OF INFORMATION SHARING 
33% 
 
¢  ¢  
Other Percentage (please specify) 
 
[OPCC] PRACTICES OF 
CONSUMER CONTROL 
32% 
 
 ¢  ¢  
Other Percentage (please specify) 
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PART 3 - DEMOGRAPHICS 
Please complete if you didn't participate in the first phase of the survey 
15. Which of the following statements best describes your opinion about the future 
of Personal Information Privacy practices implemented on Websites? 
¢    Personal Information Privacy practices implemented on Websites are adequate and 
companies will continue to adequately self regulate over the next 10 years 
 ¢   Personal Information Privacy practices implemented on Websites are adequate but 
companies need additional enforcement over the next 10 years 
¢   Personal Information Privacy practices implemented on Websites are inadequate and 
companies need additional enforcement over the next 10 years 
¢  None of the choices adequately capture my opinion. My opinion is: 
 
16. Please provide a general estimate of your background to the following questions: 
Would you classify yourself as an ‘academic’ or ‘practitioner’ in regards to your 
involvement with Information Security/Information Privacy? 
  ¢  I consider myself to be an academic  
  ¢  I am both an academic and a practitioner but am mostly focused on academics 
  ¢  I consider myself to be a practitioner  
  ¢  I am both a practitioner and academic, but am mostly focused on the practitioner  
  ¢  I consider myself to be evenly balanced as both a practitioner and academic 
17. If you consider yourself an academic, what is your experience with the subject 
area of Information Security/Information Privacy? 
How many years have you taught undergraduate or Masters 
level students in courses that have included topics in 
Information Security/Information Privacy?  
How may Doctoral students have you supervised with 
Information Security/Information Privacy related thesis or 
dissertations?  
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How many peer-reviewed journal articles have you published 
in the area of Information Security/Information Privacy? 
 
How many other periodical articles (not PRJ) have you 
published in the area of Information Security/Information 
Privacy? 
 
How many books or invited book chapters have you published 
in the area of Information Security/Information Privacy? 
 
18. If you consider yourself a practitioner, what is your experience with the subject 
area of Information Security/Information Privacy (years in each answer need not be 
mutually exclusive)? 
How many years of systems design which have involved at 
least some aspects of Information Security/Information 
Privacy?  
How many years of systems development which have involved 
at least some aspects of Information Security/Information 
Privacy?  
How many years of systems implementation which has 
involved at least some aspects of Information 
Security/Information Privacy?  
How many years of project management or supervisory 
management which have involved at least some aspects of 
Information Security/Information Privacy?  
How many years of employment or consulting engagement 
assignments have focused on building or improving 
Information Security/Information Privacy?  
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Appendix E 
 
Round II Email to Expert Panel 
 
Dear Privacy, Security, HR, Medical, and Pharmaceutical Experts, 
 
Thank you again for the previous feedback. The responses from the first phase of the 
survey have been aggregated and we need your help for the last time to validate the 
weight assignments for the criteria that will be used to develop the Personal Information 
Privacy Violations Index (PIPVI). The survey contains four questions soliciting your 
expert opinion regarding the relative importance of the criteria and four questions 
regarding your background if you did not participate in the first phase of the survey. 
Please help me by providing your expert opinion in this final phase by clicking on the 
link below to access the survey. 
 
https://www.surveymonkey.com/s/PIPVI_ExpertPanelSurvey2  
 
I need your help in providing expert feedback on a framework for an upcoming doctoral 
research study. I am a PhD Candidate in Information Systems with a concentration in 
Information Security at the Graduate School of Computer and Information Sciences, 
Nova Southeastern University. My research is seeking to develop an index to measure if 
there are (or to what extent the magnitude exist) personal information privacy violations 
by companies' Websites. To develop the index, I need assistance from those that have 
knowledge in Information Security/Information Privacy/Human 
Resources/Medical/Pharmaceutical industries. 
 
 That's where I need your help! 
 
The survey responses will be used to develop the Personal Information Privacy Violation 
Index (PIPVI) to assess the magnitude of personal information privacy violations of 
Websites, especially in the medical and/or pharmaceutical field. Your assistance and 
expertise is being solicited for the last time to perform an evaluation of the aggregated 
weight assignments based upon the responses from the first phase of the survey to the 
following criteria; 
 
      1. Document Practices of the Privacy Policy (Notice, Choice, Access, and Security) 
       2. Online Practices of Information Sharing (Choice and Access) 
       3. Online Practices of Consumer Control (Choice and Access) 
 
The information provided will be used only for this research study and in aggregated 
form. No personal identifiable information (PII) will be collected.  
 
Thank you in advance for your consideration. I appreciate your assistance and 
contribution to this research study. 
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Should you wish to receive the findings of the study, please send me an email and I will 
be happy to provide you with information about the academic research publication(s) 
resulting from this study. 
 
Regards, 
Shonda Brown, PhD Candidate  
E-mail: bshonda@nova.edu 
Information Systems with a concentration in Information Security  
Graduate School of Computer and Information Sciences  
Nova Southeastern University  
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Institutional Review Board Approval Letter 
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